

# Cancer Incidence and Mortality in Europe

Fabio Levi<sup>1</sup>, Patrick Maisonneuve<sup>2</sup>, Rosa Filiberti<sup>1,3</sup>, Carlo La Vecchia<sup>4,5</sup>, Peter Boyle<sup>2</sup>

<sup>1</sup> *Registre vaudois des tumeurs, Institut universitaire de médecine sociale et préventive, Lausanne*

<sup>2</sup> *International Agency for Research on Cancer, Lyon*

<sup>3</sup> *Istituto Nazionale per la Ricerca sul Cancro, Genova*

<sup>4</sup> *Institut universitaire de médecine sociale et préventive, Lausanne*

<sup>5</sup> *Istituto di Ricerche Farmacologiche «Mario Negri», Milano*

There are several reasons for a general and comprehensive overview of descriptive epidemiology of cancer in Europe. First, 45 cancer registries from 19 countries were in operation in the early 1980's, and produced data of sufficient reliability to be included in the fifth volume of Cancer Incidence in Five Continents [1]. Second, mortality data are available from most European countries, and their quality, although certainly somewhat heterogeneous, is probably acceptable for several important cancer sites in most countries. Third, the range of variation in mortality is considerably greater than in most other developed areas of the world, particularly North America, probably because of large historical differences between various areas of the continent, which are still reflected in a considerable heterogeneity in the political and socioeconomic situation, environmental factors, diet and general lifestyle habits. Therefore, in this report we present in graphical form incidence data for 30 cancer sites (plus a broadly heterogeneous group of other and unspecified) from the 45 European cancer registries, and mortality data for 27 cancer sites in 26 European countries for the five-year calendar period 1978–82.

The major objective of this work is to offer a general documentation and description of the overall picture of cancer incidence and mortality in Europe and a simple reference to epidemiologists, health-statisticians and oncologists.

## Materials and Methods

Overall age-standardized (on the world standard population) incidence rates for each cancer or group of cancers in the 45 European registries were abstracted from the fifth volume of Cancer Incidence in Five Continents [1]. Age-standardized cancer mortality rates for 26 European countries (excluding the Soviet Union and a few small countries like Malta, Liechtenstein, etc) were computed for the period 1978–82 (except for selected countries and cancer sites; Table 1) on the basis of official death certification data provided by the World Health Organization database. Age-standardization was based on the world standard population [1].

Classification of cancer deaths was coded, for all calendar periods and countries, according to the Ninth Revision of the International Classification of Diseases (ICD-9). Table 2 gives the cancers or groups of cancers considered for incidence and mortality statistics, together with the corresponding ICD codes under the Eighth and Ninth Revision.

## Presentation of Results

For each cancer site, incidence and mortality rates are graphically presented in two pairs of histograms, including for each sex incidence and mortality rates, respectively.

The same scale is always adopted for both sexes in the same cancer site, in order to offer immediate inter-sex comparison. Further, to provide, as far as possible, uniform interpretation for various cancer sites, a limited number of scales has been adopted (5, 10, 15, 20, 30, 50, 100, 350/100000 for incidence and 5, 10, 15, 20, 30, 50, 100, 200, 250/100000 for mortality). A table of sex ratios for each registry or country, ranked from highest to lowest, is given. Finally, a brief comment for each cancer site is included.

Five tables are given in Appendix including separately:

- List of abbreviations used (Appendix Table 1).
- Total population for each registry or country. This can be of some help to derive, in first approximation, standard errors of rates based on the Poisson distribution (Table 2a and b).
- Table of ranks of registries or countries for each cancer or group of cancers (Table 3, incidence; Table 4, mortality).
- Table of ranks of cancers or group of cancers within each registry or country (Table 5a and b, incidence; Table 6a and b, mortality).
- Table of sex ratios within each site, and registry region or country (Table 7, incidence; Table 8, mortality).
- Ratio highest to lowest for incidence and mortality in each cancer site and sex (Table 9a and b, incidence; Table 10a and b, mortality).

## General Comment

This report has essentially a descriptive value, and is therefore not intended to draw inferences or provide interpretations. A few general comments are nonetheless worth making for assisting the interpretation of the data. First, problems related to random variability should always be considered, and are clearly greater in relation to smaller populations and rarer cancers. Second, there is substantial variability within Europe for most cancer sites in both incidence and mortality, although in some cases the changes in rates across registries or countries were approximately linear; other cancers were, however, characterized by a few high and low rates (outliers), but there are also a number of cancers which present relatively small variation. Third, we were impressed by the consistency in

the distribution of incidence and mortality rates for most cancer sites. Since the two systems of registration are independent, this is an important *a posteriori* confirmation of the overall acceptable reliability of cancer statistics in Europe.

#### Résumé

##### Incidence et mortalité du cancer en Europe

Cet ouvrage de référence, essentiellement descriptif, présente sous une forme principalement graphique, accompagnée de très brefs commentaires, les éléments suivants: 1. les taux d'incidence, standardisés par rapport à la population mondiale, pour 31 localisations ou groupes de localisations cancéreuses de 45 régions appartenant à 19 pays européens qui figurent dans le volume 5 de la série «Cancer Incidence in Five Continents»; 2. les données officielles de mortalité fournies par l'Organisation mondiale de la Santé pour 27 localisations et 26 pays pour la période correspondant à l'incidence, comprise entre 1978 et 1982. Le supplément fournit également les rapports homme/femme d'incidence et de mortalité pour chaque pays et région d'Europe considérés, ainsi que le rang de chaque localisation ou pays/région, respectivement au sein de chaque pays/région ou localisation. Parmi les constatations les plus importantes de ce rapport on relèvera:

- les taux élevés d'incidence et de mortalité par cancer pulmonaire en Ecosse dans les deux sexes et en Angleterre, les plus bas étant enregistrés en Scandinavie, Espagne et Italie du Sud;
- les niveaux élevés des néoplasies liées à l'exposition conjointe au tabac et à l'alcool en France, en Suisse romande, en Italie du Nord et en Ecosse, surtout chez la femme;
- les taux généralement faibles dans les populations méditerranéennes (Espagne, Italie du Sud et Grèce) pour la plupart des autres tumeurs fréquentes, notamment de l'estomac, du colorectum et du sein;
- les rangs particulièrement élevés des cancers génitaux en Scandinavie, en Suisse et en Italie du Nord, de l'incidence des tumeurs de la vessie dans les régions à haute concentration d'industries chimiques, des tumeurs thyroïdiennes en Scandinavie et en Suisse, et des tumeurs lymphatiques en Ecosse, en Suisse et en Italie du Nord.

Pour la majorité des sites les plus importants et, d'une façon générale, les profils d'incidence et de mortalité sont largement superposables, ce qui confirme la bonne qualité et la complémentarité de ces deux types de données. Enfin, on peut constater qu'il existe au sein de l'Europe un intervalle de variation des taux nettement plus large que dans les autres régions développées du monde; l'observation de contrastes géographiques aussi prononcés devrait stimuler la planification de futures études épidémiologiques multicentriques.

#### Zusammenfassung

##### Inzidenz und Mortalität des Krebses in Europa

Diese Arbeit bleibt weitgehend deskriptiv, ist sie doch als Referenz gedacht. Sie fasst die folgenden epidemiologischen Daten zusammen, meist in grafischer Darstellung mit einem kurzen Kommentar: 1. Altersstandardisierte Daten zur Krebsinzidenz aus 45 Regionen Europas, die 19 verschiedenen Ländern angehören. Sie betreffen 31 Krebslokalisationen und sind dem fünften Band der Reihe «Cancer in Five Continents» entnommen. 2. Die von der WHO publizierten Mortalitätsdaten. Diese betreffen 26 Länder und 27 verschiedene Krebslokalisationen. Die abgedeckte Zeitspanne, die Jahre 1978–1982, entspricht jener der Inzidenzdaten. In dieser Sonder-

nummer findet man auch Angaben über den Anteil der Männer und Frauen bei den verschiedenen Krebsformen sowohl bei der Inzidenz als auch bei der Mortalität.

Für die einzelnen Länder werden die Krebsformen nach deren Häufigkeit geordnet dargestellt und auch umgekehrt, für die einzelnen Krebslokalisationen, die Länder. Unter den Aussagen, die die gesammelten Daten ermöglichen, sind zu erwähnen:

- Der Lungenkrebs ist bei Männern und Frauen besonders häufig in Schottland und England, selten in Skandinavien, Spanien und Süditalien.
- Krebsformen, die mit der Kombination von Tabak und Alkoholkonsum in Verbindung gebracht wurden, sind häufig in Frankreich, der Westschweiz, Norditalien und Schottland.
- Bei den übrigen häufig diagnostizierten Krebsformen ist die Inzidenz in der Regel in den Mittelmeerländern niedriger. Es gilt dies für den Magen-, den Dickdarm- und den Brustkrebs.
- Die grosse Zahl der Karzinome der Geschlechtsorgane, bedingt durch die Blasenkrebe in den Regionen mit chemischer Industrie, in Skandinavien, der Schweiz und Norditalien.

Relativ häufig ist der Schilddrüsenkrebs in Skandinavien und in der Schweiz, und die lymphatischen Neoplasien sind es in Schottland, der Schweiz und Norditalien. Die Daten über Inzidenz und Mortalität stimmen im allgemeinen gut überein. Dies spricht für eine gute Qualität der Datenquellen.

Schliesslich stellt man fest, dass die Unterschiede innerhalb Europas grösser sind als jene, die man in anderen industrialisierten Weltgegenden beobachtet. Die Beobachtung dieser grossen Unterschiede sollte eine Anregung sein, neue multizentrische Studien zur Krebs-epidemiologie anzuregen.

#### References

- [1] Muir C., Waterhouse J., Mack T., Powell J., Whelan S. Cancer incidence in five continents, vol. V. Lyon, International Agency for Research on Cancer, 1987 (IARC Scientific Publication, no. 88.)
- [2] Doll R., Peto R. The causes of cancer: Quantitative estimates of avoidable risks of cancer in the United States today. JNCI 1981; 66, 1191-1308.
- [3] U.S. Office on Smoking and Health: The health consequences of smoking: cancer. A Report of the Surgeon General of the Public Health Service. Washington: U.S. G.P.O., 1982.
- [4] Doll R., Peto J. Effects on health of exposure to asbestos. London, Her Majesty's Stationery Office, 1985 (Health and Safety Commission).
- [5] Matanoski G.M., Elliott E.A. Bladder cancer epidemiology. Epidemiol Rev 1981, 203-229.
- [6] Saxen E. Histopathology in cancer epidemiology. Pathol Annu 1979; 14: 203-217. (The Maude Abbott Lecture).

#### Acknowledgements

The contribution of the Swiss and St-Gall Leagues against cancer is gratefully acknowledged. We wish to thank Florence Golay and Christine Janin for graphical and editorial assistance.

#### Address for correspondence:

Dr. Fabio Levi  
Registre vaudois des tumeurs  
Institut universitaire de médecine sociale et préventive  
CHUV BH-06  
CH-1011 Lausanne

# **Incidence and Mortality Tables and Figures**

TABLE 1 - COUNTRIES AND CANCER SITES FOR WHICH CALENDAR PERIODS DIFFERENT FROM 1978-82 WERE AVAILABLE FOR MORTALITY DATA

COUNTRY	MPHA	OSO	STOM	INTE	LIVE	GALL	PANC	LARY	LUNG	PLEU	BONE	CONN	SKIT	BREA	UTER	OVAR	PROS	TEST	BLAD	KYDN	EYE	BRAI	THYR	HODG	MHOD	MNMYE	LEIK	TOTA	COUNTRY	
AUSTRIA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	AUSTRIA	
BELGIUM	-	-	-	-	-	-	78-82	-	-	-	-	-	-	-	-	-	-	-	-	-	-	78	78	-	-	-	-	-	BELGIUM	
BULGARIA	-	-	-	-	-	-	-	-	80-82	-	-	-	-	-	-	-	-	-	-	-	-	78-79	78-79	-	-	-	-	-	BULGARIA	
CZECHOSLOVAKIA	-	-	-	-	-	-	-	-	79-82	-	-	-	-	-	-	-	-	-	-	-	-	78	78	-	-	-	-	-	CZECHOSLOVAKIA	
DENMARK	-	-	-	-	-	-	-	-	78-81	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	DENMARK	
ENGLAND & WALES	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	78	78	-	-	-	-	-	ENGLAND & WALES	
FRG	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	78	78	-	-	-	-	-	FRG	
FINLAND	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	FINLAND	
FRANCE	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	78	78	-	-	-	-	-	FRANCE	
GDR	80-82	80-82	80-82	N/A	80-82	N/A	80-82	80-82	N/A	80-82	80-82	80-82	80-82	80-82	80-82	80-82	80-82	80-82	80-82	80-82	N/A	N/A	N/A	80-82	N/A	N/A	80-82	80-82	GDR	
GREECE	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	78	78	-	-	-	-	-	GREECE	
HUNGARY	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	78	78	-	-	-	-	-	HUNGARY	
IRELAND	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	78	78	-	-	-	-	-	IRELAND	
ITALY	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	78	78	-	-	-	-	-	ITALY	
LUXEMBOURG	-	-	-	-	-	-	79-82	-	79-82	-	-	-	-	-	-	-	-	-	-	-	-	N/A	N/A	79-82	79-82	79-82	-	-	LUXEMBOURG	
NETHERLANDS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	78	78	-	-	-	-	-	NETHERLANDS	
NORTHERN IRELAND	-	-	-	-	-	-	-	-	79-82	-	-	-	-	-	-	-	-	-	-	-	-	78	78	-	-	-	-	-	NORTHERN IRELAND	
NORWAY	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NORWAY	
POLAND	-	-	-	-	78-79	80-82	N/A	80-82	-	N/A	-	-	-	-	-	-	-	-	-	-	-	N/A	N/A	80-82	N/A	N/A	-	-	POLAND	
PORTUGAL	-	-	-	-	78-79	80-82	N/A	80-82	-	N/A	-	-	-	-	-	-	-	-	-	-	-	N/A	N/A	80-82	N/A	N/A	-	-	PORTUGAL	
ROMANIA	-	-	-	-	78	80-82	N/A	80-82	-	N/A	-	-	-	-	-	-	-	-	-	-	-	N/A	N/A	N/A	N/A	N/A	-	-	ROMANIA	
SCOTLAND	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	78	78	-	-	-	-	-	SCOTLAND	
SPAIN	78-81	78-81	78-81	78-81	78-81	78-81	78-81	78-81	78-81	78-81	78-81	78-81	78-81	78-81	78-81	78-81	78-81	78-81	78-81	78-81	78-81	N/A	78-79	78-81	78-81	78-81	78-81	78-81	78-81	SPAIN
SWEDEN	-	-	-	-	-	-	-	-	-	N/A	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	SWEDEN	
SWITZERLAND	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	SWITZERLAND	
YUGOSLAVIA	-	-	-	-	-	-	-	-	79-82	-	-	-	-	-	-	-	-	-	-	-	-	78	78	-	-	-	-	-	YUGOSLAVIA	

\*N/A means not available


TABLE 2 - CANCERS OR GROUPS OF CANCERS CONSIDERED

TYPE OF CANCER	8 I.C.D.	9 I.C.D.	ABBREVIATION
Mouth or pharynx	140-149	140-149	MPHA
Oesophagus	150	150	OESO
Stomach	151	151	STOM
Colon +	153	153	COLO
Rectum +	154	154	RECT
Intestines total, chiefly colon and rectum	152-154	152-154+159	INTE
Liver	155	155.0	LIVE
Gallbladder and bile ducts	156	156	GALL
Pancreas	157	157	PANC
Larynx	161	161	LARY
Trachea, bronchus and lung	162	162	LUNG
Pleura	163.0	163	PLEU
Bone	170	170	BONE
Connective and soft tissue sarcomas	171	171	CONN
Melanoma of the skin +	172	172	MELA
Non-melanomatous skin neoplasms +	173	173	SKIN
Skin, including melanoma ++	172-173	172-173	SKIT
Breast (females)	174	174	BREA
Cervix uteri +	180	180	CERV
Corpus uteri +	182	182	CORP
Uterus (cervix and corpus) ++	180-182	179-182	UTER
Ovary	183	183	OVAR
Prostate	185	185	PROS
Testis	186	186	TEST
Bladder	188	188	BLAD
Kidney and other urinary sites	189	189	KYDN
Eye	190	190	EYE
Brain and nerves, malignant	191-192	191-192	BRAI
Thyroid	193	193	THYR
Hodgkin's disease	201	201	HODG
All other lymphomas	200+202+208+209	200+202	NHOD
Multiple myeloma	203	203	MMYE
Leukaemias	204-207	204-208	LEUK
Unknown or uncertain primary site +	159+163.9+195-199	159+165+195-199	UNKN
Total, all sites, all histologies #	140-209	140-208	TOTA

+ Incidence only ; ++ Mortality only; # As regards incidence, non-melanomatous skin neoplasms (ICD-9 : 173) were excluded.

AVERAGE AGE-STANDARDIZED (WORLD) INCIDENCE RATES PER 100,000 IN EUROPEAN CANCER REGISTRY REGIONS, 1978-82.

Mouth or pharynx (ICD-9 : 140-9)





SEX RATIOS (M/F) FOR INCIDENCE IN EUROPEAN CANCER REGISTRY REGIONS, 1978-82 (RANKED).

1	FRANCE, BAS-RHIN	15.3
2	FRANCE, CALVADOS	13.5
3	FRANCE, DOUBS	12.7
4	YUGOSLAVIA, SLOVENIA	11.1
5	SPAIN, ZARAGOZA	9.3
6	FRANCE, ISERE	9.3
7	SPAIN, TARRAGONA	8.6
8	ITALY, RAGUSA	8.3
9	SPAIN, NAVARRA	7.9
10	HUNGARY, SZABOLCS	7.8
11	CZECH., SLOVAKIA	7.7
12	ITALY, VARESE	7.4
13	SWITZERLAND, BASEL	6.7
14	IRELAND, SOUTHERN	6.3
15	ITALY, PARMA	5.8
16	SWITZERLAND, VAUD	5.6
17	HUNGARY, VAS	5.5
18	SWITZERLAND, GENEVA	5.3
19	FRG, SAARLAND	4.8
20	ROMANIA, COUNTY CLUJ	4.7
21	SWITZERLAND, ZURICH	4.5
22	GERMAN DEM. REP.	4.3
23	POLAND, NOWY SĄCZ	4.2
24	POLAND, WARSAW CITY	3.9
25	FRG, HAMBURG	3.6
26	SWITZERLAND, NEUCHÂTEL	3.4
27	FINLAND	3.4
28	NORWAY	3.3
29	DENMARK	3.0
30	UK, EAST SCOTLAND	2.8
31	UK, SOUTH THAMES	2.7
32	UK, BIRMINGHAM	2.7
33	UK, NORTH WESTERN	2.6
34	UK, WEST SCOTLAND	2.5
35	UK, NORTH SCOTLAND	2.5
36	UK, NE SCOTLAND	2.4
37	ICELAND	2.3
38	UK, OXFORD	2.3
39	NETH., EINDHOVEN	2.3
40	UK, NORTH WESTERN	2.2
41	UK, SOUTH WESTERN	2.1
42	UK, MERSEY	2.1
43	UK, SE SCOTLAND	2.1
44	UK, SOUTH THAMES	2.0
45	UK, TRENT	2.0

SOURCE : Muir et al., 1987.

AVERAGE AGE-STANDARDIZED (WORLD) MORTALITY RATES  
PER 100,000 IN EUROPEAN COUNTRIES, 1978-82.

Mouth or pharynx (ICD-9 : 140-9)



SOURCE: WHO

SEX RATIOS (M/F) FOR MORTALITY IN EUROPEAN COUNTRIES, 1978-82 (RANKED).

1	FRANCE	12.9
2	AUSTRIA	7.3
3	ITALY	6.9
4	SPAIN	6.8
5	HUNGARY	6.7
6	LUXEMBOURG	6.0
7	SWITZERLAND	5.9
8	PORTUGAL	5.8
9	YUGOSLAVIA	5.7
10	CZECHOSLOVAKIA	5.7
11	FRG	5.1
12	POLAND	4.7
13	GDR	4.4
14	BELGIUM	4.3
15	ROMANIA	4.0
16	BULGARIA	3.2
17	NORWAY	2.9
18	IRELAND	2.9
19	SWEDEN	2.9
20	GREECE	2.7
21	NETHERLANDS	2.6
22	DENMARK	2.2
23	ENGLAND & WALES	2.2
24	FINLAND	2.1
25	SCOTLAND	2.1
26	NORTHERN IRELAND	1.7


In males, the overall variation was about ten-fold, with high incidence areas in the four French registries followed by the French speaking part of Switzerland, Slovenia (Yugoslavia), Italy and Spain. In Calvados, the oral cavity was the first-ranked site for incidence in males, even higher than the lung. Lowest incidence areas for males were in various British registries, and Hamburg (Federal Republic of Germany). In females

incidence was high in Scotland, together with the French speaking part of Switzerland and France. The range of variation in females was about four-fold, and the sex ratio ranged between 15 in Bas-Rhin to 2 in most British registries. The figures for mortality are generally comparable to incidence, with a substantial excess in France for males, whose rate is about double than the second one in Hungary, followed by Luxem-

bourg, Switzerland and Italy. Lowest mortality rates were registered in Greece, Scandinavian countries and the United Kingdom. In females, mortality rates, too, were high in Scotland, Ireland, Denmark, England and Wales, and low in Bulgaria, German Democratic Republic, Austria, Greece and Spain.

AVERAGE AGE-STANDARDIZED (WORLD) INCIDENCE RATES  
PER 100,000 IN EUROPEAN CANCER REGISTRY REGIONS, 1978-82.

Oesophagus (ICD-9 : 150)





SOURCE : Muir et al., 1987.

SEX RATIOS (MF) FOR INCIDENCE IN EUROPEAN CANCER REGISTRY REGIONS, 1978-82 (RANKED).

Rank	Region	Sex Ratio (MF)
1	HUNGARY, VAS	29.0
2	HUNGARY, SZABOLCS	25.0
3	FRANCE, CALVADOS	24.9
4	FRANCE, DOUBS	20.3
5	FRANCE, BAS-RHIN	16.7
6	CZECH., SLOVAKIA	13.7
7	SPAIN, TARRAGONA	13.2
8	SPAIN, ZARAGOZA	12.2
9	POLAND, NOWY SĄCZ	12.0
10	FRANCE, ISERE	11.4
11	ITALY, VARESE	11.4
12	SPAIN, NAVARRA	9.9
13	SWITZERLAND, GENEVA	9.0
14	YUGOSLAVIA, SLOVENIA	8.9
15	ITALY, RAGUSA	8.2
16	FRG, SAARLAND	7.0
17	GERMAN DEM. REP.	6.0
18	ROMANIA, COUNTY CLUJ	6.0
19	SWITZERLAND, BASEL	5.9
20	SWITZERLAND, NEUCHÂTEL	5.4
21	SWITZERLAND, ZÜRICH	5.3
22	FRG, HAMBURG	4.8
23	ITALY, PARMA	4.6
24	POLAND, WARSAW CITY	4.5
25	SWITZERLAND, VAUD	4.4
26	SWITZERLAND, GENEVA	4.1
27	POLAND, CRACOW CITY	4.1
28	NETH., EINDHOVEN	3.9
29	NORWAY	3.8
30	SWEDEN	3.6
31	DENMARK	2.4
32	UK, NE SCOTLAND	2.2
33	UK, NORTH SCOTLAND	2.0
34	UK, WEST SCOTLAND	2.0
35	UK, TRENT	2.0
36	UK, NORTH WESTERN	1.9
37	UK, SOUTH WESTERN	1.9
38	UK, SOUTH THAMES	1.9
39	UK, MERSEY	1.9
40	ICELAND	1.8
41	UK, SE SCOTLAND	1.7
42	UK, EAST SCOTLAND	1.6
43	UK, BIRMINGHAM	1.6
44	FINLAND	1.5
45	IRELAND, SOUTHERN	1.4
46	UK, OXFORD	1.2

AVERAGE AGE-STANDARDIZED (WORLD) MORTALITY RATES  
PER 100,000 IN EUROPEAN COUNTRIES, 1978-82.

Oesophagus (ICD-9 : 150)



SOURCE: WHO

SEX RATIOS (M/F) FOR MORTALITY IN EUROPEAN COUNTRIES, 1978-82 (RANKED):

Rank	Country	Sex Ratio (M/F)
1	FRANCE	12.7
2	AUSTRIA	7.4
3	HUNGARY	7.4
4	SWITZERLAND	7.3
4	CZECHOSLOVAKIA	7.3
6	SPAIN	6.3
7	ITALY	5.7
8	FRG	5.4
9	GFR	5.2
10	LUXEMBOURG	5.1
11	YUGOSLAVIA	5.0
12	POLAND	4.9
13	NORWAY	4.2
14	BELGIUM	4.0
15	NETHERLANDS	3.7
16	PORTUGAL	3.5
17	ROMANIA	3.4
18	BULGARIA	3.3
19	GREECE	3.1
20	DENMARK	3.0
21	NETHERLANDS	2.9
22	NORTHERN IRELAND	2.1
22	ENGLAND & WALES	2.1
24	SCOTLAND	2.0
25	FINLAND	1.6
25	IRELAND	1.6


In males, high incidence rates were recorded in France, Scotland and French speaking Swiss registries and in Varese, Northern Italy. Spain, England, Wales and Germany tended to have intermediate rates, while incidence was low generally in Eastern countries and Scandinavia. The ratio between the highest and lowest registry was 25 for males. As for oral cavity, the highest incidence rates for females were found in Scotland

and other British registries; the French speaking part of Switzerland and France were intermediate; Eastern countries, Italy and Spain had the lowest rates. The sex ratio for incidence was high in France, Spain and Italy (ranging between 25 and 11), and low in the United Kingdom (around 1). Mortality closely corresponds to the incidence figures, with an exceedingly high rate in France for males, and

in the U.K. (particularly Scotland) for females. Lowest mortality rates were observed in Eastern countries, Norway and Sweden. It is possible that the low rates in Eastern Europe could be due to classification problems with stomach cancer for tumours arising in the cardiac region, since rates for stomach cancer are very high in these countries.

AVERAGE AGE-STANDARDIZED (WORLD) INCIDENCE RATES  
PER 100,000 IN EUROPEAN CANCER REGISTRY REGIONS, 1978-82.



Stomach (ICD-9 : 151)



SOURCE : Muir et al., 1987.

AVERAGE AGE-STANDARDIZED (WORLD) MORTALITY RATES  
PER 100,000 IN EUROPEAN COUNTRIES, 1978-82.

Stomach (ICD-9 : 151)



SOURCE: WHO

SEX RATIOS (MF) FOR MORTALITY IN EUROPEAN COUNTRIES, 1978-82 (RANKED):

1	POLAND	2.6
2	ROMANIA	2.4
2	NETHERLANDS	2.4
4	FRANCE	2.3
4	ENGLAND & WALES	2.3
4	HUNGARY	2.3
7	SCOTLAND	2.1
7	CZECHOSLOVAKIA	2.1
7	ITALY	2.1
7	BELGIUM	2.1
7	YUGOSLAVIA	2.1
7	GDR	2.1
7	AUSTRIA	2.1
7	SWITZERLAND	2.1
15	PORTUGAL	2.0
15	LUXEMBOURG	2.0
15	SPAIN	2.0
15	NORWAY	2.0
15	DENMARK	2.0
20	NORTHERN IRELAND	1.9
20	FINLAND	1.9
20	FRG	1.9
20	SWEDEN	1.9
24	IRELAND	1.8
24	GREECE	1.8
26	BULGARIA	1.7

In both sexes, the highest incidence rates were in Northern Italy and Eastern European countries. Rates were low in France, Switzerland, but also Southern Italy and Spain. The range of variation in incidence


was around 4 in both sexes, and sex ratios were around 2 in most registries.

Mortality was highest in Eastern countries, Portugal and Austria for both sexes, and lowest in Greece,

France, Switzerland and Scandinavian countries, with an overall range of variation of about 3 in both sexes.

AVERAGE AGE-STANDARDIZED (WORLD) INCIDENCE RATES  
PER 100,000 IN EUROPEAN CANCER REGISTRY REGIONS, 1978-82.


Colon (ICD-9 : 153)



SOURCE : Muir et al., 1987.

AVERAGE AGE-STANDARDIZED (WORLD) INCIDENCE RATES  
PER 100,000 IN EUROPEAN CANCER REGISTRY REGIONS, 1978-82.



Rectum (ICD-9 : 154)



SOURCE : Muir et al., 1987.

AVERAGE AGE-STANDARDIZED (WORLD) INCIDENCE RATES  
PER 100,000 IN EUROPEAN CANCER REGISTRY REGIONS, 1978-82.

Intestines, chiefly colon and rectum (ICD-9 : 152-4)





SOURCE: Muir et al., 1987.

SEX RATIOS (M/F) FOR INCIDENCE IN EUROPEAN  
CANCER REGISTRY REGIONS, 1978-82 (RANKED).

1	FRANCE, BAS-RHIN	1.8
2	SWITZERLAND, BASEL	1.7
3	FRANCE, CALVADOS	1.6
3	SWITZERLAND, ZÜRICH	1.6
5	HUNGARY, VAS	1.5
5	ITALY, PARMA	1.5
5	FRANCE, DOUBS	1.5
5	CZECH, SLOVAKIA	1.5
5	ITALY, VARESE	1.5
5	FRANCE, ISERE	1.5
5	FRANCE, EBRE	1.5
12	POLAND, CRACOW CITY	1.5
12	SPAIN, NAVARRA	1.4
12	SWITZERLAND, GENEVA	1.4
12	SWITZERLAND, VAUD	1.4
12	HUNGARY, SZABOLCS	1.4
12	FRG, SAARLAND	1.4
12	UK, NORTH WESTERN	1.4
12	YUGOSLAVIA, SLOVENIA	1.4
12	ITALY, RAGUSA	1.4
12	UK, TRENT	1.4
12	UK, BIRMINGHAM	1.4
12	UK, BIRMINGHAM	1.4
12	POLAND, WARSAW CITY	1.4
12	SWITZERLAND, NEUCHÂTEL	1.4
24	POLAND, NOWY SĄCZ	1.3
24	UK, MERSEY	1.3
24	UK, WEST SCOTLAND	1.3
24	SPAIN, ZARAGOZA	1.3
24	UK, NORTH SCOTLAND	1.3
24	UK, SOUTH WESTERN	1.3
24	UK, OXFORD	1.3
24	SPAIN, TARRAGONA	1.3
32	UK, NE SCOTLAND	1.2
32	NETH, EINDHOVEN	1.2
32	UK, EAST SCOTLAND	1.2
32	UK, SOUTH THAMES	1.2
32	ROMANIA, COUNTY CLUJ	1.2
32	FRG, HAMBURG	1.2
32	SWEDEN	1.2
32	DENMARK	1.2
32	IRELAND, SOUTHERN	1.2
32	GERMAN DEM. REP.	1.2
32	FINLAND	1.2
32	NORWAY	1.2
44	UK, SE SCOTLAND	1.1
44	ICELAND	1.1

AVERAGE AGE-STANDARDIZED (WORLD) MORTALITY RATES  
PER 100,000 IN EUROPEAN COUNTRIES, 1978-82.

Intestines, chiefly colon and rectum (ICD-9 : 152-4, 159) #



SEX RATIOS (M/F) FOR MORTALITY IN EUROPEAN COUNTRIES, 1978-82 (RANKED).

1	FRANCE	1.6
1	CZECHOSLOVAKIA	1.6
3	SWITZERLAND	1.5
3	AUSTRIA	1.5
5	ITALY	1.4
5	LUXEMBOURG	1.4
5	YUGOSLAVIA	1.4
8	ENGLAND & WALES	1.3
8	BULGARIA	1.3
8	HUNGARY	1.3
8	PORTUGAL	1.3
8	DENMARK	1.3
8	BELGIUM	1.3
8	SWEDEN	1.3
8	FRG	1.3
8	POLAND	1.3
8	SCOTLAND	1.3
8	IRELAND	1.3
8	NETHERLANDS	1.3
8	FINLAND	1.3
8	SPAIN	1.3
22	GDR	1.2
22	NORWAY	1.2
22	NORTHERN IRELAND	1.2
25	ROMANIA	1.1
25	GREECE	1.1


We decided to maintain the distinction between colon and rectum for incidence, but not for mortality whose data on exact localisation are too imprecise and unreliable. Furthermore, a large proportion of cases in several countries is simply certified as "intestines, unspecified site of origin". In both sexes, colon cancer incidence was elevated in Scotland and low in Eastern

countries, Spain and Finland. Low incidence areas were similar for rectal cancer, while the highest incidence area was observed in Germany, and Scotland was intermediate. A large number of registries was clustered around similar, intermediate rates. The sex ratio in incidence ranged between 1 and 2.

In both sexes, mortality rates for all intestinal sites were high in Denmark and in a few Central European countries (Czechoslovakia, Hungary, Austria), and low in Greece, other Southern European countries, and also Finland and Poland.

AVERAGE AGE-STANDARDIZED (WORLD) INCIDENCE RATES PER 100,000 IN EUROPEAN CANCER REGISTRY REGIONS, 1978-82.

Liver (ICD-9 : 155)





SOURCE: Muir et al., 1987.

SEX RATIOS (M/F) FOR INCIDENCE IN EUROPEAN CANCER REGISTRY REGIONS, 1978-82 (RANKED).

1	FRANCE, CALVADOS	12.6
2	SWITZERLAND, GENEVA	6.8
3	SWITZERLAND, BASEL	5.8
4	FRANCE, BAS-RHIN	4.6
5	FRANCE, ISERE	4.2
6	UK, NORTH SCOTLAND	4.2
7	SWITZERLAND, VAUD	4.1
8	FRANCE, DOUBS	3.7
9	SWITZERLAND, ZÜRICH	3.6
10	HUNGARY, VAS	3.1
11	HUNGARY, SZABOLCS	2.9
12	FRG, HAMBURG	2.8
13	ITALY, VARESE	2.8
14	ITALY, VARESE	2.8
15	SWITZERLAND, NEUCHÂTEL	2.8
16	ITALY, PARMA	2.6
17	GERMAN DEM. REP.	2.6
18	UK, NE SCOTLAND	2.5
19	UK, WEST SCOTLAND	2.5
20	UK, OXFORD	2.3
21	UK, SOUTH THAMES	2.3
22	UK, BIRMINGHAM	2.2
23	UK, NORTH WESTERN	2.1
24	UK, SE SCOTLAND	2.1
25	ROMANIA, COUNTY CLUJ	2.1
26	NETH., EINDHOVEN	2.0
27	UK, MERSEY	1.9
28	POLAND, NOWY SĄCZ	1.9
29	CZECH., SLOVAKIA	1.8
30	FRG, SAARLAND	1.8
31	ICELAND	1.8
32	UK, TRENT	1.8
33	UK, EAST SCOTLAND	1.8
34	SPAIN, TARRAGONA	1.6
35	SWEDEN	1.7
36	FINLAND	1.7
37	SPAIN, NAVARRA	1.7
38	YUGOSLAVIA, SLOVENIA	1.7
39	NORWAY	1.6
40	POLAND, WARSAW CITY	1.6
41	DENMARK	1.6
42	UK, SOUTH WESTERN	1.5
43	ITALY, RAGUSA	1.4
44	SPAIN, ZARAGOZA	1.3
45	POLAND, CRACOW CITY	1.3
	IRELAND, SOUTHERN	0.3

AVERAGE AGE-STANDARDIZED (WORLD) MORTALITY RATES  
PER 100,000 IN EUROPEAN COUNTRIES, 1978-82.

Liver (ICD-9 : 155.0)



SOURCE: WHO.

SEX RATIOS (M/F) FOR MORTALITY IN EUROPEAN COUNTRIES, 1978-82 (RANKED).

1	FRANCE	4.5
2	SWITZERLAND	3.5
3	AUSTRIA	2.7
4	SCOTLAND	2.4
4	ENGLAND & WALES	2.4
6	FRS	2.3
7	NETHERLANDS	2.2
7	ROMANIA	2.2
9	GREECE	2.1
9	ITALY	2.1
9	PORTUGAL	2.1
13	HUNGARY	2.0
14	IRELAND	1.9
15	NORWAY	1.8
15	CZECHOSLOVAKIA	1.8
17	BELGIUM	1.7
17	SWEDEN	1.7
17	YUGOSLAVIA	1.7
20	BULGARIA	1.6
20	FINLAND	1.6
22	LUXEMBOURG	1.5
22	NORTHERN IRELAND	1.5
24	SPAIN	1.4
24	DENMARK	1.4
26	POLAND	1.1


Liver cancer incidence and, particularly, mortality rates should be interpreted with utmost caution, since the liver is a common site of secondaries and diagnosis and certification are often unreliable [2]. For males, the highest incidence rates were observed in Switzerland, Northern Italy, Spain and France, while for

females incidence was high in Spain, Poland and other Eastern countries, but low in France. In both sexes, low incidence rates were observed in the U.K. The sex ratio was highest in Calvados (12.6) and around 5-6 in Swiss registries. This can be related to the role of alcohol in the aetiology of this neoplasm, since the

same pattern was observed for other alcohol-related neoplasms (mouth or pharynx, oesophagus) [2]. For both sexes, certified mortality was high in Spain and Eastern countries, but low in Portugal and Northern Europe.

AVERAGE AGE-STANDARDIZED (WORLD) INCIDENCE RATES  
PER 100,000 IN EUROPEAN CANCER REGISTRY REGIONS, 1978-82.



Gallbladder and bile ducts (ICD-9 : 156)



SOURCE : Muir et al., 1987.

AVERAGE AGE-STANDARDIZED (WORLD) MORTALITY RATES PER 100,000 IN EUROPEAN COUNTRIES, 1978-82.

Gallbladder and bile ducts (ICD-9 : 156)



SOURCE: WHO.

SEX RATIOS (M/F) FOR MORTALITY IN EUROPEAN COUNTRIES, 1978-82 (RANKED).


1	ENGLAND & WALES	0.9
1	SCOTLAND	0.9
3	NORWAY	0.8
3	BELGIUM	0.8
3	IRELAND	0.8
6	NORTHERN IRELAND	0.7
6	FRANCE	0.7
6	ITALY	0.7
9	NETHERLANDS	0.6
9	DENMARK	0.6
9	AUSTRIA	0.6
9	SWITZERLAND	0.6
9	CZECHOSLOVAKIA	0.6
9	LUXEMBOURG	0.6
9	FINLAND	0.6
9	GREECE	0.6
9	BULGARIA	0.6
9	FRG	0.6
9	SWEDEN	0.6
20	SPAIN	0.5
20	YUGOSLAVIA	0.5
22	HUNGARY	0.4
23	GDR	0.0
24	POLAND	0.0
25	PORTUGAL	0.0
26	ROMANIA	0.0

This is one of the few anatomical sites with a similar function in either sex where the incidence and mortality rates are higher in females than in males. The sex ratios in incidence were around 0.5 for most registries. In both sexes, registered incidence was elevated in

urban Poland, Germany and Czechoslovakia and low in Romania, U.K. and France. Italian incidence rates tended to be elevated, but are somewhat inconsistent especially between the two sexes.

Mortality from gallbladder cancer was highest in Central Europe (Hungary, Czechoslovakia, Germany) and in Nordic Countries (except Norway), but low in Britain and Southern Europe (Greece, Bulgaria, Spain).

AVERAGE AGE-STANDARDIZED (WORLD) INCIDENCE RATES  
PER 100,000 IN EUROPEAN CANCER REGISTRY REGIONS, 1978-82.  
Pancreas (ICD-9 : 157)





SOURCE : Muir et al., 1987.

SEX RATIOS (M/F) FOR INCIDENCE IN EUROPEAN CANCER REGISTRY REGIONS, 1978-82 (RANKED).

1	SWITZERLAND, NEUCHÂTEL	2.5
1	FRANCE, BAS-RHIN	2.5
3	FRANCE, DOUBS	2.3
4	ROMANIA, COUNTY CLUJ	2.1
5	FRANCE, CALVADOS	2.0
5	SPAIN, ZARAGOZA	2.0
7	FRANCE, ISERE	1.9
7	ITALY, VARESE	1.9
9	CZECH, SLOVAKIA	1.8
9	POLAND, WARSAW CITY	1.8
9	SPAIN, NAVARRA	1.8
9	GERMAN DEM. REP.	1.8
9	FRG, SAARLAND	1.8
9	UK, BIRMINGHAM	1.8
9	UK, MERSEY	1.8
16	YUGOSLAVIA, SLOVENIA	1.7
16	SWITZERLAND, VAUD	1.7
16	UK, NORTH WESTERN	1.7
19	UK, SOUTH THAMES	1.6
19	ITALY, PARMA	1.6
19	SPAIN, TARRAGONA	1.6
19	NETH., EINDHOVEN	1.6
19	SWITZERLAND, GENEVA	1.6
19	ITALY, RAGUSA	1.6
19	NORWAY	1.6
19	UK, SE SCOTLAND	1.6
19	HUNGARY, SZABOLCS	1.6
19	FINLAND	1.6
19	POLAND, CRACOW CITY	1.6
19	UK, NE SCOTLAND	1.6
31	UK, OXFORD	1.5
31	POLAND, NOWY SĄCZ	1.5
31	FRG, HAMBURG	1.5
31	UK, SOUTH WESTERN	1.5
31	UK, TRENT	1.5
31	IRELAND	1.5
37	HUNGARY, VAS	1.4
37	UK, NORTH SCOTLAND	1.4
37	IRELAND, SOUTHERN	1.4
37	SWITZERLAND, ZÜRICH	1.4
37	SWITZERLAND, BASEL	1.4
37	SWEDEN	1.4
43	UK, WEST SCOTLAND	1.3
43	DENMARK	1.3
45	UK, EAST SCOTLAND	1.2

AVERAGE AGE-STANDARDIZED (WORLD) MORTALITY RATES  
PER 100,000 IN EUROPEAN COUNTRIES, 1978-82.

Pancreas (ICD-9 : 157)



SOURCE: WHO

SEX RATIOS (M/F) FOR MORTALITY IN EUROPEAN COUNTRIES, 1978-82 (RANKED).

1	LUXEMBOURG	2.3
2	FRANCE	2.1
3	ROMANIA	1.9
4	SPAIN	1.8
4	ITALY	1.8
4	GREECE	1.8
7	BELGIUM	1.7
7	CZECHOSLOVAKIA	1.7
7	BULGARIA	1.7
7	PORTUGAL	1.7
7	NETHERLANDS	1.7
7	GDR	1.7
7	YUGOSLAVIA	1.7
14	ENGLAND & WALES	1.6
14	FRG	1.6
14	POLAND	1.6
14	NORWAY	1.6
14	SWITZERLAND	1.6
14	HUNGARY	1.6
14	AUSTRIA	1.6
21	NORTHERN IRELAND	1.5
21	IRELAND	1.5
21	SCOTLAND	1.5
24	IRELAND	1.4
24	SWEDEN	1.4
26	DENMARK	1.3


This is another site with major diagnosis and classification problems. In both sexes, incidence rates were high in the U.K., Scandinavian countries and urban Poland, and low in France and Spain. The overall range of

variation was over 3 in both sexes and the sex ratio was between 1 and 2 in most registries, except France where it tended to be greater than 2.

Mortality figures were reasonably consistent with incidence, with highest rates in Northern Europe and lowest in Spain, Portugal and Greece, but the U.K. had intermediate values.

AVERAGE AGE-STANDARDIZED (WORLD) INCIDENCE RATES PER 100,000 IN EUROPEAN CANCER REGISTRY REGIONS, 1978-82.



Larynx (ICD-9 : 161)



SOURCE : Muir et al., 1987.

AVERAGE AGE-STANDARDIZED (WORLD) MORTALITY RATES  
PER 100,000 IN EUROPEAN COUNTRIES, 1978-82.

Larynx (ICD-9 : 161)



SOURCE: WHO

SEX RATIOS (M/F) FOR MORTALITY IN EUROPEAN COUNTRIES, 1978-82 (RANKED).

1	FINLAND	30.9
2	SPAIN	30.2
3	FRANCE	29.9
4	GDR	26.9
5	CZECHOSLOVAKIA	21.6
6	ITALY	21.5
7	AUSTRIA	21.3
8	SWITZERLAND	17.5
9	LUXEMBOURG	16.1
10	GREECE	15.6
11	FRG	15.4
12	POLAND	15.2
13	HUNGARY	13.8
14	NETHERLANDS	13.4
15	BELGIUM	12.9
16	PORTUGAL	12.8
17	YUGOSLAVIA	11.9
18	BULGARIA	10.9
19	NORWAY	10.0
20	ROMANIA	9.4
21	SWEDEN	8.4
22	DENMARK	6.2
23	ENGLAND & WALES	4.6
24	SCOTLAND	4.5
25	IRELAND	3.9
26	NORTHERN IRELAND	3.2


This is the non sex-related site with the highest sex ratio, ranging between over 100 in Tarragona, Spain, and about 3 in England, Scotland and Ireland. In general, the sex ratios tended to be low in the U.K. for all tobacco-related sites, probably reflecting the longer duration of smoking among British women [2, 3]. Incidence rates for males were high in Spain and Northern

Italy, but not particularly elevated in a few areas of France (such as Calvados), where the highest rates for cancers of the oral cavity and oesophagus are registered. Overall national mortality for males, nonetheless, was highest in France, followed by Spain and Italy. Among men, both incidence and mortality were low in the

U.K. and other Northern European countries. Rates for females are less stable, in consideration of the lower absolute numbers. The overall pattern, however, is apparently different, since both incidence and mortality tend to be high in Ireland and the U.K.

AVERAGE AGE-STANDARDIZED (WORLD) INCIDENCE RATES  
PER 100,000 IN EUROPEAN CANCER REGISTRY REGIONS, 1978-82.



Trachea, bronchus and lung (ICD-9 : 162)



SOURCE : Muir et al., 1987.

AVERAGE AGE-STANDARDIZED (WORLD) MORTALITY RATES  
PER 100,000 IN EUROPEAN COUNTRIES, 1978-82.

Trachea, bronchus and lung (ICD-9 : 162)



SOURCE : WHO

SEX RATIOS (M/F) FOR MORTALITY IN EUROPEAN COUNTRIES, 1978-82 (RANKED).

1	NETHERLANDS	12.8
2	BELGIUM	12.5
3	LUXEMBOURG	11.7
4	FINLAND	11.4
5	FRANCE	11.0
6	CZECHOSLOVAKIA	10.3
7	GDR	9.9
8	SWITZERLAND	9.3
9	ITALY	8.9
10	SPAIN	8.7
11	FRG	8.5
12	POLAND	8.0
13	GREECE	7.0
14	AUSTRIA	6.7
15	BULGARIA	6.3
16	YUGOSLAVIA	6.1
17	HUNGARY	5.9
18	PORTUGAL	5.5
19	ROMANIA	5.4
20	NORWAY	4.6
21	ENGLAND & WALES	4.0
22	NORTHERN IRELAND	4.0
23	SCOTLAND	3.8
24	DENMARK	3.6
25	SWEDEN	3.4
26	IRELAND	3.0


In males (excluding non-melanomatous skin neoplasms), lung cancer was the first ranked incident site in most registries, except Calvados (mouth or pharynx), Iceland, Norway and Sweden (prostate). Incidence rates were highest in Scotland and other British registries, and lowest in Iceland, Southern Spain and Southern Italy. In females, the highest inci-

dence rates were, again, in Scotland and the U.K., but rates were elevated in Iceland and Denmark, too. The lowest rates for females were registered in France, Southern Italy and Spain. The overall range of variation was about 4 in males and 10 in females, and the sex ratios were highest (between 10 and 18) in France and Italy.

For both sexes, the highest mortality rates were in Scotland and the lowest in Portugal, and all-age mortality tended to be high in the U.K. and low in Southern Europe, Norway and Sweden being low in females, too.

AVERAGE AGE-STANDARDIZED (WORLD) INCIDENCE RATES PER 100,000 IN EUROPEAN CANCER REGISTRY REGIONS, 1978-82.

Pleura (ICD-9 : 163)





SOURCE : Muir et al., 1987.

SEX RATIOS (M/F) FOR INCIDENCE IN EUROPEAN CANCER REGISTRY REGIONS, 1978-82 (RANKED).

1	SWITZERLAND, ZURICH	13.0
2	FRANCE, ISERE	9.0
3	UK, SOUTH WESTERN	9.0
4	NORWAY	8.0
5	UK, TRENT	6.0
6	UK, WEST SCOTLAND	6.0
7	YUGOSLAVIA, SLOVENIA	6.0
8	FRG, HAMBURG	5.5
9	UK, BIRMINGHAM	5.0
10	UK, OXFORD	4.5
11	UK, SE SCOTLAND	4.5
12	FRANCE, BAS-RHIN	4.0
13	POLAND, WARSAW CITY	4.0
14	SWITZERLAND, BASEL	4.0
15	UK, SOUTH THAMES	4.0
16	UK, MERSEY	4.0
17	UK, NE SCOTLAND	4.0
18	GERMAN DEM. REP.	3.7
19	SWITZERLAND, NEUCHÂTEL	3.7
20	FINLAND	3.5
21	ITALY, VARESE	3.5
22	SWEDEN	3.3
23	DENMARK	3.0
24	HUNGARY, SZABOLCS	3.0
25	HUNGARY, VAS	3.0
26	UK, NORTH WESTERN	2.7
27	FRANCE, CALVADOS	2.5
28	NETH., EINDHOVEN	2.0
29	ROMANIA, COUNTY CLUJ	2.0
30	SPAIN, NAVARRA	2.0
31	SWITZERLAND, VAUD	2.0
32	FRANCE, DOUBS	1.8
33	CZECH., SLOVAKIA	1.5
34	FRG, SAARLAND	1.5
35	UK, NORTH SCOTLAND	1.5
36	ITALY, PARMA	1.3
37	SWITZERLAND, GENEVA	1.3
38	SPAIN, ZARAGOZA	1.2
39	POLAND, CRACOW CITY	0.8
40	SPAIN, TARRAGONA	0.8
41	ICELAND	0.2
42	IRELAND, SOUTHERN	
43	ITALY, RAGUSA	
44	POLAND, NOWY SĄCZ	
45	UK, EAST SCOTLAND	

AVERAGE AGE-STANDARDIZED (WORLD) MORTALITY RATES  
PER 100,000 IN EUROPEAN COUNTRIES, 1978-82.

Pleura (ICD-9 : 163)



SOURCE :WHO

SEX RATIOS (M/F) FOR MORTALITY IN EUROPEAN COUNTRIES, 1978-82 (RANKED).

1	SCOTLAND	9.8
2	NORWAY	6.2
3	NETHERLANDS	6.0
4	SWITZERLAND	4.2
5	ENGLAND & WALES	4.1
6	NORTHERN IRELAND	3.7
7	FINLAND	2.9
8	FRANCE	2.7
9	CZECHOSLOVAKIA	2.5
10	BELGIUM	2.5
11	ITALY	2.3
12	DENMARK	2.2
13	IRELAND	2.2
14	FRG	2.2
15	YUGOSLAVIA	1.7
16	SPAIN	1.6
17	HUNGARY	1.6
18	LUXEMBOURG	1.4
19	AUSTRIA	1.2
20	GREECE	1.0
21	BULGARIA	0.7
22	GER	0.0
23	POLAND	0.0
24	PORTUGAL	0.0
25	ROMANIA	0.0
26	SWEDEN	0.0

For this neoplasm, too, there are substantial diagnosis and certification difficulties and problems of random variability due to low absolute numbers. Nonetheless, highest incidence areas were in Sweden, West Scotland


and Switzerland, where important asbestos manufactures were located [4] and the highest sex ratios were around 10.

The highest recorded mortality rates for males were

found in the Netherlands, France, Italy and Finland, and the lowest ones in Greece, Bulgaria and Ireland. Problems in the interpretation of mortality data are, however, even greater than for incidence.

AVERAGE AGE-STANDARDIZED (WORLD) INCIDENCE RATES PER 100,000 IN EUROPEAN CANCER REGISTRY REGIONS, 1978-82.



Bone (ICD-9 : 170)



SOURCE : Muir et al., 1987.

AVERAGE AGE-STANDARDIZED (WORLD) MORTALITY RATES  
PER 100,000 IN EUROPEAN COUNTRIES, 1978-82.

Bone (ICD-9 : 170)



SOURCE : WHO

SEX RATIOS (M/F) FOR MORTALITY IN EUROPEAN COUNTRIES, 1978-82 (RANKED).

1	FRANCE	2.4
2	NORWAY	2.3
3	AUSTRIA	2.2
4	FINLAND	2.1
5	HUNGARY	1.9
6	ITALY	1.8
7	SPAIN	1.8
8	NORTHERN IRELAND	1.8
9	BELGIUM	1.8
10	IRELAND	1.7
10	POLAND	1.7
10	FRG	1.7
10	ROMANIA	1.7
10	DENMARK	1.7
15	GREECE	1.6
15	YUGOSLAVIA	1.6
15	ENGLAND & WALES	1.6
15	CZECHOSLOVAKIA	1.6
15	PORTUGAL	1.6
15	GDR	1.6
21	BULGARIA	1.5
22	SWITZERLAND	1.4
22	SCOTLAND	1.4
22	NETHERLANDS	1.4
25	IRELAND	1.2
26	LUXEMBOURG	1.0


This is another common site of secondaries [2]. Consequently, its incidence and, particularly, mortality data are difficult to interpret. Except for a few outliers, the variation in incidence is small in both sexes, and some

tendency is evident for low rates in several registries in the U.K. and Switzerland. The sex ratio in incidence is between 1 and 2 in most areas. Mortality rates were in both sexes high in Greece,

Portugal, Spain and several Eastern countries, and low in Norway and other Nordic countries, Switzerland and England and Wales, probably indirectly reflecting the quality of death certification.

AVERAGE AGE-STANDARDIZED (WORLD) INCIDENCE RATES PER 100,000 IN EUROPEAN CANCER REGISTRY REGIONS, 1978-82.



Connective and soft tissue sarcomas (ICD-9 : 171)



SOURCE : Muir et al., 1987.

AVERAGE AGE-STANDARDIZED (WORLD) MORTALITY RATES PER 100,000 IN EUROPEAN COUNTRIES, 1978-82.

Connective and soft tissue sarcomas (ICD-9 : 171)



SOURCE : WHO

SEX RATIOS (M/F) FOR MORTALITY IN EUROPEAN COUNTRIES, 1978-82 (RANKED).

Rank	Country	Sex Ratio (M/F)
1	YUGOSLAVIA	1.9
2	HUNGARY	1.8
2	SCOTLAND	1.8
2	NORWAY	1.8
5	CZECHOSLOVAKIA	1.7
6	IRELAND	1.5
6	DENMARK	1.5
8	NORTHERN IRELAND	1.4
8	SPAIN	1.4
8	FRANCE	1.4
8	LUXEMBOURG	1.4
8	NETHERLANDS	1.4
8	BULGARIA	1.4
8	ITALY	1.4
8	ENGLAND & WALES	1.4
8	BELGIUM	1.4
17	FRG	1.3
17	SWEDEN	1.3
19	FINLAND	1.2
19	AUSTRIA	1.2
21	SWITZERLAND	1.1
22	GREECE	1.0
23	GDR	0.0
24	POLAND	0.0
25	PORTUGAL	0.0
26	ROMANIA	0.0


There are considerable problems in the interpretation of rates from this group of neoplasms, on account of difficulties in diagnosis and certification. No clear pattern was evident, since low and high incidence areas

were rather scattered in various countries, although West German registries had high incidence rates in both sexes, and Eastern countries low rates. Mortality is even more difficult to interpret, and the apparently

high rates in Hungary, Norway, and the low ones in Italy and Bulgaria should be interpreted with due caution.

AVERAGE AGE-STANDARDIZED (WORLD) INCIDENCE RATES  
PER 100,000 IN EUROPEAN CANCER REGISTRY REGIONS, 1978-82.

Melanoma of skin (ICD-9 : 172)





SOURCE : Muir et al., 1987.

SEX RATIOS (M/F) FOR INCIDENCE IN EUROPEAN  
CANCER REGISTRY REGIONS, 1978-82 (RANKED).

1	ITALY, RAGUSA	1.9
2	SPAIN, ZARAGOZA	1.6
3	POLAND, WARSAW CITY	1.0
3	SWITZERLAND, BASEL	1.0
3	FRJ, AND	1.0
6	HUNGARY, VAS	0.9
6	ITALY, VARESE	0.9
6	SPAIN, TARRAGONA	0.9
6	SWITZERLAND, GENEVA	0.9
6	SPAIN, NAVARRA	0.9
6	YUGOSLAVIA, SLOVENIA	0.9
6	CZECH., SLOVAKIA	0.9
6	FRG, SAARLAND	0.9
6	SWEDEN	0.9
6	FRG, HAMBURG	0.9
6	SWITZERLAND, ZURICH	0.9
17	UK, SCOTLAND	0.8
17	UK, NE SCOTLAND	0.8
17	GERMAN DEM. REP.	0.8
17	SWITZERLAND, VAUD	0.8
17	ITALY, PARMA	0.8
17	ROMANIA, COUNTY CLUJ	0.8
17	UK, TRENT	0.8
24	DENMARK	0.7
24	HUNGARY, SZABOLCS	0.7
24	NETH., EINDHOVEN	0.7
24	FRANCE, BAS-RHIN	0.7
24	FRANCE, DOUBS	0.7
29	UK, WEST SCOTLAND	0.6
29	UK, MERSEY	0.6
29	UK, EAST SCOTLAND	0.6
29	SWITZERLAND, NEUCHÂTEL	0.6
29	UK, SOUTH THAMES	0.6
29	FRANCE, ISERE	0.6
29	POLAND, CRACOW CITY	0.6
29	UK, SE SCOTLAND	0.6
29	UK, OXFORD	0.6
38	IRELAND	0.5
38	UK, NORTH WESTERN	0.5
38	FRANCE, CALVADOS	0.5
38	UK, SOUTH WESTERN	0.5
38	UK, BIRMINGHAM	0.5
38	POLAND, NOWY SACZ	0.5
44	IRELAND, SOUTHERN	0.4
44	UK, NORTH SCOTLAND	0.4

AVERAGE AGE-STANDARDIZED (WORLD) MORTALITY RATES  
PER 100,000 IN EUROPEAN COUNTRIES, 1978-82.

Skin, including melanoma (ICD-9 : 172-3)



SOURCE: WHO

SEX RATIOS (M/F) FOR MORTALITY IN EUROPEAN COUNTRIES, 1978-82 (RANKED).

1	FINLAND	1.9
2	SPAIN	1.7
3	NORWAY	1.7
4	SWITZERLAND	1.6
5	BELGIUM	1.6
6	ITALY	1.5
7	CZECHOSLOVAKIA	1.5
8	NETHERLANDS	1.5
9	SWEDEN	1.5
10	AUSTRIA	1.5
11	ROMANIA	1.4
12	FRG	1.4
13	HUNGARY	1.4
14	PORTUGAL	1.4
15	FRANCE	1.4
16	YUGOSLAVIA	1.3
17	POLAND	1.3
18	GDR	1.3
19	DENMARK	1.3
20	BULGARIA	1.3
21	SCOTLAND	1.2
22	GREECE	1.2
23	ENGLAND & WALES	1.2
24	IRELAND	1.0
25	NORTHERN IRELAND	0.8
26	LUXEMBOURG	0.5



Incidence rates were presented separately for melanoma and non-melanomatous skin cancers, although the latter simply represents the different accuracy and extent of registration in various situations, rather than real variation in incidence (there was, for instance, a 60-fold difference in *registered*

incidence between Basel and Zürich). In both sexes, melanoma incidence was high in Switzerland and Nordic countries, and low in Eastern and Southern Europe. U.K., France and Germany had intermediate rates. The male/female ratios tended to be below unity for incidence, but above unity for mortality.

The pattern of incidence was well reflected in mortality figures, with high rates in Nordic countries, Switzerland, Czechoslovakia and Austria, and low rates in Mediterranean countries.

AVERAGE AGE-STANDARDIZED (WORLD) INCIDENCE RATES PER 100,000 IN EUROPEAN CANCER REGISTRY REGIONS, 1978-82.

Skin, excluding melanoma (ICD-9 : 173)




SOURCE : Muir et al., 1987.

SEX RATIOS (MF) FOR INCIDENCE IN EUROPEAN CANCER REGISTRY REGIONS, 1978-82 (RANKED).

1	FRANCE, ISERE	2.6
2	ITALY, RAGUSA	2.5
3	ITALY, SWEDEN	2.3
4	ITALY, PARMA	2.2
4	FRG, HAMBURG	2.2
6	SPAIN, ZARAGOZA	2.1
6	SPAIN, NAVARRA	2.1
8	ITALY, VARESE	1.9
9	FRANCE, BAS-RHIN	1.8
9	SWITZERLAND, ZÜRICH	1.8
11	SWITZERLAND, BASEL	1.7
11	NORWAY	1.7
11	FRANCE, CALVADOS	1.7
11	NETH., EINDHOVEN	1.7
11	UK, SE SCOTLAND	1.7
11	UK, NE SCOTLAND	1.7
11	SPAIN, TARRAGONA	1.7
11	UK, SOUTH THAMES	1.7
11	UK, WEST SCOTLAND	1.7
11	UK, NORTH SCOTLAND	1.7
21	GERMAN DEM. REP.	1.6
21	SWITZERLAND, NEUCHÂTEL	1.6
21	UK, SOUTH WESTERN	1.6
21	UK, EAST SCOTLAND	1.6
21	UK, BIRMINGHAM	1.6
21	UK, OXFORD	1.6
21	UK, BIRMINGHAM	1.6
21	SWITZERLAND, VAUD	1.6
21	UK, MERSEY	1.6
28	FRG, SAARLAND	1.5
28	UK, WEST SCOTLAND	1.5
28	POLAND, WARSAW CITY	1.5
28	SWITZERLAND, GENEVA	1.5
33	UK, TRENT	1.4
33	FRANCE, DOUBS	1.4
33	HUNGARY, VAS	1.4
33	UK, SE SCOTLAND	1.4
33	POLAND, NOWY SĄCZ	1.4
33	DENMARK	1.4
33	POLAND, CRACOW CITY	1.4
33	UK, NORTH WESTERN	1.4
41	IRELAND, SOUTHERN	1.3
41	CZECH., SLOVAKIA	1.3
41	ROMANIA, COUNTY CLUJ	1.3
44	YUGOSLAVIA, SLOVENIA	1.2
45	HUNGARY, SZABOLCS	1.1


The histograms of mortality from non-melanomatous skin cancer are not produced, on account of major problems in cancer certification reliability. These are reflected in incidence rates as well, since most of the variation is clearly due to differences in case ascertainment and certification. The histograms of incidence are nonetheless presented to illustrate and quantify the extent of this variation.

AVERAGE AGE-STANDARDIZED (WORLD) INCIDENCE RATES  
PER 100,000 IN EUROPEAN CANCER REGISTRY REGIONS, 1978-82.




SOURCE : Muir et al., 1987.

AVERAGE AGE-STANDARDIZED (WORLD) MORTALITY RATES  
PER 100,000 IN EUROPEAN COUNTRIES, 1978-82.



For breast cancer the highest incidence rates were registered in Switzerland, Netherlands and the U.K., and the lowest areas in Eastern Europe, Spain, Southern Italy and Finland. The majority of rates was, however, included within a relatively narrow range of variation (between 52 and 67/100000).




The highest mortality rates were observed in various regions of U.K., followed by the Netherlands, Belgium and Denmark, while Switzerland had an intermediate rank. The lowest mortality rates were located in Eastern countries, Spain and Greece.

Ovarian cancer incidence rates were elevated in Scandinavian countries and the U.K., and low in Spain, several Eastern countries, France and Southern Italy.


The picture is well reflected in mortality statistics, with the highest rates in Denmark and Sweden and the lowest ones in Greece, Portugal and Spain. The highest/lowest ratio was greater for mortality than for incidence (about 5 and 3, respectively), possibly reflecting the difficulties in diagnosis and certification of the disease and hence the different reliability of mortality data in various countries.

AVERAGE AGE-STANDARDIZED (WORLD) INCIDENCE RATES  
PER 100,000 IN EUROPEAN CANCER REGISTRY REGIONS, 1978-82.



SOURCE : Muir et al., 1987.

AVERAGE AGE-STANDARDIZED (WORLD) MORTALITY RATES  
PER 100,000 IN EUROPEAN COUNTRIES, 1978-82.




On the basis of incidence registration, but not of death certification, it was possible to distinguish between cervix and corpus uteri. The pattern for the two sites was largely different, and this is easily explainable in consideration of the different determinants and correlates of the two neoplasms. For cervical cancer, incidence was highest in East Germany, Poland and other

Eastern countries, Hamburg and Denmark, and low in Finland, Spain and Switzerland. The highest endometrial cancer rates were registered in two Swiss registries (Zürich and Neuchâtel), and rates were generally high in Switzerland, Germany, Hungary and Denmark, and low in Eastern countries, the U.K. and Spain. The low incidence in the U.K. is noteworthy, since it is at


variance with the pattern observed for breast cancer, a neoplasm whose epidemiology is in several aspects similar to endometrial cancer. Mortality from all uterine cancers (cervix and corpus) was elevated in Eastern countries, Denmark and Austria, but low in Greece, Finland and Ireland.

AVERAGE AGE-STANDARDIZED (WORLD) INCIDENCE RATES  
PER 100,000 IN EUROPEAN CANCER REGISTRY REGIONS, 1978-82.



SOURCE : Muir et al., 1987.

AVERAGE AGE-STANDARDIZED (WORLD) MORTALITY RATES  
PER 100,000 IN EUROPEAN COUNTRIES, 1978-82.




The highest prostatic cancer incidence rates were registered in Switzerland and in Scandinavian countries, and the lowest ones in Eastern countries and Southern Europe. Germany, France and the U.K. had intermediate values. In three countries where lung cancer is low (Iceland, Norway and Sweden), prostate was the first ranked site of incidence in males. The highest/lowest ratio for incidence was over a factor 5.

The range of variation was only about a factor 3 for mortality, but the pattern was very similar to incidence, with highest rates in Norway, Switzerland and Sweden, and the lowest ones in Romania, Bulgaria and Greece. As for cancer of the prostate, for testicular cancer, too, the highest incidence rates were registered in Switzerland, Denmark and Norway, and the lowest ones in

Southern Italy, Spain and Eastern countries. U.K., Germany and France had intermediate values. The ratio between highest and lowest registry was around a factor 10. The variation was lower in relation to mortality, and the pattern was somewhat different from that of incidence. Highest mortality rates were in East Germany, Hungary and Czechoslovakia and the lowest areas in Greece, Portugal and Spain.



AVERAGE AGE-STANDARDIZED (WORLD) INCIDENCE RATES  
PER 100,000 IN EUROPEAN CANCER REGISTRY REGIONS, 1978-82.  
Bladder (ICD-9 : 188)



SOURCE : Muir et al., 1987.

AVERAGE AGE-STANDARDIZED (WORLD) MORTALITY RATES  
PER 100,000 IN EUROPEAN COUNTRIES, 1978-82.

Bladder (ICD-9 : 188)



SOURCE : WHO

SEX RATIOS (M/F) FOR MORTALITY IN EUROPEAN COUNTRIES, 1978-82 (RANKED).

Rank	Country	Sex Ratio (M/F)
1	POLAND	7.3
2	SPAIN	6.3
3	CZECHOSLOVAKIA	6.1
4	ITALY	5.9
5	GREECE	5.8
6	HUNGARY	5.3
7	FRANCE	5.2
8	FINLAND	5.1
9	GDR	4.9
10	BULGARIA	4.8
11	NETHERLANDS	4.7
12	BELGIUM	4.5
13	FRG	4.3
14	PORTUGAL	4.3
15	YUGOSLAVIA	4.1
16	SWITZERLAND	4.1
17	ROMANIA	3.9
18	DENMARK	3.7
19	AUSTRIA	3.7
20	LUXEMBOURG	3.7
21	ENGLAND & WALES	3.5
22	NORTHERN IRELAND	3.4
23	IRELAND	3.3
24	SWEDEN	3.2
25	NORWAY	3.1
26	SCOTLAND	2.7


For males, the highest bladder cancer incidence was in Basel (Switzerland), Varese (Italy) and Denmark, and the lowest was in rural areas of Hungary and Ireland. Among females, the highest incidence rates were in Scotland, and the lowest were again in Hungary and Italy (Ragusa). Cigarette smoking and occupational exposure to chemical carcinogens are recognized risk

factors for the disease [5]. The pattern of females is well consistent with that observed for other tobacco-related risks, while that for males could reflect the concentration of chemical industries in high incidence areas. However, the distinction between papillomas and carcinomas may differ in different areas, and this could introduce artefactual variations in rates in different registries [6]. The sex ratio in incidence was about 5 in most countries, with a peak in Ragusa

(Italy) (probably due to instability of rates), but only around 3 in the U.K. The figures for mortality in males were rather scattered, with highest rates in Denmark, Belgium and Italy, and lowest ones in Sweden and some Eastern countries. Scotland, Denmark, England and Wales had the highest mortality rates for bladder cancer in females, while the lowest mortality was observed in Eastern and Southern Europe and Finland.

AVERAGE AGE-STANDARDIZED (WORLD) INCIDENCE RATES PER 100,000 IN EUROPEAN CANCER REGISTRY REGIONS, 1978-82.



Kidney and other urinary sites (ICD-9 : 189)



SOURCE : Muir et al., 1987.

AVERAGE AGE-STANDARDIZED (WORLD) MORTALITY RATES  
PER 100,000 IN EUROPEAN COUNTRIES, 1978-82.

Kidney and other urinary sites (ICD-9 : 189)



SOURCE: WHO

SEX RATIOS (M/F) FOR MORTALITY IN EUROPEAN COUNTRIES, 1978-82 (RANKED).

1	LUXEMBOURG	3.3
2	ITALY	2.4
3	CZECHOSLOVAKIA	2.3
4	FRG	2.2
4	FRANCE	2.2
4	ENGLAND & WALES	2.2
4	GREECE	2.2
9	HUNGARY	2.1
10	NORTHERN IRELAND	2.0
11	NORWAY	1.9
11	NETHERLANDS	1.9
11	SCOTLAND	1.9
11	FINLAND	1.9
15	AUSTRIA	1.8
15	BELGIUM	1.8
15	SWEDEN	1.8
15	IRELAND	1.8
19	BULGARIA	1.7
19	SWITZERLAND	1.7
21	YUGOSLAVIA	1.5
22	DENMARK	1.3
23	GER	0.0
24	POLAND	0.0
25	PORTUGAL	0.0
26	ROMANIA	0.0


In both sexes, the highest incidence rates were observed in Iceland, Sweden, a few Swiss registries and Denmark. Incidence was low in Eastern countries, Spain and Southern Italy. Scotland, England and Wales and most Central Europe had intermediate rates. This is therefore the only one tobacco-related

site for which Scottish women did not have the highest rate in Europe. However, although tobacco is related to cancer of the renal pelvis, its association with renal cell carcinoma is not proven [3]. This may explain the relatively low sex ratio, which was approximately 2 in most countries, including the U.K.

With the exception of Czechoslovakia, mortality figures were consistent with incidence, with high rates in Northern Europe, intermediate in Central Europe and lowest ones in Eastern and Southern Europe.

AVERAGE AGE-STANDARDIZED (WORLD) INCIDENCE RATES  
PER 100,000 IN EUROPEAN CANCER REGISTRY REGIONS, 1978-82.



Eye (ICD-9 : 190)



SOURCE : Muir et al., 1987.

AVERAGE AGE-STANDARDIZED (WORLD) MORTALITY RATES  
PER 100,000 IN EUROPEAN COUNTRIES, 1978-82.

Eye (ICD-9 : 190)



SOURCE: WHO

SEX RATIOS (M/F) FOR MORTALITY IN EUROPEAN COUNTRIES, 1978-82 (RANKED).

1	HUNGARY	3.8
2	IRELAND	3.0
3	BELGIUM	2.7
4	GREECE	2.1
5	AUSTRIA	1.8
6	SCOTLAND	1.6
7	ITALY	1.6
8	SWITZERLAND	1.5
9	SWEDEN	1.5
10	FRANCE	1.4
11	NORWAY	1.4
12	FRG	1.3
13	DENMARK	1.3
14	FINLAND	1.2
15	NETHERLANDS	1.2
16	YUGOSLAVIA	1.2
17	ENGLAND & WALES	1.1
18	CZECHOSLOVAKIA	1.0
19	BULGARIA	0.8
20	NORTHERN IRELAND	0.0
21	GDR	0.0
22	LUXEMBOURG	0.0
23	POLAND	0.0
24	PORTUGAL	0.0
25	ROMANIA	0.0
26	SPAIN	0.0


Incidence rates for eye cancer were low in all areas, and possibly influenced by variations in registration

completeness. Not surprisingly, therefore, the pattern is only partly consistent in the two sexes. It is difficult

to state how much of the apparent variation is real.

AVERAGE AGE-STANDARDIZED (WORLD) INCIDENCE RATES  
PER 100,000 IN EUROPEAN CANCER REGISTRY REGIONS, 1978-82.



Brain, nervous system (ICD-9 : 191-2)



SOURCE : Muir et al., 1987.

AVERAGE AGE-STANDARDIZED (WORLD) MORTALITY RATES  
PER 100,000 IN EUROPEAN COUNTRIES, 1978-82.

Brain, nervous system (ICD-9 : 191-2)



SOURCE: WHO

SEX RATIOS (M/F) FOR MORTALITY IN EUROPEAN COUNTRIES, 1978-82 (RANKED).

1	GREECE	1.8
2	YUGOSLAVIA	1.7
2	NETHERLANDS	1.7
4	FRANCE	1.6
4	ENGLAND & WALES	1.6
4	AUSTRIA	1.6
4	ITALY	1.6
8	SPAIN	1.5
8	FRG	1.5
8	CZECHOSLOVAKIA	1.5
8	HUNGARY	1.5
12	NORTHERN IRELAND	1.4
12	SWITZERLAND	1.4
12	SCOTLAND	1.4
12	NORWAY	1.4
12	BULGARIA	1.4
12	SWEDEN	1.4
18	DENMARK	1.3
18	IRELAND	1.3
18	BELGIUM	1.3
18	FINLAND	1.3
22	GDR	0.0
23	LUXEMBOURG	0.0
24	POLAND	0.0
25	PORTUGAL	0.0
26	ROMANIA	0.0


In both sexes, the highest incidence was registered in Nordic countries, but also in registries from Poland, Northern Italy and Spain. Rates were low in Hungary, Hamburg (Germany) and a few other registries from Eastern Europe and France. The rate of variation was

apparently greater for females than for males, and the sex ratio was somewhat above unity in most areas. This is another cancer site for which there are major diagnostic and certification difficulties [2], following the availability of computerized axial tomography and

other techniques. It is therefore difficult to state how much of the variation is real, particularly for mortality, and how much artefactual.

AVERAGE AGE-STANDARDIZED (WORLD) INCIDENCE RATES PER 100,000 IN EUROPEAN CANCER REGISTRY REGIONS, 1978-82.



Thyroid (ICD-9 : 193)



SOURCE : Muir et al., 1987.

AVERAGE AGE-STANDARDIZED (WORLD) MORTALITY RATES  
PER 100,000 IN EUROPEAN COUNTRIES, 1978-82.

Thyroid (ICD-9 : 193)



SOURCE : WHO

SEX RATIOS (M/F) FOR MORTALITY IN EUROPEAN COUNTRIES, 1978-82 (RANKED).

1	SWITZERLAND	0.9
2	AUSTRIA	0.8
3	DENMARK	0.8
4	ITALY	0.7
4	YUGOSLAVIA	0.7
4	FRANCE	0.7
4	FRG	0.7
4	HUNGARY	0.7
4	SCOTLAND	0.7
10	SWEDEN	0.6
10	CZECHOSLOVAKIA	0.6
10	SPAIN	0.6
10	NETHERLANDS	0.6
10	FINLAND	0.6
10	ENGLAND & WALES	0.6
10	GREECE	0.6
10	IRELAND	0.6
18	NORWAY	0.5
18	BULGARIA	0.5
18	NORTHERN IRELAND	0.5
18	BELGIUM	0.5
22	LUXEMBOURG	0.4
23	GDR	0.0
24	POLAND	0.0
25	PORTUGAL	0.0
26	ROMANIA	0.0

This is, together with gallbladder, one of the two non sex-related sites where rates were higher in females, most sex ratios in incidence and mortality being around (or less than) 0.5. By far, the highest incidence rates were from Iceland, followed by other Nordic countries (Finland, Norway, Sweden), and some registries around the Alp belt in Switzerland, Northern


Italy, Germany and France. In both sexes, the lowest rates were from the U.K., Spain and Poland.

Mortality data were not available for Iceland, and the highest rates were from countries located in the Alps (Austria and Switzerland). U.K., Spain and Greece had low rates in both sexes. The extent of variation was greater for incidence (over a factor 10 in both

sexes) than for mortality (a factor 3 for females and 4 for males). This is probably influenced by instability of rates and random variation in small registries, but possibly reflects the different aetiology and prognostic correlates of various histotypes of thyroid cancer and the spread of more sophisticated diagnostic techniques.

AVERAGE AGE-STANDARDIZED (WORLD) INCIDENCE RATES PER 100,000 IN EUROPEAN CANCER REGISTRY REGIONS, 1978-82.

Non-Hodgkin's lymphomas and other reticuloses (ICD-9 : 200,202)





SOURCE : Muir et al., 1987.

SEX RATIOS (M/F) FOR INCIDENCES IN EUROPEAN CANCER REGISTRY REGIONS, 1978-82 (RANKED).

1	POLAND, NOWY SACZ	3.9
2	SPAIN, ZARAGOZA	3.7
3	POLAND, CRACOW CITY	2.4
4	ITALY, VARESE	2.2
5	HUNGARY, SZABOLCS	2.1
6	CZECH., SLOVAKIA	2.1
7	ITALY, RAGUSA	2.1
8	SWITZERLAND, BASEL	2.0
9	NETH., EINDHOVEN	1.9
9	SWITZERLAND, GENEVA	1.9
11	YUGOSLAVIA, SLOVENIA	1.8
11	SWITZERLAND, VAUD	1.8
11	POLAND, WARSZAW CITY	1.9
14	UK, TRENT	1.7
14	UK, BIRMINGHAM	1.7
16	ROMANIA, COUNTY CLUJ	1.6
16	FRANCE, DOUBS	1.6
16	SPAIN, NAVARRA	1.6
16	GERMAN DEM. REP.	1.6
16	FINLAND	1.6
16	UK, MERSEY	1.6
16	SWITZERLAND, ZURICH	1.6
16	SWITZERLAND, NEUCHÂTEL	1.6
16	FRG, SAARLAND	1.6
25	DENMARK	1.5
25	UK, NORTH SCOTLAND	1.5
25	FRANCE, ISERE	1.5
25	FRG, HAMBURG	1.5
25	SWEDEN	1.5
30	UK, SOUTH THAMES	1.4
30	NORWAY	1.4
30	UK, OXFORD	1.4
30	ITALY, PARMA	1.4
30	UK, WEST SCOTLAND	1.4
30	FRANCE, BAS-RHIN	1.4
30	UK, NORTH WESTERN	1.4
30	FRANCE, CALVADOS	1.3
37	UK, SOUTH WESTERN	1.3
37	UK, EAST SCOTLAND	1.3
37	ICELAND	1.3
41	SPAIN, TARRAGONA	1.2
41	UK, NE SCOTLAND	1.2
41	IRELAND, SOUTHERN	1.2
44	UK, SE SCOTLAND	1.0
45	HUNGARY, VAS	0.9

AVERAGE AGE-STANDARDIZED (WORLD) MORTALITY RATES  
PER 100,000 IN EUROPEAN COUNTRIES, 1978-82.

Non-Hodgkin's lymphomas and other reticuloses (ICD-9 : 200,202)



SOURCE :WHO

SEX RATIOS (M/F) FOR MORTALITY IN EUROPEAN COUNTRIES, 1978-82 (RANKED).

1	GREECE	2.0
2	SPAIN	1.8
2	HUNGARY	1.8
2	FRANCE	1.8
2	BULGARIA	1.8
2	ITALY	1.8
2	FINLAND	1.8
8	CZECHOSLOVAKIA	1.7
8	AUSTRIA	1.7
8	SWITZERLAND	1.7
8	DENMARK	1.7
12	FRG	1.6
12	YUGOSLAVIA	1.6
12	NETHERLANDS	1.6
12	ENGLAND & WALES	1.6
12	SWEDEN	1.6
12	BELGIUM	1.6
12	IRELAND	1.6
19	NORTHERN IRELAND	1.5
20	NORWAY	1.4
20	SCOTLAND	1.4
22	LUXEMBOURG	1.3
23	GER	0.0
24	POLAND	0.0
25	PORTUGAL	0.0
26	ROMANIA	0.0


The highest incidence rates were in Switzerland and Northern Italy (Varese) for males, and in Scotland and Switzerland for females. Certified incidence was low in Eastern countries, particularly Poland and Hungary.

The observation that high and low incidence areas were, at least in part, similar for Hodgkin's and non-Hodgkin's lymphomas does not support the hypothesis of substantial misclassification between various lym-

phomas in these areas. As for Hodgkin's disease, the sex ratio in incidence ranged between 1 and 2 in most areas.

AVERAGE AGE-STANDARDIZED (WORLD) INCIDENCE RATES PER 100,000 IN EUROPEAN CANCER REGISTRY REGIONS, 1978-82.

Hodgkin's disease (ICD-9 : 201)





SOURCE : Muir et al., 1987.

SEX RATIOS (M/F) FOR INCIDENCE IN EUROPEAN CANCER REGISTRY REGIONS, 1978-82 (RANKED).

1	IRELAND, SOUTHERN	3.9
2	SPAIN, ZARAGOZA	3.2
3	UK, NORTH SCOTLAND	2.6
4	FRG, SAARLAND	2.3
4	SWITZERLAND, BASEL	2.3
6	ITALY, RAGUSA	2.1
6	ITALY, PARMA	2.1
8	SPAIN, NAVARRA	2.0
9	UK, EAST SCOTLAND	1.9
9	POLAND, NOWY SĄCZ	1.9
9	SWITZERLAND, VAUD	1.9
9	ITALY, VARESE	1.9
13	ICELAND	1.8
13	UK, SOUTH WESTERN	1.8
15	UK, SOUTH THAMES	1.7
15	UK, SE SCOTLAND	1.7
17	FINLAND	1.6
17	UK, OXFORD	1.6
17	UK, MERSEY	1.6
17	FRANCE, CALVADOS	1.6
17	DENMARK	1.6
17	NORWAY	1.6
17	UK, BIRMINGHAM	1.6
17	UK, NORTH WESTERN	1.6
17	SWITZERLAND, ZÜRICH	1.6
25	CZECH., SLOVAKIA	1.5
25	SWEDEN	1.5
25	UK, TRENT	1.5
25	FRANCE, ISÈRE	1.5
25	UK, NE SCOTLAND	1.5
25	FRANCE, DOUBS	1.5
25	FRANCE, CALVADOS	1.5
25	UK, MERSEY	1.5
32	UK, WEST SCOTLAND	1.4
32	NETH., EINDHOVEN	1.4
32	POLAND, CRACOW CITY	1.4
32	SPAIN, TARRAGONA	1.4
32	GERMAN DEM. REP.	1.4
37	HUNGARY, VAS	1.3
37	HUNGARY, SZABOLCS	1.3
37	FRG, HAMBURG	1.3
40	SWITZERLAND, GENEVA	1.2
41	YUGOSLAVIA, SLOVENIA	1.1
42	POLAND, WARSAW CITY	1.0
42	ROMANIA, COUNTY CLUJ	1.0
42	SWITZERLAND, NEUCHÂTEL	1.0
42	FRANCE, BAS-RHIN	1.0

AVERAGE AGE-STANDARDIZED (WORLD) MORTALITY RATES PER 100,000 IN EUROPEAN COUNTRIES, 1978-82.

Hodgkin's disease (ICD-9 : 201)



SOURCE: WHO

SEX RATIOS (MF) FOR MORTALITY IN EUROPEAN COUNTRIES, 1978-82 (RANKED).

1	BULGARIA	2.4
1	NORTHERN IRELAND	2.4
3	GREECE	2.2
3	ROMANIA	2.2
5	NETHERLANDS	2.0
5	NORWAY	2.0
5	SPAIN	2.0
5	DENMARK	2.0
9	FINLAND	1.9
9	BELGIUM	1.9
9	PORTUGAL	1.9
9	FRANCE	1.9
9	POLAND	1.9
14	GFR	1.8
14	ENGLAND & WALES	1.8
14	FRG	1.8
14	CZECHOSLOVAKIA	1.8
14	AUSTRIA	1.8
19	ITALY	1.7
19	SWEDEN	1.7
19	HUNGARY	1.7
22	YUGOSLAVIA	1.6
22	LUXEMBOURG	1.6
22	SWITZERLAND	1.6
25	IRELAND	1.5
26	SCOTLAND	1.3



Certified incidence rates were high for both sexes in Italy, Scotland and several Swiss registries, and low in most Eastern registries (including Slovenia, Yugoslavia), Spain and Sweden. Thus, the high mortality rate in Yugoslavia is most likely artefactual, and ex-

plainable in terms of classification problems for various lymphoid neoplasms (Yugoslavia had the lowest Non-Hodgkin's lymphomas and leukaemia rates for both sexes). As for incidence, mortality was high in Switzerland and Italy, too, but the overall variation

across various European countries was rather limited. The sex ratio, both for incidence and mortality, was between 1 and 2 in most areas.

AVERAGE AGE-STANDARDIZED (WORLD) INCIDENCE RATES PER 100,000 IN EUROPEAN CANCER REGISTRY REGIONS, 1978-82.

Multiple myeloma (ICD-9 : 203)





SOURCE : Muir et al., 1987.

SEX RATIOS (M/F) FOR INCIDENCE IN EUROPEAN CANCER REGISTRY REGIONS, 1978-82 (RANKED).

Rank	Region	Sex Ratio (M/F)
1	HUNGARY, SZABOLCS	5.0
2	POLAND, CRACOW CITY	2.5
3	SPAIN, TARRAGONA	2.4
4	IRELAND, SOUTHERN	2.3
4	UK, NORTH SCOTLAND	2.3
6	ITALY, PARMA	2.2
6	SWITZERLAND, VAUD	2.2
6	SWITZERLAND, BASEL	2.2
9	ICELAND	2.0
10	SWITZERLAND, GENEVA	1.8
10	YUGOSLAVIA, SLOVENIA	1.8
12	UK, BIRMINGHAM	1.7
12	UK, OXFORD	1.7
14	ROMANIA, COUNTY CLUJ	1.6
14	NORWAY	1.6
14	FRANCE, BAS-RHIN	1.6
14	NETH, EINDHOVEN	1.6
18	UK, EAST SCOTLAND	1.5
18	UK, SOUTH THAMES	1.5
18	SWITZERLAND, ZÜRICH	1.5
18	SWEDEN	1.5
18	DENMARK	1.5
18	UK, SE SCOTLAND	1.5
24	UK, WEST SCOTLAND	1.4
24	UK, TRENT	1.4
24	GERMAN DEM. REP.	1.4
24	ITALY, VARESE	1.4
24	UK, SOUTH WESTERN	1.4
24	SPAIN, NAVARRA	1.4
30	SWITZERLAND, NEUCHÂTEL	1.3
30	CZECH., SLOVAKIA	1.3
30	FRANCE, CALVADOS	1.3
30	FRANCE, ISERE	1.3
30	FINLAND	1.3
30	UK, MERSEY	1.3
30	HUNGARY, VAS	1.3
30	ITALY, RAGUSA	1.3
38	UK, NORTH WESTERN	1.2
38	UK, NE SCOTLAND	1.2
38	FRG, SAARLAND	1.2
38	FRG, HAMBURG	1.2
38	SPAIN, ZARAGOZA	1.2
43	POLAND, NOWY SĄCZ	1.1
44	POLAND, WARSAW CITY	0.9
44	FRANCE, DOUBS	0.9

AVERAGE AGE-STANDARDIZED (WORLD) MORTALITY RATES  
PER 100,000 IN EUROPEAN COUNTRIES, 1978-82.

Multiple myeloma (ICD-9 : 203)



SOURCE : WHO

SEX RATIOS (M/F) FOR MORTALITY IN EUROPEAN COUNTRIES, 1978-82 (RANKED).

Rank	Country	Sex Ratio (M/F)
1	NORTHERN IRELAND	1.7
2	NORWAY	1.6
2	SCOTLAND	1.6
2	SWITZERLAND	1.6
5	LUXEMBOURG	1.5
6	FRG	1.4
6	DENMARK	1.4
6	ENGLAND & WALES	1.4
6	IRELAND	1.4
6	HUNGARY	1.4
6	CZECHOSLOVAKIA	1.4
6	SWEDEN	1.4
6	NETHERLANDS	1.4
6	BELGIUM	1.4
6	YUGOSLAVIA	1.4
6	ITALY	1.4
17	FRANCE	1.3
17	SPAIN	1.3
18	FINLAND	1.2
18	AUSTRIA	1.2
19	AUSTRIA	1.2
22	GREECE	1.1
22	BULGARIA	1.1
23	GER	0.0
24	POLAND	0.0
25	PORTUGAL	0.0
26	ROMANIA	0.0


Incidence rates for multiple myeloma, as for most other lymphoid neoplasms, were highest in Scotland, Switzerland and Northern Italy, and lowest in Eastern

Europe and Spain, and the sex ratios were between 1 and 2 in most areas. This is another neoplasm whose certification is influenced by differential availability of

diagnostic technologies, and it is therefore difficult to quantify how much of the observed variation is real [2].

AVERAGE AGE-STANDARDIZED (WORLD) INCIDENCE RATES PER 100,000 IN EUROPEAN CANCER REGISTRY REGIONS, 1978-82.

Leukaemias (ICD-9 : 204-8)





SOURCE : Muir et al., 1987.

SEX RATIOS (M/F) FOR INCIDENCE IN EUROPEAN CANCER REGISTRY REGIONS, 1978-82 (RANKED).

1	UK, EAST SCOTLAND	2.1
2	SPAIN, TARRAGONA	2.0
4	FRANCE, DOUBS	2.0
5	FRANCE, ISERE	1.9
5	UK, BIRMINGHAM	1.8
5	ICELAND	1.7
5	IRELAND, SOUTHERN	1.7
5	POLAND, CRACOW CITY	1.7
5	UK, SOUTH WESTERN	1.7
5	SPAIN, NAVARRA	1.7
5	ROMANIA, COUNTY CLUJ	1.7
5	UK, SOUTH THAMES	1.7
13	UK, OXFORD	1.6
13	FRANCE, BAS-RHIN	1.6
13	NETH, ENDHOVEN	1.6
13	UK, MERSEY	1.6
13	UK, NE SCOTLAND	1.6
13	UK, WEST SCOTLAND	1.6
19	UK, NORTH WESTERN	1.5
19	CZECH., SLOVAKIA	1.5
19	FRG, SAARLAND	1.5
19	DENMARK	1.5
19	NORWAY	1.5
19	UK, TRENT	1.5
19	FINLAND	1.5
26	SWEDEN	1.4
26	GERMAN DEM. REP.	1.4
26	SPAIN, ZARAGOZA	1.4
26	POLAND, NOWY SĄCZ	1.4
26	POLAND, WARSAW CITY	1.4
26	UK, SE SCOTLAND	1.4
26	YUGOSLAVIA, SLOVENIA	1.4
26	SWITZERLAND, VAUD	1.4
34	ITALY, RAGUSA	1.3
34	FRG, HAMBURG	1.3
34	UK, NORTH SCOTLAND	1.3
34	SWITZERLAND, BASEL	1.3
34	SWITZERLAND, GENEVA	1.3
39	ITALY, VARESE	1.2
39	SWITZERLAND, ZÜRICH	1.2
39	SWITZERLAND, NEUCHÂTEL	1.2
42	HUNGARY, SZABOLCS	1.1
42	HUNGARY, VAS	1.1
44	ITALY, PARMA	1.0
45	FRANCE, CALVADOS	0.8

AVERAGE AGE-STANDARDIZED (WORLD) MORTALITY RATES  
PER 100,000 IN EUROPEAN COUNTRIES, 1978-82.

Leukaemias (ICD-9 : 204-8)



SEX RATIOS (M/F) FOR MORTALITY IN EUROPEAN COUNTRIES, 1978-82 (RANKED).

1	FINLAND	1.6
1	NORTHERN IRELAND	1.6
1	GREECE	1.6
1	SCOTLAND	1.6
1	IRELAND	1.6
1	FRANCE	1.6
1	ENGLAND & WALES	1.6
1	CZECHOSLOVAKIA	1.6
1	NORWAY	1.6
1	DENMARK	1.6
1	ITALY	1.6
12	NETHERLANDS	1.5
12	BELGIUM	1.5
12	POLAND	1.5
12	GDR	1.5
12	FRG	1.5
12	AUSTRIA	1.5
12	SWEDEN	1.5
12	LUXEMBOURG	1.5
12	SWITZERLAND	1.5
12	HUNGARY	1.5
22	ROMANIA	1.4
22	SPAIN	1.4
22	YUGOSLAVIA	1.4
25	PORTUGAL	1.3
26	BULGARIA	1.2

For both sexes, the highest incidence rates were registered in Varese (Northern Italy) but the variation was relatively limited for most other areas, except for a few Eastern European registries which, as for most other lympho-reticular neoplasms, had low rates. The highest/lowest ratio was only about 3, and most of the


registries were restricted to a relatively limited range. The sex ratio was slightly above unity in most registries.

Mortality was highest in Czechoslovakia, Denmark, France and Italy, and lowest in Yugoslavia, Romania and Spain in both sexes. This figure, however, should

be considered critically in relation with the pattern described for lymphomas and myelomas, since it may be influenced by a variable degree of misclassification between various lymphoid neoplasms.

AVERAGE AGE-STANDARDIZED (WORLD) INCIDENCE RATES  
PER 100,000 IN EUROPEAN CANCER REGISTRY REGIONS, 1978-82.

Unknown or uncertain primary sites




SOURCE : Muir et al., 1987.

Only incidence data were available for this category of neoplasms. There was a substantial variation (over five-fold in both sexes) in certified incidence for this heterogeneous group of neoplasms (ICD-9: 159, 165 and 195–9). Saarland (Federal Republic of Germany) and East Scotland had elevated rates in both sexes, while incidence was apparently low in Hungary, East Germany and Italy. It is difficult to interpret these rates in terms of evaluating quality of registration, on account of the heterogeneity of data sources and anatomico-pathological entities.

AVERAGE AGE-STANDARDIZED (WORLD) INCIDENCE RATES PER 100,000 IN EUROPEAN CANCER REGISTRY REGIONS, 1978-82.

All sites, excluding non-melanomatous skin cancers




SOURCE: Muir et al., 1987.

SEX RATIOS (MF) FOR INCIDENCE IN EUROPEAN CANCER REGISTRY REGIONS, 1978-82 (RANKED).


1	POLAND, NOWY SĄCZ	1.7
2	HUNGARY, SZABOLCS	1.6
2	FRANCE, DOUBS	1.6
2	ITALY, VARESE	1.6
2	FRANCE, CALVADOS	1.6
2	FRANCE, BAS-RHIN	1.6
2	SPAIN, NAVARRA	1.6
2	CZECH., SLOVAKIA	1.6
2	SWITZERLAND, BASEL	1.5
9	SPAIN, ZARAGOZA	1.5
9	YUGOSLAVIA, SLOVENIA	1.5
9	FINLAND	1.5
9	FRANCE, ISERE	1.5
14	SWITZERLAND, GENEVA	1.4
14	NETH, EINDHOVEN	1.4
14	SWITZERLAND, VAUD	1.4
14	FRG, SAARLAND	1.4
14	ITALY, PARMA	1.4
19	HUNGARY, VAS	1.3
19	ITALY, RAGUSA	1.3
19	POLAND, CRACOW CITY	1.3
19	SPAIN, TARRAGONA	1.3
19	SWITZERLAND, ZÜRICH	1.3
19	UK, WEST SCOTLAND	1.3
19	POLAND, WARSAW CITY	1.3
19	UK, NORTH WESTERN	1.3
19	ROMANIA, COUNTY CLUJ	1.3
19	UK, NORTH SCOTLAND	1.3
29	SWITZERLAND, NEUCHÂTEL	1.2
29	UK, MERSEY	1.2
29	UK, BIRMINGHAM	1.2
29	UK, TRENT	1.2
29	UK, EAST SCOTLAND	1.2
29	UK, SOUTH THAMES	1.2
29	UK, SE SCOTLAND	1.2
29	UK, OXFORD	1.2
29	GERMAN DEM. REP.	1.2
29	FRG, HAMBURG	1.2
29	UK, SOUTH WESTERN	1.2
40	NORWAY	1.1
40	UK, NORTH SCOTLAND	1.1
40	DENMARK	1.1
40	IRELAND, SOUTHERN	1.1
44	SWEDEN	1.0
44	ICELAND	1.0

AVERAGE AGE-STANDARDIZED (WORLD) MORTALITY RATES  
PER 100,000 IN EUROPEAN COUNTRIES, 1978-82.

All sites (ICD-9 : 140-208)



For males, the highest incidence rates (excluding non-melanomatous skin cancers) were in Varese (Northern Italy), Bas-Rhin (France), Geneva and Basel in Switzerland, followed by Saarland (Federal Republic of Germany) and several Scottish registries. The lowest rates were found in rural Romania, Hungary, Southern Spain and Italy (Ragusa). Among females, the



highest incidence rates were in Denmark, Scotland, and Nordic countries (Iceland, Sweden). The lowest rates were, again, in a few Eastern registries (Hungary, Poland, Romania) and in Southern Europe (Spain and Italy). These figures, of course, reflect the different impact of major sites (particularly lung, stomach, intestines, breast and prostate) in different geographic areas and in the two sexes.

With reference to mortality among males, the highest rates were observed in Belgium, Czechoslovakia, Hun-


SEX RATIOS (M/F) FOR MORTALITY IN EUROPEAN COUNTRIES, 1978-82 (RANKED).

Rank	Country	Sex Ratio (M/F)
1	FRANCE	2.2
2	FINLAND	1.9
2	BELGIUM	1.9
2	ITALY	1.9
5	SPAIN	1.8
5	CZECHOSLOVAKIA	1.8
5	NETHERLANDS	1.8
5	GREECE	1.8
9	LUXEMBOURG	1.7
9	POLAND	1.7
9	SWITZERLAND	1.7
9	YUGOSLAVIA	1.7
9	HUNGARY	1.7
14	PORTUGAL	1.6
14	AUSTRIA	1.6
14	FRG	1.6
14	GDR	1.6
18	BULGARIA	1.5
18	SCOTLAND	1.5
18	ROMANIA	1.5
22	ENGLAND & WALES	1.4
22	NORWAY	1.4
24	NORTHERN IRELAND	1.4
24	IRELAND	1.3
24	DENMARK	1.3
24	SWEDEN	1.3

gary and Scotland, and the lowest were in Romania, Bulgaria, Portugal and Greece. For females, the highest mortality rates were in Scotland, Denmark and Hungary, and the lowest ones in Spain, Greece, Bulgaria and Romania. Thus, the tendency for Southern Europe to have low rates was consistent both for incidence and mortality, while Central Europe and Scotland were in the upper part of the graph. Likewise, both incidence and mortality tended to be low for Norwegian and Swedish males.

AVERAGE AGE-STANDARDIZED (WORLD) INCIDENCE RATES PER 100,000 IN EUROPEAN CANCER REGISTRY REGIONS, 1978-82.



All sites, excluding non-melanomatous skin and lung cancers



SOURCE: Muir et al., 1987.

AVERAGE AGE-STANDARDIZED (WORLD) MORTALITY RATES PER 100,000 IN EUROPEAN COUNTRIES, 1978-82.

All sites, excluding lung cancers



SOURCE: WHO

SEX RATIOS (M/F) FOR MORTALITY IN EUROPEAN COUNTRIES, 1978-82 (RANKED):

1	FRANCE	1.8
2	SPAIN	1.5
3	PORTUGAL	1.4
3	ITALY	1.4
5	GREECE	1.3
5	YUGOSLAVIA	1.3
5	SWITZERLAND	1.3
5	CZECHOSLOVAKIA	1.3
5	HUNGARY	1.3
5	FINLAND	1.3
5	POLAND	1.3
5	AUSTRIA	1.3
13	BELGIUM	1.2
13	LUXEMBOURG	1.2
13	NORWAY	1.2
13	ROMANIA	1.2
13	FRG	1.2
13	BULGARIA	1.2
19	NETHERLANDS	1.2
20	SWEDEN	1.2
21	GDR	1.1
21	IRELAND	1.1
21	SCOTLAND	1.1
21	ENGLAND & WALES	1.1
21	NORTHERN IRELAND	1.1
26	DENMARK	1.0

In males, incidence rates for all cancers except lung (and non-melanomatous skin cancers) were highest in several areas of France, Switzerland and Germany, and lowest in Eastern countries, Southern Spain and Italy, but also several British registries tended to have rates in the lower half of the distribution. Among females, the highest incidence rates were in Scandina-

vian countries, Switzerland, Scotland and Germany, and the lowest ones in Eastern and Southern Europe. The highest mortality rates among males for all cancers excluding lung were in France, as for incidence, but they were followed by Hungary, Czechoslovakia, Austria and Belgium. The lowest mortality rates were in Balkan countries (Romania, Bulgaria, Yugoslavia),

Greece and the Democratic Republic of Germany. As for incidence, the highest mortality rates for females were in Denmark followed by Hungary and Scotland, and the lowest ones in Southern and Eastern Europe. In both sexes, the highest/lowest ratio for incidence and mortality was approximately a factor 2.

# APPENDIX

**TABLE 1 - ABBREVIATIONS\* USED IN THE APPENDICES FOR DEFINITION OF REGISTRIES AND COUNTRIES**

CANCER REGISTRY REGION	ABBREVIATION	COUNTRY	ABBREVIATION
CZECH., SLOVAKIA	CZEC	AUSTRIA	AUST
DENMARK	DENM	BELGIUM	BELG
FINLAND	FINL	BULGARIA	BULG
FRG, HAMBURG	FRGH	CZECHOSLOVAKIA	CZEC
FRG, SAARLAND	FRGS	DENMARK	DENM
FRANCE, BAS-RHIN	FRAB	ENGLAND & WALES	ENGL
FRANCE, CALVADOS	FRAC	FRG	FRG
FRANCE, DOUBS	FRAD	FINLAND	FINL
FRANCE, ISERE	FRAI	FRANCE	FRAN
GERMAN DEM. REP.	GDR	GDR	GDR
HUNGARY, SZABOLCS	HUNS	GREECE	GREE
HUNGARY, VAS	HUNV	HUNGARY	HUNG
ICELAND	ICEL	IRELAND	IREL
IRELAND, SOUTHERN	IRES	ITALY	ITAL
ITALY, PARMA	ITAP	LUXEMBOURG	LUXE
ITALY, RAGUSA	ITAR	NETHERLANDS	NETH
ITALY, VARESE	ITAV	NORTHERN IRELAND	NIRE
NETH., EINDHOVEN	NETH	NORWAY	NORW
NORWAY	NORW	POLAND	POLA
POLAND, CRACOW CITY	POLC	PORTUGAL	PORT
POLAND, NOWY SACZ	POLN	ROMANIA	ROMA
POLAND, WARSAW CITY	POLW	SCOTLAND	SCOT
ROMANIA, COUNTY CLUJ	ROMA	SPAIN	SPAI
SPAIN, NAVARRA	SPAN	SWEDEN	SWED
SPAIN, TARRAGONA	SPAT	SWITZERLAND	SWIT
SPAIN, ZARAGOZA	SPAZ	YUGOSLAVIA	YUGO
SWEDEN	SWED		
SWITZERLAND, BASEL	SWIB		
SWITZERLAND, GENEVA	SWIG		
SWITZERLAND, NEUCHATEL	SWIN		
SWITZERLAND, VAUD	SWIV		
SWITZERLAND, ZURICH	SWIZ		
UK, BIRMINGHAM	UKBI		
UK, MERSEY	UKME		
UK, NORTH WESTERN	UKNW		
UK, OXFORD	UKOX		
UK, SOUTH THAMES	UKST		
UK, SOUTH WESTERN	UKSW		
UK, TRENT	UKTR		
UK, EAST SCOTLAND	UKES		
UK, NORTH SCOTLAND	UKNS		
UK, N.E. SCOTLAND	UKNE		
UK, S.E. SCOTLAND	UKSE		
UK, WEST SCOTLAND	UKWS		
YUGOSLAVIA, SLOVENIA	YUGO		

\* SEE TEXT TABLE 1 FOR ABBREVIATIONS OF CANCER SITES

**TABLE 2 a - ANNUAL POPULATION IN EUROPEAN CANCER REGISTRY REGIONS (1978-82)**

<b>COUNTRIES</b>	<b>MALES</b>	<b>FEMALES</b>
CZECH., SLOVAKIA (1978-82) #	2,451,661	2,532,670
DENMARK (1978-82)	2,527,631	2,591,947
FRG, HAMBURG (1978-79)	772,127	892,178
FRG, SAARLAND (1978-82)	505,984	561,825
FINLAND (1977-81)	2,309,112	2,466,143
FRANCE, BAS-RHIN (1978-81)	439,827	461,379
FRANCE, CALVADOS (1978-82)	285,616	303,644
FRANCE, DOUBS (1978-82)	236,144	241,527
FRANCE, ISERE (1979-82)	452,870	463,094
GERMAN DEM. REP. (1978-82)	7,844,560	8,889,714
HUNGARY, SZABOLCS (1978-82)	307,970	313,077
HUNGARY, VAS (1978-82)	139,403	145,940
ICELAND (1973-82)	112,521	110,455
IRELAND, SOUTHERN (1980-82)	265,880	259,355
ITALY, PARMA (1978-82)	193,497	206,695
ITALY, RAGUSA (1981-82)	134,338	140,245
ITALY, VARESE (1978-81)	380,373	407,302
NETH., EINDHOVEN (1978-82)	418,666	410,569
NORWAY (1978-82)	2,024,720	2,060,900
POLAND, CRACOW CITY (1978-81)	340,212	375,497
POLAND, NOWY SACZ (1978-81)	200,869	207,380
POLAND, WARSAW CITY (1980-82)	723,864	829,911
ROMANIA, COUNTY CLUJ (1979-82)	365,033	371,810
SPAIN, NAVARRA (1978-82)	252,142	255,079
SPAIN, TARRAGONA (1980-83)	255,093	258,691
SPAIN, ZARAGOZA (1978-82)	406,342	422,246
SWEDEN (1978-82)	4,114,890	4,190,255
SWITZERLAND, BASEL (1981-82)	204,559	219,178
SWITZERLAND, GENEVA (1979-82)	165,358	183,682
SWITZERLAND, NEUCHATEL (1978-82)	75,537	81,606
SWITZERLAND, VAUD (1978-82)	254,466	274,281
SWITZERLAND, ZURICH (1980-82)	546,198	576,641
UK, BIRMINGHAM (1979-82)	2,512,649	2,585,960
UK, MERSEY (1978-82)	1,185,600	1,268,900
UK, NORTH WESTERN (1979-82)	1,954,100	2,083,500
UK, OXFORD (1979-82)	1,153,200	1,165,800
UK, SOUTH THAMES (1978-82)	3,107,500	3,393,500
UK, SOUTH WESTERN (1979-82)	1,498,600	1,602,700
UK, TRENT (1979-82)	2,223,130	2,297,590
UK, EAST SCOTLAND (1978-82)	188,925	208,130
UK, NORTH SCOTLAND (1978-82)	111,187	115,264
UK, N.E. SCOTLAND (1978-82)	259,973	269,955
UK, S.E. SCOTLAND (1978-82)	571,937	620,499
UK, WEST SCOTLAND (1978-82)	1,362,338	1,471,492
YUGOSLAVIA, SLOVENIA (1978-81)	918,766	973,098

# Calendar period for which incidence data were available are given in parentheses.

**TABLE 2b - AVERAGE ANNUAL POPULATION (X 100) IN VARIOUS EUROPEAN COUNTRIES**

<b>COUNTRIES</b>	<b>MALES</b>	<b>FEMALES</b>
AUSTRIA	35519	39549
BELGIUM	48147	50346
BULGARIA	44155	44465
CZECHOSLOVAKIA	74414	78335
DENMARK	25254	25913
FRG	293692	321416
FINLAND	23138	24708
FRANCE	263266	274566
GDR	78445	88896
GREECE	47088	48870
HUNGARY	51858	55165
IRELAND	17094	16924
ITALY	277617	291241
LUXEMBOURG	1771	1854
NETHERLANDS	70149	71230
NORWAY	20249	20613
POLAND	173565	182697
PORTUGAL	47076	51582
ROMANIA	109541	112496
SPAIN	183668	190610
SWEDEN	41147	41903
SWITZERLAND	30846	32528
ENGLAND & WALES	240229	253235
NORTHERN IRELAND	7562	7794
SCOTLAND	24868	26763
YUGOSLAVIA	110142	113152

TABLE 3 - RANKS OF REGISTRIES WITHIN CANCER SITES FOR INCIDENCE RATES IN EUROPEAN CANCER REGISTRY REGIONS, 1978-82 (1= HIGHEST)

SITE/CD9	SEX	CZC	DENM	FRGH	PROS	FINL	FRAC	FRAD	FRAU	GDR	HUNS	HUNV	KEL	IREL	ITAP	ITAV	METH	NORW	POLC	PCJN	PCJW	PCJX	SPAN	SPAT	SWED	SWIB	SWMG	SWNV	SWRZ	UKBR	UKBNW	UKOX	UKST	UKSW	UKTR	UKME	UKBE	UKNS	UKNE	UKSE	UKMS	YUDD				
140-9	M	9	27	39	18	28	1	2	3	4	40	13	17	35	11	22	14	8	36	31	29	25	30	16	10	23	15	33	19	5	12	7	21	44	37	41	45	43	42	38	34	20	24	26	32	6
	F	33	14	42	26	23	8	7	13	12	44	36	32	10	21	40	39	25	19	31	9	30	35	16	34	45	43	20	41	2	1	6	29	37	18	24	28	27	17	15	22	4	5	3	11	38
150	M	30	41	26	25	33	2	1	3	4	39	44	40	28	17	37	36	9	43	42	32	35	27	45	16	22	24	38	29	6	12	5	31	23	19	34	21	20	18	10	8	11	15	14	7	13
	F	42	19	23	35	16	22	18	36	25	37	45	44	14	2	33	40	34	32	31	24	41	21	43	30	39	38	27	29	20	17	16	28	7	9	12	13	11	10	4	1	6	8	5	3	26
151	M	8	42	14	15	13	36	34	38	45	12	7	11	10	44	1	26	3	22	29	9	3	24	7	8	32	21	39	28	43	30	37	40	24	18	25	35	33	23	19	17	41	31	27	20	4
	F	5	38	15	14	10	34	30	37	43	12	11	13	6	45	1	27	2	22	23	6	2	24	7	8	32	16	33	29	41	36	44	40	26	20	31	39	35	25	19	17	42	28	21	16	4
153	M	34	13	28	6	39	4	31	18	27	35	42	33	30	20	14	32	7	8	23	41	44	38	45	37	36	43	25	5	3	12	11	15	24	16	19	29	26	21	22	10	1	2	17	9	40
	F	36	5	17	10	33	24	35	26	28	31	41	34	23	11	27	32	12	4	8	42	44	37	45	39	38	43	15	25	14	29	20	30	22	16	9	29	28	18	13	3	2	1	8	7	40
154	M	12	5	17	1	39	3	21	4	11	24	36	2	43	29	27	41	6	13	16	38	44	40	42	34	37	45	33	8	30	25	18	20	10	15	23	32	28	7	9	22	35	14	31	26	19
	F	16	3	10	1	37	23	32	9	27	6	39	4	41	22	26	44	13	12	5	40	45	42	38	36	25	43	31	20	7	2	14	21	19	30	34	33	29	15	11	35	24	8	18	28	17
155	M	17	25	21	31	22	8	12	23	20	24	27	28	33	45	2	14	7	44	38	13	16	11	4	5	10	6	19	3	1	9	15	18	42	39	41	40	43	37	26	34	35	30	29	32	36
	F	10	15	17	19	14	30	44	36	35	25	29	33	21	45	8	5	12	43	32	3	9	4	6	2	7	1	11	24	20	13	23	27	41	38	40	39	37	34	16	22	42	26	18	31	28
156	M	6	22	16	12	15	19	42	30	28	4	18	21	25	35	11	1	7	5	41	2	40	3	45	20	10	24	9	27	8	44	14	17	34	39	33	38	37	31	29	43	36	23	32	28	13
	F	6	17	11	7	13	19	38	28	40	3	5	4	32	37	24	22	14	12	36	2	26	1	44	10	18	23	8	25	16	21	15	20	39	35	34	43	41	31	42	33	45	29	30	27	9
157	M	17	7	28	31	2	37	40	43	44	27	38	13	4	32	24	39	16	29	10	5	36	22	33	41	45	42	8	35	12	1	21	26	23	9	20	11	25	19	6	15	34	14	3	18	30
	F	24	1	22	35	5	42	40	45	43	52	36	9	3	23	21	37	30	29	12	8	34	28	38	39	44	41	4	27	15	31	20	18	25	14	17	16	19	11	13	2	26	10	7	6	33
161	M	12	24	44	23	31	5	13	4	8	25	15	17	38	42	7	10	2	22	43	16	5	9	20	1	11	3	45	30	18	14	21	37	36	26	33	41	40	32	27	34	35	39	29	28	19
	F	32	14	18	27	39	26	38	31	30	37	17	42	6	16	11	24	25	29	36	13	15	2	35	41	45	34	33	40	3	1	22	44	21	7	23	20	28	10	9	5	43	8	12	4	19
162	M	16	27	18	12	9	20	36	32	35	23	31	28	45	37	21	41	7	2	43	10	34	29	39	38	42	40	44	19	11	25	22	33	14	5	17	15	24	8	3	6	30	13	4	1	26
	F	30	11	18	27	28	40	43	45	39	36	26	33	10	17	23	44	32	35	25	15	37	16	34	38	42	41	22	21	19	20	29	24	13	6	7	8	12	9	3	4	14	5	2	1	31
163	M	41	6	9	30	24	38	10	23	17	8	40	29	42	-	37	16	22	28	21	33	-	36	35	20	43	32	1	3	15	7	27	4	31	19	14	18	13	26	5	12	39	34	11	2	25
	F	30	12	29	11	28	41	10	9	40	20	39	27	-	19	-	26	18	38	3	8	37	25	6	7	5	2	4	1	17	16	36	35	15	24	23	34	33	14	-	22	32	21	13	31	
170	M	21	32	38	20	14	8	19	2	7	26	13	37	12	6	31	44	36	30	25	18	11	10	3	17	9	4	24	23	42	1	43	35	34	16	29	33	41	15	5	22	45	40	28	27	39
	F	24	41	43	17	33	10	23	7	16	32	31	40	22	12	21	-	15	39	38	11	14	37	6	13	4	2	3	36	30	1	35	29	42	20	34	28	27	28	5	19	44	9	8	25	18
171	M	21	29	7	3	28	38	37	19	25	36	35	45	8	18	10	2	13	12	6	24	20	42	34	5	17	44	16	1	4	11	43	15	41	32	33	31	27	40	23	14	9	22	26	30	39
	F	24	42	2	1	23	14	16	9	20	33	32	41	19	22	13	6	26	18	12	31	45	44	40	5	15	30	10	39	38	11	4	8	37	25	21	36	29	35	43	17	3	28	7	34	27
172	M	20	7	11	12	8	18	31	17	39	23	43	14	27	26	37	15	13	10	2	36	45	35	44	34	40	33	4	5	1	9	6	3	41	42	25	28	16	30	38	19	32	22	21	24	29
	F	30	4	20	24	17	19	21	16	34	28	40	27	14	10	36	43	26	12	1	25	38	41	44	39	42	45	6	9	2	7	6	3	31	35	18	23	8	33	32	15	11	29	13	22	37
173	M	20	14	44	32	43	36	30	11	38	29	28	13	42	3	34	15	25	4	41	33	39	35	37	24	19	21	40	1	6	5	2	45	23	12	18	16	27	17	9	7	8	10	26	31	
	F	15	12	44	32	42	38	33	9	40	31	19	11	43	1	36	26	27	6	39	30	37	34	35	28	23	29	41	3	5	4	2	45	20	18	14	22	17	21	16	10	8	13	7	24	25
174	F	42	7	20	23	34	8	26	30	21	35	44	39	12	13	19	32	15	2	31	36	45	41	43	37	33	40	11	3	1	4	6	14	27	29	9	28	24	17	16	22	10	25	5	18	38

(cont.)

TABLE 3 - RANKS OF REGISTRIES WITHIN CANCER SITES FOR INCIDENCE RATES IN EUROPEAN CANCER REGISTRY REGIONS, 1978-82 (1= HIGHEST) (contd)

SITE/ICD9		SEX	CZE	DEN	FRG	FIN	FRAC	FRAD	FRAI	GDR	HUN	HUN1	ICE	IRE	ITA	ITA1	ITA2	NET	NOR	POL	POL1	POL2	POL3	POL4	POL5	POL6	POL7	POL8	POL9	POL10	POL11	POL12	POL13	POL14	POL15	POL16	POL17	POL18	POL19	POL20	POL21	POL22	POL23	POL24	POL25	POL26	POL27	POL28	POL29	POL30	POL31	POL32	POL33	POL34	POL35	POL36	POL37	POL38	POL39	POL40	POL41	POL42	POL43	POL44	POL45	POL46	POL47	POL48	POL49	POL50	POL51	POL52	POL53	POL54	POL55	POL56	POL57	POL58	POL59	POL60	POL61	POL62	POL63	POL64	POL65	POL66	POL67	POL68	POL69	POL70	POL71	POL72	POL73	POL74	POL75	POL76	POL77	POL78	POL79	POL80	POL81	POL82	POL83	POL84	POL85	POL86	POL87	POL88	POL89	POL90	POL91	POL92	POL93	POL94	POL95	POL96	POL97	POL98	POL99	POL100
180	F	13	5	3	16	45	10	8	22	19	1	33	6	25	42	32	31	28	40	11	2	21	15	4	44	39	43	30	41	38	14	29	27	20	12	34	36	26	18	7	9	35	24	23	17	37																																																																										
182	F	9	4	23	8	18	14	29	28	27	7	36	3	11	43	10	17	16	25	19	33	45	30	44	15	22	38	12	8	5	2	13	1	34	42	24	32	26	31	39	40	21	37	35	41	20																																																																										
183	F	32	3	6	34	28	20	38	37	40	9	44	31	4	36	16	39	27	17	1	11	12	26	41	43	42	45	2	33	10	18	35	25	22	19	7	15	14	13	24	21	30	5	8	23	29																																																																										
185	M	40	12	16	10	8	13	14	19	22	31	42	39	6	30	37	35	29	11	4	41	44	43	45	28	26	38	2	1	5	9	7	3	34	27	21	25	20	23	33	18	32	17	15	24	36																																																																										
186	M	33	2	7	11	38	13	36	22	34	9	43	26	28	30	31	45	25	27	6	35	42	37	40	41	44	39	24	1	5	10	3	4	29	23	17	20	19	21	15	18	14	8	12	16	32																																																																										
188	M	34	3	28	8	32	5	37	23	31	36	45	44	27	43	21	35	2	12	24	39	38	40	41	7	4	29	26	1	11	14	30	15	25	17	13	18	22	20	16	19	33	9	6	10	42																																																																										
189	F	39	4	25	23	32	24	30	29	34	38	43	44	9	28	26	45	19	27	13	37	36	40	35	31	22	42	18	7	21	6	33	20	17	5	12	16	15	11	10	8	14	3	1	2	41																																																																										
189	M	26	7	15	4	13	3	30	16	23	12	43	35	1	40	19	44	8	9	10	25	39	22	45	29	41	42	2	6	5	18	21	11	36	34	28	37	31	33	32	27	14	20	17	24	38																																																																										
190	M	15	10	45	20	9	37	27	1	19	14	44	13	3	32	36	43	18	42	8	12	26	25	31	7	41	35	11	2	24	40	17	30	34	39	29	23	22	21	38	6	5	16	28	4	33																																																																										
191-2	F	17	11	45	34	10	33	16	32	31	9	26	8	3	7	44	41	25	15	5	4	6	30	29	40	43	42	14	28	1	24	23	13	39	38	22	37	21	27	36	20	35	19	12	2	18																																																																										
193	M	35	4	42	25	20	24	44	19	29	34	45	43	3	10	7	18	28	17	5	2	13	12	40	6	32	11	1	37	39	21	33	23	22	31	16	9	27	36	8	30	38	15	14	26	41																																																																										
193	F	22	32	33	11	3	15	31	27	18	21	26	37	1	25	13	36	10	30	4	43	42	44	35	17	14	34	7	2	12	6	8	5	41	39	45	40	29	28	9	24	20	23	16	38	19																																																																										
201	M	31	30	15	24	23	41	29	22	13	34	45	40	6	14	4	2	1	39	28	36	12	43	44	35	21	27	38	33	19	5	11	10	26	25	20	18	9	17	32	37	3	7	8	16	42																																																																										
200,202	F	26	35	4	41	25	6	34	16	8	18	45	33	15	44	14	7	2	32	31	24	23	30	38	40	11	43	37	42	3	1	22	10	29	28	21	20	17	13	19	39	36	5	12	9	27																																																																										
203	M	26	11	39	16	7	8	37	24	19	30	44	45	36	35	22	33	3	6	20	42	43	40	41	25	38	28	10	2	5	32	1	4	27	29	14	23	18	15	31	13	21	9	12	17	34																																																																										
203	F	31	19	26	41	12	30	29	15	28	39	45	33	14	44	25	18	22	6	3	40	27	38	43	35	42	34	5	37	11	1	24	10	32	21	17	20	8	9	23	2	16	4	7	13	36																																																																										
204-8	M	10	3	17	31	12	5	44	2	9	35	43	45	14	13	25	34	1	11	22	24	33	41	38	7	6	42	8	4	19	18	16	39	37	32	28	36	21	20	27	26	30	15	29	23	40																																																																										
159,165	F	29	35	6	2	37	1	40	8	5	44	43	45	42	30	32	41	31	17	21	26	36	27	39	19	10	33	34	16	24	38	23	25	11	14	18	28	7	4	22	3	13	15	12	9	20																																																																										
195-9	F	23	33	6	1	37	4	44	29	28	42	43	45	32	13	38	40	34	20	17	26	39	25	41	27	7	30	31	22	35	36	21	19	10	11	16	24	2	5	15	3	12	14	9	8	18																																																																										
TOTAL SKIN (-173)	M	20	19	23	5	21	2	17	9	25	36	44	37	35	42	13	41	1	7	28	27	39	38	45	26	40	43	31	4	3	10	11	16	29	18	24	34	32	22	14	12	33	15	8	6	30																																																																										
TOTAL SKIN (-173)	F	34	1	12	11	31	20	36	32	33	28	45	35	3	30	23	41	17	18	13	29	44	38	42	39	40	43	6	16	7	4	25	22	26	21	19	27	24	15	9	5	14	10	2	8	37																																																																										
TOTAL	M	23	15	24	6	25	1	9	5	18	37	45	36	17	42	11	38	2	19	14	34	40	43	44	12	33	41	13	3	4	7	8	10	35	31	29	39	32	27	26	21	30	16	20	22	28																																																																										
TOTAL	F	35	1	9	7	31	11	34	32	33	26	45	36	4	29	18	41	13	12	8	28	44	40	42	38	39	43	3	14	5	2	20	16	27	25	23	30	24	22	19	10	17	15	6	21	37																																																																										

CZE: CZECH REPUBLIC; DEN: DENMARK; FRG: GERMANY; FIN: FINLAND; FRAC: FRANCE (CANTON); FRAD: FRANCE (DEPARTMENT); FRAI: FRANCE (REGION); GDR: GERMANY (EAST); HUN: HUNGARY; HUN1: HUNGARY (BUDAPEST); ICE: ICELAND; IRE: IRELAND; ITA: ITALY; ITA1: ITALY (NORTH); ITA2: ITALY (CENTRAL); NET: NETHERLANDS; NOR: NORWAY; POL: POLAND; POL1: POLAND (WEST); POL2: POLAND (CENTRAL); POL3: POLAND (EAST); POL4: POLAND (SOUTH); POL5: POLAND (SOUTH); POL6: POLAND (SOUTH); POL7: POLAND (SOUTH); POL8: POLAND (SOUTH); POL9: POLAND (SOUTH); POL10: POLAND (SOUTH); POL11: POLAND (SOUTH); POL12: POLAND (SOUTH); POL13: POLAND (SOUTH); POL14: POLAND (SOUTH); POL15: POLAND (SOUTH); POL16: POLAND (SOUTH); POL17: POLAND (SOUTH); POL18: POLAND (SOUTH); POL19: POLAND (SOUTH); POL20: POLAND (SOUTH); POL21: POLAND (SOUTH); POL22: POLAND (SOUTH); POL23: POLAND (SOUTH); POL24: POLAND (SOUTH); POL25: POLAND (SOUTH); POL26: POLAND (SOUTH); POL27: POLAND (SOUTH); POL28: POLAND (SOUTH); POL29: POLAND (SOUTH); POL30: POLAND (SOUTH); POL31: POLAND (SOUTH); POL32: POLAND (SOUTH); POL33: POLAND (SOUTH); POL34: POLAND (SOUTH); POL35: POLAND (SOUTH); POL36: POLAND (SOUTH); POL37: POLAND (SOUTH); POL38: POLAND (SOUTH); POL39: POLAND (SOUTH); POL40: POLAND (SOUTH); POL41: POLAND (SOUTH); POL42: POLAND (SOUTH); POL43: POLAND (SOUTH); POL44: POLAND (SOUTH); POL45: POLAND (SOUTH); POL46: POLAND (SOUTH); POL47: POLAND (SOUTH); POL48: POLAND (SOUTH); POL49: POLAND (SOUTH); POL50: POLAND (SOUTH); POL51: POLAND (SOUTH); POL52: POLAND (SOUTH); POL53: POLAND (SOUTH); POL54: POLAND (SOUTH); POL55: POLAND (SOUTH); POL56: POLAND (SOUTH); POL57: POLAND (SOUTH); POL58: POLAND (SOUTH); POL59: POLAND (SOUTH); POL60: POLAND (SOUTH); POL61: POLAND (SOUTH); POL62: POLAND (SOUTH); POL63: POLAND (SOUTH); POL64: POLAND (SOUTH); POL65: POLAND (SOUTH); POL66: POLAND (SOUTH); POL67: POLAND (SOUTH); POL68: POLAND (SOUTH); POL69: POLAND (SOUTH); POL70: POLAND (SOUTH); POL71: POLAND (SOUTH); POL72: POLAND (SOUTH); POL73: POLAND (SOUTH); POL74: POLAND (SOUTH); POL75: POLAND (SOUTH); POL76: POLAND (SOUTH); POL77: POLAND (SOUTH); POL78: POLAND (SOUTH); POL79: POLAND (SOUTH); POL80: POLAND (SOUTH); POL81: POLAND (SOUTH); POL82: POLAND (SOUTH); POL83: POLAND (SOUTH); POL84: POLAND (SOUTH); POL85: POLAND (SOUTH); POL86: POLAND (SOUTH); POL87: POLAND (SOUTH); POL88: POLAND (SOUTH); POL89: POLAND (SOUTH); POL90: POLAND (SOUTH); POL91: POLAND (SOUTH); POL92: POLAND (SOUTH); POL93: POLAND (SOUTH); POL94: POLAND (SOUTH); POL95: POLAND (SOUTH); POL96: POLAND (SOUTH); POL97: POLAND (SOUTH); POL98: POLAND (SOUTH); POL99: POLAND (SOUTH); POL100: POLAND (SOUTH)

TABLE 4 - RANKS OF COUNTRIES WITHIN CANCER SITES FOR MORTALITY RATES IN EUROPE, 1978-82 (1= HIGHEST)

		AUST	BELG	BULG	CZEC	DENM	ENGL	FRG	FINL	FRAN	GDR	GREE	HUNG	IREL	ITAL	LUXE	NETH	NIRE	NORW	POLA	PORT	ROMA	SCOT	SPAI	SWED	SWIT	YUGO
140-9	M	9	14	24	6	18	19	13	21	1	15	26	2	12	5	3	25	23	22	8	7	17	16	11	20	4	10
	F	24	17	23	13	3	5	21	9	7	22	25	8	4	14	6	20	2	16	11	16	18	1	26	12	10	19
150	M	15	11	25	20	18	8	14	17	1	21	24	13	5	10	3	19	9	23	12	7	26	2	8	22	4	16
	F	23	10	25	24	9	3	17	6	11	21	19	22	2	15	7	8	4	20	13	6	26	1	14	16	12	18
151	M	5	19	6	4	25	18	9	11	24	8	28	1	20	7	17	15	14	21	2	3	13	16	12	23	22	10
	F	4	18	2	5	25	19	7	9	26	10	23	3	14	8	16	21	13	20	6	1	15	17	12	24	22	11
152-4,159	M	6	10	20	2	3	12	7	21	9	17	26	4	5	15	1	13	11	16	24	18	25	8	22	19	14	23
	F	10	8	23	9	4	12	5	20	15	14	26	6	2	18	1	11	3	13	22	17	25	7	21	18	19	24
155	M	11	12	2	22	14	23	19	10	13	16	17	3	26	6	7	21	24	18	4	25	15	20	1	9	8	5
	F	12	10	3	19	11	24	18	7	20	14	17	4	25	8	6	23	22	15	1	26	16	21	2	9	13	5
156	M	3	9	21	2	10	17	4	7	14	-	22	1	13	12	11	6	19	18	-	-	-	16	20	5	8	15
	F	3	12	17	2	10	21	4	8	14	-	22	1	15	13	9	7	19	20	-	-	-	18	16	5	8	11
157	M	8	14	23	7	4	12	15	2	17	19	24	6	9	20	1	3	11	13	18	25	21	10	26	5	16	22
	F	7	15	23	10	1	12	13	3	20	18	25	6	4	19	16	9	8	11	17	24	22	5	26	2	14	21
161	M	13	9	14	10	18	22	17	19	1	20	11	4	16	3	6	21	24	25	7	8	12	23	2	26	16	5
	F	19	12	13	18	14	9	21	26	10	25	16	4	1	15	11	22	2	23	7	5	6	8	17	24	20	3
162	M	14	2	21	5	11	4	15	7	19	13	18	8	17	12	6	3	9	23	10	28	24	1	22	26	16	20
	F	7	13	19	10	4	2	17	20	25	22	11	6	3	15	16	14	5	18	9	26	23	1	24	8	21	12
163	M	14	16	20	6	8	11	7	3	2	-	21	15	19	4	13	1	18	12	-	-	-	10	17	-	6	9
	F	3	15	17	8	5	14	1	9	6	-	20	10	21	2	4	11	18	16	-	-	-	19	13	-	12	7
170	M	14	13	11	12	20	23	15	18	10	16	1	6	22	7	9	24	17	25	8	4	3	19	5	21	26	2
	F	18	12	7	11	20	24	15	21	13	14	2	10	16	9	1	22	17	26	8	6	4	19	6	23	25	3
171	M	12	18	20	7	15	9	5	4	14	-	22	1	8	21	17	3	13	2	-	-	-	8	18	10	11	19
	F	7	15	20	11	16	10	4	1	13	-	19	2	8	21	17	3	12	6	-	-	-	14	18	9	5	22
172-3	M	8	19	23	3	6	16	12	7	17	15	26	4	9	14	25	10	20	1	11	24	21	13	22	5	2	18
	F	10	22	21	4	3	13	15	17	18	16	25	6	2	20	1	14	9	7	11	24	23	12	26	8	5	19
174	F	12	6	24	14	7	1	10	19	15	18	21	11	3	13	9	4	5	17	22	20	26	2	23	16	8	26
179-182	F	6	17	18	7	5	14	12	25	16	4	26	1	24	11	9	23	22	15	2	10	3	19	20	21	13	8
183	F	3	14	20	10	1	4	12	16	19	5	24	13	15	21	6	7	17	8	18	25	23	11	26	2	9	22
185	M	11	4	25	19	9	17	8	6	12	22	24	10	13	20	5	7	15	1	23	14	28	18	16	3	2	21
186	M	5	21	11	3	7	14	6	22	16	1	24	2	8	17	13	19	15	12	10	25	23	9	26	18	4	20
188	M	12	2	25	9	1	5	7	20	14	11	18	10	22	3	19	6	17	18	13	21	26	4	8	23	15	24
	F	6	4	26	18	2	3	7	24	17	12	21	16	15	13	11	10	8	5	23	20	25	1	19	14	9	22
189	M	4	12	22	1	5	16	3	6	13	-	20	9	18	15	11	7	17	8	-	-	-	14	19	2	10	21
	F	4	10	20	3	1	16	7	5	13	-	22	11	14	17	18	8	15	9	-	-	-	12	21	2	6	19
190	M	7	12	15	16	6	8	19	4	10	-	11	14	1	18	-	9	20	3	-	-	-	2	-	13	5	17
	F	11	18	9	10	5	4	19	1	13	-	18	20	12	17	-	8	7	3	-	-	-	2	-	14	6	15
191-2	M	18	2	21	16	4	7	20	14	19	-	1	9	11	15	-	5	8	10	-	-	-	13	3	5	12	17
	F	18	1	21	15	2	13	20	7	19	-	4	11	6	16	-	14	8	9	-	-	-	10	5	3	12	17
193	M	1	16	17	5	8	20	3	4	12	-	22	6	11	7	13	14	19	16	-	-	-	18	21	9	2	10
	F	1	11	15	5	14	20	7	4	16	-	21	6	9	10	2	18	17	12	-	-	-	19	22	8	3	13
201	M	12	5	14	3	21	15	5	9	23	10	8	20	11	4	25	16	13	17	7	24	28	22	19	18	2	1
	F	9	7	25	3	23	14	6	10	21	11	13	16	5	4	17	18	19	20	8	24	26	12	22	16	2	1
200,202	M	11	17	20	12	6	7	16	1	14	-	21	4	13	15	18	2	9	8	-	-	-	5	19	3	10	22
	F	12	17	20	13	8	6	18	3	15	-	22	9	10	16	14	4	7	5	-	-	-	1	19	2	11	21
203	M	16	12	22	15	8	11	17	10	13	-	20	18	5	14	6	3	9	1	-	-	-	7	19	2	4	21
	F	15	10	21	16	8	9	17	4	13	-	18	20	5	14	7	3	12	1	-	-	-	11	19	2	6	22
204-8	M	15	9	24	1	3	20	11	8	4	18	7	6	19	5	2	12	13	14	17	21	25	22	23	10	16	26
	F	13	8	20	2	3	22	9	15	6	18	10	4	21	6	1	12	17	16	19	11	25	24	23	7	14	26
TOTAL(-SKIN) (-173)	M	9	1	25	2	13	8	11	12	6	18	20	4	17	10	3	7	16	21	14	24	26	5	19	23	15	22
	F	10	11	25	8	2	4	9	19	20	14	24	3	5	18	6	12	7	17	15	21	26	1	23	13	16	22
TOTAL(-LUNG+SKIN) (-162+173)	M	5	6	25	4	10	19	7	20	1	22	24	2	14	8	3	13	21	15	12	16	26	11	17	18	9	23
	F	8	7	24	5	1	11	6	19	20	15	25	2	9	18	3	12	10	17	16	21	26	4	22	13	14	23

TABLE 5a - RANKS OF SITES FOR INCIDENCE RATES IN EUROPEAN CANCER REGISTRY REGIONS, MALES, 1978-82 . (1= HIGHEST)

RANK	CZEC	DENM	FRGH	FRGS	FINL	FRAB	FRAC	FRAD	FRAI	GDR	HUNS	HUNV	ICEL	IREB	ITAP
1	LUNG	LUNG	LUNG	LUNG	LUNG	LUNG	MPHA	LUNG	LUNG	LUNG	LUNG	LUNG	PROS	LUNG	LUNG
2	STOM	PROS	PROS	PROS	PROS	MPHA	LUNG	MPHA	MPHA	STOM	STOM	STOM	STOM	PROS	STOM
3	MPHA	BLAD	STOM	STOM	STOM	PROS	CEBO	PROS	PROS	PROS	MPHA	RECT	LUNG	OCLO	OCLO
4	PROS	OCLO	OCLO	RECT	BLAD	OCLO	PROS	OCLO	RECT	RECT	MPHA	RECT	BLAD	MPHA	BLAD
5	RECT	RECT	BLAD	OCLO	RECT	BLAD	STOM	RECT	RECT	OCLO	RECT	MPHA	OCLO	RECT	PROS
6	BLAD	STOM	RECT	BLAD	OCLO	UNKN	RECT	BLAD	BLAD	BLAD	LARY	OCLO	KYDN	STOM	RECT
7	OCLO	KYDN	UNKN	UNKN	PANC	RECT	OCLO	STOM	STOM	KYDN	OCLO	LARY	PANC	BLAD	LARY
8	LARY	PANC	LEUK	MPHA	MPHA	CEBO	BLAD	UNKN	UNKN	PANC	BLAD	PANC	BRAI	UNKN	MPHA
9	UNKN	MPHA	KYDN	KYDN	KYDN	STOM	LARY	LARY	LARY	LEUK	PANC	BLAD	LEUK	LEUK	LIVE
10	LEUK	LEUK	PANC	LARY	LEUK	LARY	LIVE	CEBO	CEBO	MPHA	UNKN	RECT	RECT	BRAI	UNKN
11	PANC	BRAI	MPHA	LEUK	NHOD	KYDN	KYDN	LEUK	LEUK	TEST	LIVE	LEUK	MPHA	PANC	PANC
12	KYDN	TEST	TEST	PANC	BRAI	LEUK	PANC	KYDN	LARY	LARY	LEUK	LEUK	THYR	CEBO	BRAI
13	NHOD	NHOD	CEBO	NHOD	UNKN	NHOD	UNKN	BRAI	BRAI	BRAI	KYDN	LIVE	UNKN	NHOD	LEUK
14	LIVE	UNKN	LIVE	BRAI	MELA	LIVE	LEUK	NHOD	NHOD	NHOD	CEBO	TEST	CEBO	KYDN	KYDN
15	BRAI	MELA	MELA	TEST	LARY	BRAI	NHOD	PANC	PANC	UNKN	BRAI	CEBO	NHOD	LARY	NHOD
16	CEBO	LARY	NHOD	CEBO	LIVE	PANC	HODG	LIVE	LIVE	LIVE	NHOD	UNKN	MMYE	HODG	HODG
17	GALL	LIVE	BRAI	MELA	CEBO	TEST	BRAI	TEST	TEST	GALL	GALL	BRAI	LARY	TEST	MMYE
18	MELA	CEBO	LARY	CONN	HODG	MELA	MELA	MELA	MELA	CEBO	MELA	HODG	HODG	MELA	CEBO
19	TEST	MMYE	HODG	LIVE	MMYE	MMYE	TEST	BONE	BONE	MELA	BONE	NHOD	TEST	CONN	TEST
20	HODG	HODG	CONN	HODG	GALL	GALL	MMYE	HODG	HODG	HODG	CONN	GALL	LIVE	BONE	GALL
21	MMYE	GALL	GALL	GALL	CONN	HODG	CONN	CONN	CONN	MMYE	TEST	MMYE	MELA	MMYE	CONN
22	CONN	CONN	MMYE	THYR	THYR	BONE	GALL	MMYE	CONN	HODG	CONN	CONN	GALL	MELA	MELA
23	BONE	LEUK	LEUK	MMYE	TEST	CONN	BONE	LEUK	LEUK	MMYE	MMYE	THYR	CONN	THYR	THYR
24	EYE	EYE	BONE	BONE	BONE	THYR	LEUK	GALL	GALL	THYR	THYR	BONE	BONE	EYE	BONE
25	THYR	BONE	THYR	EYE	EYE	THYR	THYR	THYR	THYR	BONE	LEUK	CONN	EYE	LIVE	LEUK
26	LEUK	THYR	EYE	LEUK	LEUK	EYE	EYE	LEUK	LEUK	EYE	EYE	LEUK	LEUK	LEUK	EYE

RANK	ITAR	ITAV	NETH	NORW	POLC	POLN	POLW	ROMA	SPAN	SPAT	SPAZ	SWED	SWIB	SWIG	SWIN
1	LUNG	LUNG	LUNG	PROS	LUNG	LUNG	LUNG	LUNG	LUNG	LUNG	LUNG	PROS	LUNG	LUNG	LUNG
2	STOM	STOM	PROS	LUNG	STOM	STOM	STOM	STOM	BLAD	STOM	STOM	LUNG	PROS	PROS	PROS
3	PROS	BLAD	STOM	STOM	PROS	LARY	PROS	MPHA	BLAD	PROS	BLAD	PROS	OCLO	MPHA	BLAD
4	MPHA	OCLO	OCLO	OCLO	BLAD	BLAD	BLAD	LARY	PROS	STOM	LARY	BLAD	OCLO	OCLO	OCLO
5	OCLO	PROS	BLAD	BLAD	RECT	PROS	OCLO	BLAD	MPHA	UNKN	BLAD	STOM	STOM	BLAD	STOM
6	BLAD	MPHA	RECT	RECT	UNKN	MPHA	BLAD	RECT	LARY	OCLO	MPHA	RECT	RECT	STOM	MPHA
7	LARY	RECT	UNKN	UNKN	PANC	RECT	UNKN	LARY	OCLO	LARY	RECT	KYDN	MPHA	RECT	RECT
8	RECT	LARY	KYDN	MELA	LARY	BRAI	RECT	LIVE	RECT	MPHA	LIVE	BRAI	UNKN	LIVE	PANC
9	LEUK	LEUK	LEUK	KYDN	BRAI	LEUK	MPHA	PANC	UNKN	RECT	UNKN	PANC	NHOD	UNKN	LARY
10	BRAI	NHOD	LARY	PANC	MPHA	UNKN	PANC	LEUK	LEUK	LEUK	BRAI	LEUK	KYDN	KYDN	LEUK
11	LIVE	KYDN	NHOD	BRAI	OCLO	PANC	BRAI	UNKN	LIVE	LIVE	OCLO	MPHA	LEUK	CEBO	CEBO
12	PANC	UNKN	PANC	MPHA	LEUK	LIVE	LIVE	BRAI	BRAI	CEBO	LEUK	NHOD	LIVE	MELA	LIVE
13	NHOD	PANC	BRAI	LEUK	KYDN	OCLO	KYDN	OCLO	CEBO	BRAI	NHOD	MELA	TEST	LARY	KYDN
14	UNKN	CEBO	MPHA	NHOD	LIVE	KYDN	LEUK	NHOD	KYDN	NHOD	UNKN	MELA	NHOD	BRAI	BRAI
15	HODG	LIVE	MELA	TEST	GALL	CEBO	CEBO	BONE	NHOD	KYDN	PANC	LIVE	PANC	PANC	UNKN
16	GALL	BRAI	MMYE	MMYE	CEBO	HODG	GALL	KYDN	PANC	PANC	KYDN	MMYE	BRAI	LEUK	TEST
17	CONN	HODG	TEST	LARY	NHOD	NHOD	NHOD	CONN	CONN	HODG	HODG	TEST	LARY	TEST	NHOD
18	MELA	MELA	GALL	CEBO	MMYE	CONN	MELA	TEST	HODG	GALL	MELA	CEBO	CEBO	BRAI	MMYE
19	CEBO	TEST	CEBO	CONN	TEST	MMYE	TEST	HODG	MELA	MMYE	BONE	GALL	CONN	MMYE	MELA
20	MMYE	GALL	HODG	HODG	HODG	BONE	HODG	MMYE	GALL	CONN	GALL	LARY	MMYE	HODG	HODG
21	KYDN	MMYE	CONN	LIVE	MELA	THYR	BONE	CEBO	MMYE	MELA	MMYE	LEUK	HODG	GALL	BONE
22	LEUK	CONN	LIVE	THYR	CONN	GALL	CONN	MELA	TEST	BONE	TEST	HODG	THYR	CONN	THYR
23	THYR	THYR	THYR	GALL	BONE	MELA	MMYE	THYR	BONE	TEST	CONN	CONN	GALL	THYR	CONN
24	TEST	BONE	BONE	BONE	EYE	TEST	EYE	GALL	EYE	THYR	LEUK	THYR	LEUK	LEUK	LEUK
25	BONE	LEUK	LEUK	EYE	THYR	EYE	LEUK	EYE	LEUK	EYE	THYR	BONE	EYE	BONE	GALL
26	EYE	EYE	EYE	LEUK	LEUK	LEUK	THYR	LEUK	THYR	LEUK	EYE	EYE	BONE	EYE	EYE

RANK	SWHV	SWIZ	UKBI	UKNW	LXOX	UKST	UKSW	UKTR	UKME	UKES	UKNS	UKNE	UKSE	UKWS	YUGO
1	LUNG	LUNG	LUNG	LUNG	LUNG	LUNG	LUNG	LUNG	LUNG	LUNG	LUNG	LUNG	LUNG	LUNG	LUNG
2	PROS	PROS	STOM	STOM	PROS	PROS	PROS	PROS	STOM	PROS	OCLO	PROS	PROS	STOM	STOM
3	MPHA	BLAD	PROS	PROS	STOM	BLAD	BLAD	STOM	PROS	STOM	PROS	OCLO	BLAD	PROS	MPHA
4	OCLO	OCLO	OCLO	BLAD	BLAD	STOM	STOM	BLAD	BLAD	OCLO	STOM	STOM	OCLO	PROS	PROS
5	STOM	STOM	BLAD	OCLO	OCLO	OCLO	OCLO	OCLO	OCLO	BLAD	BLAD	STOM	OCLO	BLAD	RECT
6	RECT	RECT	RECT	RECT	RECT	RECT	UNKN	RECT	RECT	UNKN	RECT	RECT	RECT	RECT	UNKN
7	BLAD	MPHA	UNKN	UNKN	UNKN	UNKN	RECT	UNKN	UNKN	RECT	RECT	UNKN	UNKN	UNKN	BLAD
8	NHOD	UNKN	PANC	PANC	PANC	PANC	LEUK	PANC	PANC	PANC	MPHA	MPHA	PANC	CEBO	OCLO
9	UNKN	KYDN	LEUK	LEUK	BRAI	PANC	LEUK	CEBO	CEBO	CEBO	PANC	PANC	MPHA	PANC	LARY
10	CEBO	NHOD	BRAI	MPHA	NHOD	LEUK	NHOD	NHOD	BRAI	MPHA	KYDN	LEUK	LEUK	MPHA	CEBO
11	LARY	MELA	NHOD	CEBO	BRAI	NHOD	CEBO	CEBO	CEBO	LEUK	LEUK	NHOD	CEBO	LEUK	PANC
12	LEUK	TEST	CEBO	KYDN	KYDN	CEBO	KYDN	MPHA	MPHA	NHOD	PANC	CEBO	KYDN	KYDN	LEUK
13	PANC	PANC	KYDN	LARY	MPHA	KYDN	BRAI	KYDN	KYDN	NHOD	NHOD	BRAI	NHOD	NHOD	KYDN
14	TEST	LEUK	MPHA	BRAI	LARY	MPHA	MPHA	BRAI	LARY	BRAI	BRAI	BRAI	NHOD	BRAI	NHOD
16	KYDN	BRAI	LARY	NHOD	TEST	LARY	TEST	LARY	NHOD	MMYE	MMYE	TEST	TEST	LARY	BRAI
16	MELA	LIVE	TEST	TEST	CEBO	TEST	LARY	TEST	TEST	LARY	TEST	LARY	LARY	TEST	TEST
17	LIVE	CEBO	HODG	HODG	MMYE	HODG	MELA	MMYE	LIVE	TEST	HODG	LIVE	LIVE	HODG	MELA
18	BRAI	LARY	MMYE	MMYE	HODG	MMYE	HODG	HODG	HODG	MELA	LARY	HODG	MMYE	MMYE	GALL
19	MMYE	HODG	MELA	LIVE	MELA	MELA	MMYE	MELA	LIVE	CONN	MELA	HODG	HODG	LIVE	MMYE
20	HODG	MMYE	LIVE	MELA	LIVE	CONN	CONN	LIVE	MELA	HODG	MELA	MMYE	MELA	MELA	LIVE
21	GALL	THYR	GALL	CONN	GALL	LIVE	LIVE	GALL	BONE	CONN	LIVE	GALL	CONN	LEUK	HODG
22	THYR	GALL	CONN	GALL	CONN	GALL	GALL	CONN	CONN	EYE	GALL	CONN	GALL	GALL	CONN
23	CONN	CONN	BONE	BONE	LEUK	LEUK	LEUK	BONE	GALL	BONE	THYR	THYR	BONE	CONN	THYR
24	EYE	LEUK	LEUK	LEUK	BONE	BONE	BONE	BONE	THYR	GALL	EYE	EYE	EYE	EYE	BONE
25	LEUK	BONE	THYR	THYR	EYE	EYE	THYR	LEUK	LEUK	LEUK	LEUK	THYR	THYR	BONE	LEUK
26	BONE	EYE	EYE	EYE	THYR	THYR	EYE	EYE	EYE	THYR	BONE	LEUK	EYE	THYR	EYE

TABLE 5b - RANKS OF SITES FOR INCIDENCE RATES IN EUROPEAN CANCER REGISTRY REGIONS, FEMALES, 1978-82. (1= HIGHEST)

RANK	CZEC	DENM	FRGH	FRGS	FINL	FRAB	FRAC	FRAD	FRAI	GDR	HUNS	HUNV	ICEL	IRBB	ITAP
1	BREA	BREA	CERV	CERV	CERV	CERV	CERV	BREA	BREA	BREA	BREA	BREA	BREA	BREA	BREA
2	CERV	COLO	LUNG	BREA	PANC	LUNG	LUNG	COLO	COLO	CERV	STOM	CERV	LUNG	COLO	STOM
3	STOM	CERV	BREA	CORP	CORP	BREA	COLO	CERV	CERV	CORP	CERV	COLO	COLO	LUNG	CORP
4	CORP	LUNG	OVAR	LUNG	BREA	CORP	BREA	CORP	CORP	STOM	CORP	STOM	UNK	COLO	COLO
5	COLO	CORP	PANC	PLEU	OVAR	PLEU	CORP	RECT	RECT	OVAR	COLO	RECT	OVAR	OVAR	OVAR
6	OVAR	OVAR	CORP	COLO	NHCD	OVAR	OVAR	OVAR	OVAR	OVAR	COLO	LUNG	COLO	CORP	RECT
7	RECT	RECT	NHCD	STOM	STOM	STOM	PANC	STOM	LINK	RECT	RECT	OVAR	THYR	MELA	RECT
8	UNKN	MELA	PLEU	PANC	UNKN	PANC	STOM	UNKN	STOM	GALL	GALL	GALL	CERV	CERV	LEUK
9	LUNG	BRAI	STOM	OVAR	LUNG	COLO	BONE	MELA	LEUK	LUNG	OVAR	LUNG	BRAI	CORP	LUNG
10	GALL	PANC	BONE	NHCD	BONE	LARY	LIVE	BRAI	BRAI	LEUK	PANC	PANC	KYDN	BRAI	BRAI
11	LEUK	STOM	UNKN	KYDN	HODG	BONE	MELA	LEUK	NHCD	KYDN	UNK	LEUK	PANC	LEUK	UNKN
12	PANC	BLAD	LIVE	HODG	OBEO	THYR	NHCD	NHCD	LUNG	BRAI	LEUK	MELA	RECT	OBEO	PANC
13	MELA	KYDN	KYDN	BONE	PLEU	LIVE	LARY	MPHA	MELA	PANC	MELA	KYDN	LINK	PANC	NHCD
14	BRAI	UNKN	THYR	THYR	LIVE	HODG	PLEU	LUNG	MPHA	MELA	KYDN	NHCD	BLAD	STOM	LIVE
15	KYDN	LEUK	RECT	LIVE	LARY	NHCD	RECT	BLAD	KYDN	UNK	MPHA	MPHA	MELA	NHCD	BLAD
16	LIVE	NHCD	HODG	LARY	THYR	RECT	UNKN	KYDN	THYR	NHCD	THYR	UNK	LEUK	BLAD	KYDN
17	NHCD	GALL	CONN	UNKN	KYDN	MELA	THYR	THYR	BLAD	THYR	THYR	BLAD	BRAI	NHCD	MPHA
18	MPHA	MPHA	LARY	RECT	COLO	KYDN	HODG	MMYE	HODG	BLAD	BRAI	THYR	MPHA	KYDN	MELA
19	THYR	LIVE	COLO	OBEO	MELA	OBEO	PANC	PANC	PANC	HODG	LIVE	HODG	OBEO	THYR	GALL
20	BLAD	THYR	OBEO	MELA	RECT	UNKN	CONN	CONN	CONN	MPHA	CONN	MMYE	MMYE	GALL	HODG
21	HODG	MMYE	MELA	BLAD	BRAI	CONN	KYDN	HODG	HODG	LIVE	NHCD	BLAD	HODG	CONN	MPHA
22	MMYE	HODG	BLAD	CONN	BLAD	EYE	EYE	GALL	GALL	CONN	HODG	LIVE	GALL	BONE	CONN
23	CONN	OBEO	EYE	EYE	EYE	BLAD	BRAI	BONE	LIVE	MMYE	LARY	CONN	LIVE	HODG	MMYE
24	BONE	CONN	BRAI	MPHA	CONN	MPHA	MPHA	LIVE	OBEO	BONE	BONE	EYE	CONN	LARY	LARY
25	EYE	LARY	LEUK	BRAI	MPHA	BRAI	MMYE	OBEO	BONE	EYE	EYE	BONE	LARY	EYE	BONE
26	LARY	EYE	MPHA	LEUK	MMYE	LEUK	BLAD	LARY	LARY	OBEO	MMYE	LARY	EYE	MMYE	OBEO
27	OBEO	BONE	GALL	GALL	LEUK	MMYE	GALL	PLEU	EYE	LARY	OBEO	PLEU	BONE	LIVE	PLEU
28	PLEU	PLEU	MMYE	MMYE	GALL	GALL	LEUK	EYE	PLEU	PLEU	PLEU	OBEO	PLEU	PLEU	EYE

RANK	ITAR	ITAV	NETH	NORW	POLC	POLN	POLW	ROMA	SPAN	SPAT	SPAZ	SWED	SWB	SWG	SWIN
1	BREA	BREA	BREA	BREA	BREA	BREA	BREA	BREA	BREA	BREA	BREA	BREA	BREA	BREA	BREA
2	CORP	STOM	COLO	COLO	CERV	STOM	CERV	CERV	STOM	CORP	UNKN	COLO	COLO	COLO	CORP
3	COLO	COLO	OVAR	CERV	STOM	CERV	LUNG	STOM	CORP	UNKN	CORP	OVAR	CORP	OVAR	CERV
4	CERV	CORP	CORP	OVAR	LUNG	OVAR	OVAR	OVAR	COLO	COLO	UNKN	CORP	OVAR	OVAR	COLO
5	STOM	OVAR	STOM	CORP	OVAR	BRAI	CORP	RECT	RECT	RECT	CERV	RECT	RECT	LUNG	RECT
6	OVAR	CERV	RECT	MELA	CORP	COLO	STOM	LUNG	UNKN	STOM	LIVE	BRAI	STOM	RECT	OVAR
7	RECT	RECT	CERV	RECT	GALL	LUNG	COLO	CORP	OVAR	CERV	RECT	MELA	LUNG	MELA	LUNG
8	LEUK	LEUK	UNKN	STOM	UNKN	LEUK	GALL	COLO	CERV	OVAR	OVAR	RECT	UNKN	CERV	STOM
9	LIVE	LUNG	MELA	UNKN	COLO	CORP	UNKN	LIVE	BRAI	LEUK	COLO	LUNG	LEUK	STOM	MELA
10	UNKN	UNKN	LUNG	BRAI	RECT	RECT	RECT	LEUK	LEUK	LIVE	BRAI	STOM	CERV	LEUK	LEUK
11	PANC	BRAI	LEUK	LUNG	PANC	UNKN	PANC	UNKN	LIVE	BLAD	LEUK	KYDN	MELA	UNKN	BLAD
12	LUNG	NHCD	PANC	PANC	BRAI	PANC	LIVE	PANC	GALL	LUNG	LUNG	PANC	KYDN	PANC	UNKN
13	GALL	PANC	KYDN	THYR	LIVE	LIVE	BRAI	MPHA	LUNG	BRAI	GALL	UNKN	THYR	NHCD	MPHA
14	NHCD	BLAD	GALL	LEUK	LEUK	MELA	LEUK	BRAI	NHCD	NHCD	PANC	LEUK	NHCD	MPHA	BRAI
15	HODG	GALL	NHCD	BLAD	KYDN	MPHA	KYDN	BLAD	PANC	GALL	KYDN	GALL	BLAD	KYDN	THYR
16	CONN	MELA	BRAI	KYDN	MELA	KYDN	MELA	NHCD	BLAD	THYR	BONE	NHCD	PANC	BRAI	PANC
17	MPHA	THYR	BLAD	NHCD	MPHA	GALL	MPHA	THYR	THYR	HODG	THYR	THYR	BRAI	BLAD	KYDN
18	MELA	KYDN	MPHA	MMYE	BLAD	BLAD	BLAD	MELA	PANC	BLAD	BLAD	GALL	GALL	GALL	HODG
19	BRAI	LIVE	MMYE	MPHA	HODG	HODG	NHCD	BONE	MPHA	MELA	MPHA	MPHA	MPHA	THYR	MMYE
20	MMYE	MPHA	THYR	CONN	THYR	MMYE	HODG	KYDN	CONN	CONN	MELA	LIVE	HODG	NHCD	HODG
21	KYDN	HODG	HODG	HODG	CONN	THYR	LARY	HODG	KYDN	BONE	NHCD	MMYE	MMYE	GALL	GALL
22	THYR	MMYE	CONN	GALL	NHCD	THYR	THYR	GALL	MMYE	KYDN	MMYE	CONN	CONN	LIVE	LIVE
23	LARY	CONN	OBEO	LIVE	BONE	LARY	MMYE	CONN	HODG	MPHA	CONN	BONE	HODG	LARY	LARY
24	BLAD	BONE	BONE	EYE	MMYE	CONN	MMYE	BONE	BONE	MMYE	HODG	HODG	OBEO	CONN	BONE
25	OBEO	OBEO	EYE	OBEO	OBEO	EYE	CONN	EYE	OBEO	OBEO	OBEO	BONE	BONE	EYE	CONN
26	EYE	LARY	LIVE	BONE	LARY	NHCD	BONE	LARY	PLEU	PLEU	PLEU	PLEU	PLEU	OBEO	OBEO
27	PLEU	EYE	LARY	LARY	EYE	PLEU	EYE	OBEO	EYE	LARY	LARY	EYE	EYE	PLEU	EYE
28	BONE	PLEU	PLEU	PLEU	PLEU	OBEO	PLEU	PLEU	LARY	EYE	EYE	LARY	LARY	BONE	PLEU

RANK	SWIV	SWIZ	UKBI	UNKW	UOXX	UKST	UKSW	UKTR	UKME	UKES	UKNS	UKNE	UKSE	UKWS	YUGO
1	BREA	BREA	BREA	BREA	BREA	BREA	BREA	BREA	BREA	BREA	BREA	BREA	BREA	BREA	BREA
2	COLO	CORP	LUNG	LUNG	LUNG	LUNG	LUNG	LUNG	LUNG	COLO	COLO	LUNG	LUNG	COLO	COLO
3	CORP	COLO	COLO	COLO	COLO	COLO	COLO	COLO	CERV	COLO	LUNG	LUNG	COLO	COLO	CORP
4	CERV	CERV	CERV	CERV	OVAR	OVAR	UNKN	CERV	COLO	OVAR	CORP	OVAR	CERV	OVAR	OVAR
5	OVAR	OVAR	OVAR	OVAR	CORP	CORP	OVAR	OVAR	OVAR	UNKN	OVAR	CERV	OVAR	OVAR	RECT
6	RECT	MELA	UNKN	STOM	CERV	CERV	CERV	UNKN	STOM	OVAR	UNKN	RECT	STOM	STOM	CERV
7	MELA	RECT	CORP	UNKN	UNKN	RECT	CORP	CORP	RECT	STOM	CERV	UNKN	UNKN	UNKN	UNKN
8	UNKN	UNKN	RECT	RECT	STOM	UNKN	RECT	RECT	UNKN	RECT	RECT	STOM	RECT	RECT	COLO
9	LUNG	LUNG	STOM	CORP	RECT	STOM	STOM	STOM	CORP	PANC	STOM	CORP	CORP	BLAD	LUNG
10	NHCD	STOM	BRAI	BLAD	PANC	BRAI	MELA	PANC	BRAI	CORP	MELA	BLAD	BLAD	PANC	GALL
11	LEUK	NHCD	PANC	PANC	BRAI	PANC	PANC	LEUK	PANC	NHCD	LEUK	NHCD	NHCD	CORP	LEUK
12	STOM	KYDN	BLAD	LEUK	MELA	BLAD	NHCD	BLAD	BLAD	OBEO	BRAI	PANC	PANC	LEUK	PANC
13	PANC	PANC	LEUK	NHCD	BLAD	MELA	NHCD	BLAD	BLAD	LEUK	BLAD	LEUK	BRAI	NHCD	MELA
14	BRAI	LEUK	OBEO	BRAI	NHCD	NHCD	LEUK	BRAI	OBEO	BRAI	MPHA	BRAI	MELA	OBEO	BRAI
15	THYR	THYR	MELA	OBEO	LEUK	BLAD	BRAI	MELA	THYR	MELA	PANC	MPHA	MPHA	MELA	KYDN
16	KYDN	BRAI	NHCD	MELA	OBEO	OBEO	OBEO	OBEO	MELA	KYDN	NHCD	KYDN	MPHA	BRAI	THYR
17	MPHA	BLAD	KYDN	MPHA	KYDN	MPHA	KYDN	MPHA	NHCD	LEUK	OBEO	MELA	OBEO	KYDN	NHCD
18	GALL	GALL	MPHA	KYDN	MPHA	KYDN	MPHA	KYDN	MPHA	MMYE	KYDN	OBEO	KYDN	MPHA	MPHA
19	BLAD	MPHA	HODG	MMYE	HODG	HODG	MMYE	MMYE	KYDN	MPHA	THYR	MMYE	THYR	HODG	BLAD
20	OBEO	MMYE	GALL	HODG	HODG	MMYE	THYR	THYR	LIVE	THYR	CONN	THYR	MMYE	MMYE	HODG
21	CONN	HODG	THYR	GALL	GALL	THYR	HODG	HODG	HODG	GALL	MMYE	HODG	CONN	GALL	LIVE
22	HODG	CONN	MMYE	THYR	CONN	GALL	GALL	GALL	CONN	CONN	HODG	HODG	HODG	THYR	CONN
23	MMYE	LIVE	CONN	CONN	LIVE	CONN	CONN	CONN	BONE	LIVE	GALL	LIVE	LIVE	LARY	MMYE
24	LIVE	OBEO	LIVE	LARY	BONE	BONE	LIVE	LIVE	GALL	LARY	LIVE	BONE	GALL	LIVE	OBEO
25	LARY	BONE	LARY	LIVE	LARY	LIVE	BONE	LARY	LARY	HODG	BONE	CONN	BONE	CONN	BONE
26	BONE	EYE	BONE	BONE	EYE	LARY	EYE	BONE	CONN	BONE	EYE	LARY	LARY	EYE	LARY
27	EYE	LARY	EYE	PLEU	PLEU	EYE	LARY	EYE	PLEU	EYE	PLEU	EYE	EYE	BONE	EYE
28	PLEU	PLEU	PLEU	EYE	THYR	PLEU	PLEU	PLEU	EYE	PLEU	LARY	PLEU	PLEU	PLEU	PLEU

TABLE 6a - RANKS OF SITES FOR MORTALITY RATES IN EUROPEAN COUNTRIES, MALES, 1978-82. (1= HIGHEST)

RANK	AUST	BELG	BULG	CZEC	DENM	ENGL	FRG	FINL	FRAN	GDR	GREE	HUNG	IREL
1	LUNG	LUNG	LUNG	LUNG	LUNG	LUNG	LUNG	LUNG	LUNG	LUNG	LUNG	LUNG	LUNG
2	STOM	INTE	STOM	INTE	INTE	INTE	INTE	STOM	INTE	STOM	STOM	STOM	INTE
3	INTE	PROS	INTE	STOM	PROS	STOM	STOM	PROS	MPHA	INTE	INTE	INTE	STOM
4	PROS	STOM	LIVE	PROS	STOM	PROS	PROS	INTE	PROS	PROS	PROS	PROS	PROS
5	PANC	BLAD	PROS	PANC	PANC	PANC	PANC	PANC	OESO	BLAD	BRAI	PANC	PANC
6	BLAD	PANC	PANC	LEUK	BLAD	BLAD	BLAD	LEUK	STOM	PANC	LEUK	LIVE	OESO
7	LEUK	LEUK	LEUK	BLAD	LEUK	OESO	LEUK	KYDN	LARY	LEUK	BLAD	MPHA	LEUK
8	KYDN	BRAI	BLAD	KYDN	BRAI	LEUK	KYDN	BLAD	PANC	MPHA	PANC	BLAD	BRAI
9	MPHA	LARY	LARY	MPHA	KYDN	BRAI	OESO	NHOD	LEUK	OESO	LARY	LEUK	BLAD
10	OESO	OESO	BRAI	LARY	OESO	NHOD	MPHA	BRAI	BLAD	LARY	BONE	LARY	MPHA
11	LARY	KYDN	MPHA	BRAI	NHOD	KYDN	BRAI	LIVE	KYDN	LIVE	KYDN	KYDN	NHOD
12	BRAI	MPHA	NHOD	GALL	MPHA	MPHA	GALL	OESO	BRAI	SKIT	OESO	BRAI	KYDN
13	LIVE	LIVE	KYDN	OESO	SKIT	MMYE	LARY	SKIT	LIVE	TEST	NHOD	OESO	LARY
14	GALL	NHOD	BONE	NHOD	LIVE	SKIT	NHOD	MPHA	NHOD	HODG	LIVE	NHOD	MMYE
15	NHOD	MMYE	SKIT	SKIT	MMYE	LARY	SKIT	MMYE	MMYE	BONE	MPHA	GALL	SKIT
16	SKIT	GALL	OESO	HODG	LARY	HODG	LIVE	LARY	SKIT	GALL	HODG	SKIT	HODG
17	HODG	SKIT	HODG	MMYE	GALL	LIVE	HODG	GALL	BONE	PLEU	MMYE	BONE	GALL
18	MMYE	HODG	TEST	BONE	HODG	GALL	MMYE	HODG	GALL	CONNNE	SKIT	CONNNE	TEST
19	BONE	BONE	GALL	TEST	TEST	CONNNE	TEST	BONE	HODG	KYDN	TEST	TEST	LIVE
20	TEST	CONNNE	MMYE	LIVE	PLEU	TEST	BONE	PLEU	PLEU	EYE	GALL	MMYE	CONNNE
21	THYR	TEST	THYR	PLEU	BONE	BONE	CONNNE	CONNNE	TEST	BRAI	CONNNE	HODG	BONE
22	CONNNE	THYR	CONNNE	CONNNE	CONNNE	PLEU	PLEU	THYR	CONNNE	THYR	THYR	THYR	THYR
23	PLEU	PLEU	EYE	THYR	THYR	THYR	THYR	TEST	THYR	NHOD	EYE	PLEU	EYE
24	EYE	EYE	PLEU	EYE	EYE	EYE	EYE	EYE	EYE	MMYE	PLEU	EYE	PLEU

RANK	ITAL	LUXE	NETH	NIRE	NORW	POLA	PORT	ROMA	SCOT	SPAI	SWED	SWIT	YUGO
1	LUNG	LUNG	LUNG	LUNG	LUNG	LUNG	STOM	LUNG	LUNG	LUNG	LUNG	LUNG	LUNG
2	STOM	INTE	INTE	INTE	PROS	STOM	LUNG	STOM	INTE	STOM	PROS	PROS	STOM
3	INTE	STOM	STOM	STOM	INTE	INTE	INTE	INTE	STOM	PROS	INTE	INTE	INTE
4	PROS	PROS	PROS	PROS	STOM	PROS	PROS	PROS	PROS	INTE	STOM	STOM	PROS
5	BLAD	PANC	PANC	PANC	PANC	LIVE	OESO	PANC	PANC	LIVE	PANC	PANC	LIVE
6	LEUK	MPHA	BLAD	LEUK	LEUK	PANC	LARY	LARY	OESO	LARY	LEUK	OESO	LARY
7	LARY	LEUK	LEUK	BLAD	BLAD	BLAD	LEUK	LEUK	BLAD	BLAD	KYDN	BLAD	PANC
8	PANC	OESO	BRAI	OESO	KYDN	LARY	MPHA	BLAD	LEUK	BRAI	BRAI	MPHA	MPHA
9	MPHA	LARY	KYDN	BRAI	BRAI	LEUK	BLAD	MPHA	BRAI	OESO	BLAD	LEUK	BRAI
10	OESO	BLAD	NHOD	NHOD	NHOD	MPHA	PANC	BONE	KYDN	LEUK	NHOD	BRAI	BLAD
11	LIVE	LIVE	OESO	KYDN	MMYE	OESO	BONE	LIVE	NHOD	PANC	LIVE	KYDN	OESO
12	BRAI	KYDN	MMYE	MPHA	SKIT	SKIT	SKIT	SKIT	MPHA	MPHA	OESO	LIVE	LEUK
13	KYDN	MMYE	GALL	MMYE	OESO	BONE	HODG	OESO	MMYE	KYDN	MMYE	SKIT	HODG
14	NHOD	NHOD	SKIT	LARY	MPHA	HODG	LIVE	HODG	SKIT	NHOD	SKIT	NHOD	BONE
15	SKIT	BONE	MPHA	SKIT	LIVE	TEST	TEST	TEST	LARY	BONE	MPHA	LARY	KYDN
16	BONE	GALL	LARY	HODG	HODG	GALL	GALL	GALL	LIVE	SKIT	GALL	MMYE	SKIT
17	HODG	SKIT	PLEU	BONE	CONNNE	PLEU	PLEU	PLEU	GALL	MMYE	HODG	HODG	NHOD
18	MMYE	HODG	LIVE	LIVE	LARY	CONNNE	CONNNE	CONNNE	HODG	HODG	LARY	GALL	GALL
19	GALL	TEST	HODG	GALL	GALL	KYDN	KYDN	KYDN	TEST	GALL	BONE	TEST	PLEU
20	PLEU	PLEU	CONNNE	TEST	TEST	EYE	EYE	EYE	BONE	CONNNE	CONNNE	THYR	TEST
21	TEST	CONNNE	BONE	CONNNE	BONE	BRAI	BRAI	BRAI	CONNNE	PLEU	TEST	PLEU	MMYE
22	THYR	THYR	TEST	THYR	PLEU	THYR	THYR	THYR	PLEU	TEST	THYR	CONNNE	THYR
23	CONNNE	EYE	THYR	PLEU	THYR	NHOD	NHOD	NHOD	EYE	THYR	EYE	BONE	CONNNE
24	EYE	BRAI	EYE	EYE	EYE	MMYE	MMYE	MMYE	THYR	EYE	PLEU	EYE	EYE

TABLE 6b - RANKS OF SITES FOR MORTALITY RATES IN EUROPEAN COUNTRIES, FEMALES, 1978-82 . (1= HIGHEST)

RANK	AUST	BELG	BULG	CZEC	DENM	ENGL	FRG	FINL	FRAN	GDR	GREE	HUNG	IREL
1	BREA	BREA	STOM	BREA	BREA	BREA	BREA	BREA	BREA	BREA	BREA	BREA	STOM
2	INTE	INTE	BREA	INTE	INTE	LUNG	INTE	STOM	INTE	INTE	INTE	INTE	OVAR
3	STOM	STOM	INTE	STOM	LUNG	INTE	STOM	UTER	INTE	UTER	STOM	UTER	UTER
4	UTER	UTER	UTER	UTER	UTER	OVAR	UTER	PANC	OVAR	STOM	LUNG	STOM	PANC
5	OVAR	OVAR	LUNG	OVAR	OVAR	UTER	OVAR	OVAR	STOM	OVAR	UTER	LUNG	OESO
6	LUNG	LUNG	LIVE	LUNG	PANC	STOM	LUNG	LUNG	LEUK	LUNG	LEUK	GALL	LEUK
7	PANC	BRAI	OVAR	GALL	STOM	PANC	PANC	UTER	LUNG	PANC	BRAI	OVAR	BRAI
8	GALL	PANC	LEUK	PANC	LEUK	LEUK	GALL	LEUK	PANC	LEUK	PANC	PANC	BREA
9	LEUK	LEUK	PANC	LEUK	BRAI	BRAI	LEUK	GALL	BRAI	SKIT	OVAR	LEUK	SKIT
10	KYDN	KYDN	BRAI	KYDN	KYDN	OESO	KYDN	BRAI	KYDN	BLAD	BONE	LIVE	INTE
11	BRAI	GALL	GALL	BRAI	GALL	NHOD	BRAI	KYDN	GALL	LIVE	BLAD	BRAI	LUNG
12	NHOD	BLAD	SKIT	SKIT	BLAD	BLAD	BLAD	NHOD	NHOD	HODG	KYDN	KYDN	NHOD
13	BLAD	LIVE	NHOD	NHOD	NHOD	SKIT	SKIT	LIVE	MMYE	MPHA	NHOD	NHOD	GALL
14	SKIT	MMYE	BONE	BLAD	SKIT	KYDN	NHOD	OESO	BLAD	BONE	MMYE	SKIT	MMYE
15	LIVE	NHOD	KYDN	MMYE	LIVE	MMYE	HODG	MMYE	SKIT	OESO	SKIT	BLAD	KYDN
16	THYR	OESO	BLAD	HODG	MMYE	MPHA	THYR	SKIT	MPHA	LARY	LIVE	MPHA	MPHA
17	MMYE	SKIT	MPHA	MPHA	MPHA	GALL	MMYE	MPHA	OESO	GALL	HODG	BONE	BLAD
18	HODG	HODG	THYR	THYR	OESO	HODG	MPHA	THYR	BONE	PLEU	MPHA	THYR	HODG
19	MPHA	MPHA	HODG	BONE	THYR	CONN	OESO	BLAD	LIVE	CONN	OESO	MMYE	THYR
20	BONE	BONE	MMYE	LIVE	HODG	THYR	LIVE	HODG	THYR	KYDN	GALL	CONN	LARY
21	CONN	THYR	OESO	CONN	BONE	LIVE	CONN	CONN	HODG	EYE	THYR	HODG	BONE
22	OESO	CONN	LARY	OESO	CONN	BONE	BONE	BONE	CONN	BRAI	CONN	OESO	CONN
23	PLEU	LARY	CONN	PLEU	PLEU	LARY	PLEU	PLEU	LARY	THYR	LARY	LARY	LIVE
24	LARY	PLEU	EYE	LARY	LARY	EYE	LARY	EYE	PLEU	NHOD	EYE	PLEU	EYE
25	EYE	EYE	PLEU	EYE	EYE	PLEU	EYE	LARY	EYE	MMYE	PLEU	EYE	PLEU

RANK	ITAL	LUXE	NETH	NIRE	NORW	POLA	PORT	ROMA	SCOT	SPAI	SWED	SWIT	YUGO
1	BREA	BREA	BREA	BREA	BREA	BREA	BREA	UTER	BREA	BREA	BREA	BREA	BREA
2	INTE	INTE	INTE	INTE	INTE	UTER	STOM	BREA	LUNG	STOM	INTE	INTE	STOM
3	STOM	UTER	OVAR	LUNG	OVAR	STOM	INTE	STOM	INTE	INTE	OVAR	UTER	UTER
4	UTER	OVAR	STOM	STOM	UTER	INTE	UTER	INTE	STOM	UTER	LUNG	OVAR	INTE
5	LUNG	STOM	UTER	UTER	STOM	LIVE	LEUK	LUNG	OVAR	LIVE	UTER	STOM	LUNG
6	LEUK	LUNG	LUNG	OVAR	LUNG	LUNG	LUNG	OVAR	UTER	LUNG	STOM	LUNG	OVAR
7	OVAR	LEUK	PANC	PANC	PANC	OVAR	PANC	PANC	PANC	BRAI	PANC	PANC	LIVE
8	PANC	PANC	LEUK	LEUK	LEUK	PANC	OVAR	LEUK	OESO	LEUK	GALL	LEUK	PANC
9	BRAI	LIVE	GALL	BRAI	BRAI	LEUK	OESO	BONE	LEUK	PANC	LEUK	BRAI	GALL
10	LIVE	GALL	BRAI	OESO	KYDN	SKIT	BONE	SKIT	BRAI	OVAR	BRAI	GALL	BRAI
11	GALL	SKIT	NHOD	NHOD	NHOD	MPHA	BLAD	BLAD	BLAD	GALL	KYDN	KYDN	LEUK
12	NHOD	BONE	KYDN	SKIT	MMYE	BONE	SKIT	LIVE	NHOD	BLAD	NHOD	SKIT	HODG
13	BLAD	NHOD	MMYE	BLAD	SKIT	BLAD	MPHA	MPHA	KYDN	NHOD	LIVE	NHOD	BONE
14	KYDN	MMYE	BLAD	KYDN	BLAD	OESO	HODG	HODG	SKIT	BONE	MMYE	BLAD	SKIT
15	SKIT	BLAD	SKIT	MPHA	GALL	HODG	LARY	LARY	MPHA	KYDN	SKIT	MMYE	KYDN
16	MMYE	OESO	OESO	MMYE	MPHA	LARY	LIVE	OESO	MMYE	OESO	BLAD	HODG	BLAD
17	BONE	KYDN	MPHA	GALL	LIVE	GALL	GALL	GALL	GALL	SKIT	MPHA	LIVE	NHOD
18	HODG	MPHA	CONN	LIVE	THYR	PLEU	PLEU	PLEU	HODG	MMYE	OESO	MPHA	MPHA
19	MPHA	THYR	THYR	THYR	OESO	CONN	CONN	CONN	LIVE	MPHA	THYR	THYR	OESO
20	OESO	HODG	HODG	BONE	CONN	KYDN	KYDN	KYDN	BONE	HODG	HODG	OESO	THYR
21	THYR	LARY	LIVE	HODG	HODG	EYE	EYE	EYE	THYR	THYR	CONN	CONN	LARY
22	PLEU	PLEU	BONE	LARY	BONE	BRAI	BRAI	BRAI	CONN	CONN	BONE	BONE	MMYE
23	LARY	CONN	PLEU	CONN	EYE	THYR	THYR	THYR	LARY	LARY	EYE	PLEU	PLEU
24	CONN	EYE	EYE	EYE	LARY	NHOD	NHOD	NHOD	EYE	PLEU	LARY	EYE	CONN
25	EYE	BRAI	LARY	PLEU	PLEU	MMYE	MMYE	MMYE	PLEU	EYE	PLEU	LARY	EYE

TABLE 7 - SEX RATIOS (M/F) FOR INCIDENCE WITHIN EACH SITE AND EUROPEAN REGISTRY REGION, 1978-82

ICD-9	LABEL	CZEC	DENM	FRGH	FRGS	FINL	FRAB	FRAC	FRAD	FRAI	GDR	HUNS	HUNV	ICEL	IREL	ITAP
140-9	MPHA	7.7	3.0	3.6	4.8	3.4	15.3	13.5	12.7	9.3	4.3	7.8	5.5	2.3	6.3	5.8
150	OBEO	13.7	2.4	4.8	7.0	1.5	16.7	24.9	20.3	11.4	6.0	25.0	29.0	1.8	1.4	4.6
151	STOM	2.2	2.1	2.0	2.0	1.9	2.1	2.0	2.3	2.1	2.0	2.5	2.6	2.2	3.0	2.2
153	OCLO	1.3	1.0	1.0	1.2	1.0	1.6	1.3	1.3	1.3	1.0	1.1	1.2	1.0	1.0	1.4
154	RECT	1.7	1.6	1.6	1.6	1.5	2.1	1.8	1.9	1.9	1.4	1.7	1.9	1.3	1.5	1.6
155	LIVE	1.8	1.6	2.6	1.8	1.7	5.8	12.6	3.7	4.6	2.6	2.9	3.1	1.8	0.3	2.6
156	GALL	0.5	0.6	0.5	0.4	0.6	0.7	0.7	0.8	1.1	0.5	0.3	0.3	1.1	0.9	1.0
157	PANC	1.8	1.3	1.5	1.8	1.6	2.5	2.0	2.3	1.9	1.8	1.6	1.4	1.5	1.4	1.6
161	LARY	26.3	6.6	4.4	14.6	15.0	24.8	34.3	31.5	29.3	17.3	13.4	45.0	3.1	4.6	13.7
162	LUNG	10.3	3.4	5.9	10.2	10.6	15.4	13.6	18.1	11.6	10.2	7.5	9.5	1.3	3.1	7.9
163	FLEU	1.5	3.0	5.5	1.5	3.6	4.0	2.5	1.8	9.0	3.7	3.0	3.0	-	-	1.3
170	BONE	1.4	1.5	2.0	1.2	1.9	1.3	1.4	2.2	1.8	1.4	1.9	1.3	1.8	1.5	1.1
171	CONN	1.3	1.6	1.2	1.3	1.1	0.8	0.8	1.1	1.1	1.1	1.1	0.7	1.7	1.4	1.4
172	MELA	0.9	0.7	0.9	0.9	1.0	0.7	0.5	0.7	0.6	0.8	0.7	0.9	0.5	0.4	0.8
173	SKIN	1.3	1.4	2.2	1.5	1.5	1.8	1.7	1.4	2.6	1.7	1.1	1.4	1.7	1.3	2.2
188	BLAD	5.9	4.0	4.2	5.5	5.1	5.9	3.9	6.3	5.9	5.5	6.8	6.4	3.0	2.9	5.6
189	KYDN	1.9	1.5	2.0	2.3	1.8	2.3	2.3	2.5	2.2	2.0	1.4	2.0	1.6	1.6	2.2
190	EYE	1.5	1.4	2.0	1.8	1.4	1.0	1.0	4.0	1.8	1.3	0.6	1.3	1.3	0.7	4.0
191-2	BRAI	1.4	1.1	1.0	1.1	1.2	1.5	1.3	1.4	1.2	1.2	1.8	1.1	0.8	1.3	1.2
193	THYR	0.4	0.5	0.4	0.4	0.3	0.4	0.6	0.6	0.6	0.5	0.3	0.5	0.4	0.5	0.4
201	HODG	1.5	1.6	1.3	2.3	1.6	1.0	1.6	1.5	1.5	1.4	1.3	1.3	1.8	3.9	2.1
200,202	NHDD	2.1	1.5	1.5	1.6	1.6	1.4	1.3	1.6	1.5	1.6	2.2	0.9	1.3	1.2	1.4
203	MMYE	1.3	1.5	1.2	1.2	1.3	1.6	1.3	0.9	1.3	1.4	5.0	1.3	2.0	2.3	2.3
204-8	LEUK	1.5	1.5	1.3	1.5	1.5	1.6	0.8	2.0	1.9	1.4	1.1	1.1	1.7	1.7	1.0
PRIM UNK	UNKN	1.2	1.1	1.2	1.3	1.1	1.5	1.7	2.0	2.0	1.2	1.4	1.1	0.8	0.9	1.6
TOTAL minus (162+173)	TOTA minus (LUNG + SKIN)	1.2	0.9	0.9	1.1	1.1	1.4	1.4	1.4	1.2	0.9	1.3	1.0	0.9	0.9	1.1

ICD-9	LABEL	ITAR	ITAV	NETH	NORW	POLC	POLN	POLW	ROMA	SPAN	SPAT	SPAZ	SWED	SWIB	SWIG	SWIN
140-9	MPHA	6.3	7.4	2.3	3.3	2.7	4.2	3.9	4.7	7.9	8.6	9.3	2.7	6.7	6.3	3.4
150	OBEO	8.3	11.4	3.9	3.9	4.1	12.0	4.5	6.0	9.9	13.3	12.3	3.8	5.9	9.0	5.4
151	STOM	2.4	2.3	2.2	2.0	2.5	2.6	2.5	2.3	2.2	2.0	2.0	2.4	2.1	2.1	2.6
153	OCLO	1.2	1.3	1.0	1.0	1.3	1.0	1.2	1.0	1.4	1.3	1.3	1.1	1.6	1.5	1.6
154	RECT	1.8	1.9	1.6	1.6	1.6	1.8	1.6	1.3	1.5	1.2	1.3	1.5	1.8	1.3	1.2
155	LIVE	1.4	2.6	2.0	1.6	1.3	1.9	1.6	2.1	1.7	1.8	1.3	1.7	5.9	6.8	2.6
156	GALL	1.5	0.8	0.7	0.7	0.5	0.6	0.4	0.6	0.5	0.9	0.7	0.6	0.7	0.9	0.3
157	PANC	1.6	1.9	1.6	1.6	1.6	1.5	1.8	2.1	1.8	1.6	2.0	1.4	1.4	1.6	2.5
161	LARY	21.4	32.4	19.3	10.3	11.6	17.6	8.1	27.0	86.0	106.0	51.7	9.3	22.5	6.8	4.4
162	LUNG	11.8	13.0	16.3	4.2	5.9	9.8	4.6	6.0	8.7	9.5	9.5	3.3	8.0	6.6	7.3
163	FLEU	-	3.5	2.0	8.0	0.8	-	4.0	2.0	2.0	0.3	1.3	3.3	4.0	1.3	3.7
170	BONE	-	0.8	1.5	1.7	1.0	1.5	2.5	1.7	1.1	1.0	1.2	0.7	1.7	0.9	1.5
171	CONN	1.7	1.7	1.5	1.6	1.4	2.7	1.8	1.3	1.4	1.3	0.7	1.1	3.2	2.5	1.4
172	MELA	1.9	0.9	0.7	0.8	0.6	0.5	1.0	0.8	0.9	0.9	1.6	0.9	1.0	0.9	0.6
173	SKIN	2.5	1.9	1.7	1.7	1.4	1.4	1.5	1.3	2.1	1.7	2.1	2.3	1.7	1.5	1.6
188	BLAD	23.4	6.8	6.6	3.5	5.0	5.0	5.2	4.5	8.0	6.2	8.9	3.7	5.2	5.2	3.7
189	KYDN	1.2	3.0	2.1	1.9	1.5	2.0	2.3	1.3	2.9	2.5	1.7	1.8	1.5	2.1	1.7
190	EYE	1.5	1.4	0.5	1.3	1.1	0.9	1.5	1.3	3.3	3.0	4.0	1.5	3.3	0.5	0.8
191-2	BRAI	3.6	1.3	2.0	1.1	1.6	1.1	1.8	1.6	1.4	1.6	1.5	1.0	1.1	1.0	1.4
193	THYR	0.5	0.5	0.5	0.3	0.5	0.9	0.3	0.5	0.1	0.2	0.3	0.4	0.3	0.5	0.7
201	HODG	2.1	1.9	1.4	1.6	1.4	1.9	1.0	1.0	2.0	1.4	3.3	1.5	2.3	1.2	1.0
200,202	NHDD	2.1	2.2	1.9	1.4	2.4	3.9	1.8	1.6	1.6	1.2	3.7	1.5	2.0	1.9	1.8
203	MMYE	1.3	1.4	1.6	1.6	2.5	1.1	0.9	1.6	1.4	2.4	1.2	1.5	2.2	1.8	1.3
204-8	LEUK	1.3	1.2	1.6	1.6	1.7	1.4	1.4	1.7	1.7	2.0	1.4	1.4	1.3	1.3	1.2
PRIM UNK	UNKN	1.1	1.5	1.4	1.2	1.3	1.6	1.3	1.5	1.5	1.2	1.1	1.0	1.6	1.8	1.1
TOTAL minus (162+173)	TOTA minus (LUNG + SKIN)	1.1	1.3	1.0	1.0	1.0	1.3	1.1	1.1	1.4	1.1	1.3	1.0	1.3	1.2	1.0

ICD-9	LABEL	SWIV	SWIZ	UKBI	UKME	UKNW	UKOX	UKST	UKSW	UKTR	UKES	UKNS	UKNE	UKSE	UKSW	YUGO
140-9	MPHA	5.6	4.5	2.6	2.1	2.2	2.3	2.0	2.1	2.0	2.8	2.5	2.4	2.1	2.5	11.1
150	OBEO	4.4	5.3	1.6	1.9	1.9	1.2	1.9	1.9	2.0	1.6	2.0	2.2	1.7	2.0	8.9
151	STOM	3.0	2.2	2.4	2.2	2.2	2.6	2.4	2.5	2.3	2.2	2.4	2.1	2.0	2.2	2.3
153	OCLO	1.3	1.5	1.2	1.1	1.2	1.0	1.1	1.1	1.1	1.0	1.2	1.1	1.0	1.1	1.1
154	RECT	1.6	1.7	1.8	1.7	1.8	1.8	1.5	1.6	1.8	1.9	1.3	1.5	1.4	1.6	1.7
155	LIVE	4.1	3.6	2.2	1.9	2.1	2.3	2.3	1.5	1.8	1.8	4.2	2.5	2.1	2.5	1.7
156	GALL	0.7	0.6	0.9	1.3	0.8	0.9	1.1	0.9	0.9	0.6	1.5	1.1	0.8	0.9	0.5
157	PANC	1.7	1.4	1.8	1.8	1.7	1.5	1.6	1.5	1.5	1.2	1.4	1.6	1.6	1.3	1.7
161	LARY	13.3	37.0	6.2	5.0	4.6	8.4	5.8	8.8	4.9	3.4	38.0	3.5	5.9	4.1	14.5
162	LUNG	8.7	8.7	4.6	3.6	4.0	3.5	3.7	3.7	4.0	3.5	3.8	3.3	3.4	3.5	8.6
163	FLEU	2.0	13.0	5.0	4.0	2.7	4.5	4.0	9.0	6.0	-	1.5	4.0	4.5	6.0	6.0
170	BONE	0.8	1.1	1.6	1.5	1.4	1.5	1.1	1.0	1.6	1.3	0.7	0.6	0.8	1.3	0.9
171	CONN	0.5	1.1	1.1	1.9	1.1	0.9	1.4	1.3	1.1	1.4	1.1	1.4	0.8	1.4	1.0
172	MELA	0.8	0.9	0.5	0.6	0.5	0.6	0.6	0.5	0.8	0.6	0.4	0.8	0.6	0.6	0.9
173	SKIN	1.6	1.8	1.6	1.6	1.4	1.6	1.7	1.6	1.4	1.6	1.7	1.7	1.4	1.5	1.2
188	BLAD	5.8	5.0	3.8	3.8	3.4	4.1	4.0	3.9	3.7	3.5	2.7	3.2	3.0	3.1	5.8
189	KYDN	1.8	1.7	2.3	2.1	1.9	2.3	2.1	2.2	2.0	1.7	2.0	1.8	1.7	2.1	1.9
190	EYE	1.4	0.8	1.3	1.0	1.0	1.0	2.0	1.2	1.5	2.2	3.7	1.6	0.8	1.2	0.8
191-2	BRAI	1.2	1.4	1.2	1.3	1.5	1.3	1.2	1.5	1.4	1.0	0.9	1.5	1.2	1.4	1.6
193	THYR	0.4	0.6	0.4	0.4	0.5	0.4	0.4	0.4	0.4	0.2	0.5	0.4	0.3	0.3	0.3
201	HODG	1.9	1.6	1.6	1.5	1.6	1.6	1.7	1.8	1.5	1.9	2.6	1.5	1.7	1.4	1.1
200,202	NHDD	1.8	1.6	1.7	1.6	1.4	1.4	1.4	1.3	1.7	1.3	1.5	1.2	1.0	1.4	1.8
203	MMYE	2.2	1.5	1.7	1.3	1.2	1.7	1.5	1.4	1.4	1.6	2.3	1.2	1.5	1.4	1.8
204-8	LEUK	1.4	1.2	1.8	1.6	1.6	1.6	1.7	1.7	1.5	2.1	1.3	1.6	1.4	1.6	1.4
PRIM UNK	UNKN	1.3	1.2	1.3	1.2	1.3	1.3	1.3	1.0	1.3	1.3	1.4	1.3	1.3	1.3	1.3
TOTAL minus (162+173)	TOTA minus (LUNG + SKIN)	1.2	1.1	0.9	0.9	1.0	1.0	1.0	1.0	1.0	1.0	0.9	1.0	0.9	1.0	1.2

TABLE 8 - SEX RATIOS (M/F) FOR MORTALITY WITHIN EACH SITE AND EUROPEAN COUNTRY, 1978-82

ICD-9	LABEL	AUST	BELG	BULG	CZEC	DENM	ENGL	FRG	FINL	FRA	GDR	GREE	HUNG	IREL	LABEL	ICD-9
140-9	MPHA	7.3	4.3	3.2	5.7	2.2	2.2	5.1	2.1	12.9	4.4	2.7	6.7	2.9	MPHA	140-9
150	CESO	7.4	4.0	3.3	7.3	3.0	2.1	5.4	1.6	12.7	5.2	3.1	7.4	1.6	CESO	150
151	STOM	2.1	2.1	1.7	2.1	2.0	2.3	1.9	1.9	2.3	2.1	1.8	2.3	1.8	STOM	151
152-4,159	INTE	1.5	1.3	1.3	1.6	1.3	1.3	1.3	1.3	1.6	1.2	1.1	1.3	1.3	INTE	152-4,159
155.0	LIVE	2.7	1.7	1.6	1.8	1.4	2.4	2.3	1.6	4.5	2.1	2.1	2.0	1.9	LIVE	155.0
156	GALL	0.6	0.8	0.6	0.6	0.6	0.9	0.6	0.6	0.7	-	0.6	0.4	0.8	GALL	156
157	PANC	1.6	1.7	1.7	1.7	1.3	1.6	1.6	1.5	2.1	1.7	1.8	1.6	1.5	PANC	157
161	LARY	21.3	12.9	10.9	21.6	6.2	4.6	15.4	30.9	29.9	26.9	15.6	13.8	3.9	LARY	161
162	LUNG	6.7	12.5	6.3	10.3	3.6	4.0	8.5	11.4	11.0	9.9	7.0	5.9	3.0	LUNG	162
163	PLEU	1.2	2.5	0.7	2.5	2.3	4.1	2.2	2.9	2.7	-	1.0	1.6	2.3	PLEU	163
170	BONE	2.2	1.8	1.5	1.6	1.7	1.6	1.7	2.1	2.4	1.6	1.6	1.9	1.2	BONE	170
171	CONN	1.2	1.4	1.4	1.7	1.5	1.4	1.3	1.2	1.4	-	1.0	1.8	1.5	CONN	171
172-3	SKIT	1.5	1.6	1.3	1.5	1.3	1.2	1.4	1.9	1.4	1.3	1.2	1.4	1.0	SKIT	172-3
188	BLAD	3.7	4.5	4.8	6.1	3.7	3.5	4.3	5.1	5.2	4.9	5.8	5.3	3.3	BLAD	188
189	KYDN	1.8	1.8	1.7	2.3	1.3	2.2	2.2	1.9	2.2	-	2.2	2.1	1.8	KYDN	189
190	EYE	1.8	2.7	0.8	1.0	1.3	1.1	1.3	1.3	1.4	-	2.1	3.8	3.0	EYE	190
191-2	BRAI	1.6	1.3	1.4	1.5	1.3	1.6	1.5	1.3	1.6	-	1.8	1.5	1.3	BRAI	191-2
193	THYR	0.8	0.5	0.5	0.6	0.8	0.6	0.7	0.6	0.7	-	0.6	0.7	0.6	THYR	193
201	HDDG	1.8	1.9	2.4	1.8	2.0	1.8	1.8	1.9	1.9	1.8	2.2	1.7	1.5	HDDG	201
200,202	NHOD	1.7	1.6	1.8	1.7	1.7	1.6	1.6	1.8	1.8	-	2.0	1.8	1.6	NHOD	200,202
203	MMYE	1.2	1.4	1.1	1.4	1.4	1.4	1.4	1.2	1.3	-	1.2	1.4	1.4	MMYE	203
204-8	LEUK	1.5	1.5	1.2	1.6	1.6	1.6	1.6	1.6	1.6	1.5	1.6	1.5	1.6	LEUK	204-8
140-208	TOTA	1.6	1.9	1.5	1.8	1.3	1.5	1.6	1.9	2.2	1.6	1.8	1.7	1.3	TOTA	140-208
TOTAL-162	TOTA-LUNG	1.3	1.2	1.2	1.3	1.0	1.1	1.2	1.3	1.8	1.1	1.3	1.3	1.1	TOTA-LUNG	TOTAL-162

ICD-9	LABEL	ITAL	LUXE	NETH	NIRE	NORW	POLA	PORT	ROMA	SCOT	SPAI	SWED	SWIT	YUGO	LABEL	ICD-9
140-9	MPHA	6.9	6.0	2.6	1.7	2.9	4.7	5.8	4.0	2.1	6.8	2.9	5.9	5.7	MPHA	140-9
150	CESO	5.7	5.1	2.9	2.1	4.2	4.9	3.5	3.4	2.0	6.3	3.7	7.3	5.0	CESO	150
151	STOM	2.1	2.0	2.4	1.9	2.0	2.6	2.0	2.4	2.1	2.0	1.9	2.1	2.1	STOM	151
152-4,159	INTE	1.4	1.4	1.3	1.2	1.2	1.3	1.3	1.1	1.3	1.3	1.3	1.5	1.4	INTE	152-4,159
155	LIVE	2.1	1.5	2.2	1.5	1.8	1.1	2.1	2.2	2.4	1.4	1.7	3.5	1.7	LIVE	155
156	GALL	0.7	0.6	0.6	0.7	0.8	-	-	-	0.9	0.5	0.6	0.6	0.5	GALL	156
157	PANC	1.8	2.3	1.7	1.5	1.6	1.6	1.7	1.9	1.4	1.8	1.4	1.6	1.7	PANC	157
161	LARY	21.5	16.1	13.4	3.2	10.0	15.2	12.8	9.4	4.5	30.2	8.4	17.5	11.9	LARY	161
162	LUNG	8.9	11.7	12.8	4.0	4.6	8.0	5.5	5.4	3.6	8.7	3.4	9.3	6.1	LUNG	162
163	PLEU	2.3	1.4	6.0	3.7	6.2	-	-	-	9.8	1.6	-	4.3	1.7	PLEU	163
170	BONE	1.8	1.0	1.4	1.8	2.3	1.7	1.6	1.7	1.4	1.8	1.7	1.4	1.6	BONE	170
171	CONN	1.4	1.4	1.4	1.4	1.8	-	-	-	1.8	1.4	1.3	1.1	1.9	CONN	171
172-3	SKIT	1.5	0.5	1.5	0.8	1.7	1.3	1.4	1.4	1.2	1.7	1.5	1.6	1.3	SKIT	172-3
188	BLAD	5.9	3.7	4.7	3.4	3.1	7.3	4.3	3.9	2.7	6.3	3.2	4.1	4.1	BLAD	188
189	KYDN	2.4	3.3	1.9	2.0	1.9	-	-	-	1.9	2.2	1.8	1.7	1.6	KYDN	189
190	EYE	1.6	-	1.2	0.0	1.4	-	-	-	1.6	-	1.5	1.5	1.2	EYE	190
191-2	BRAI	1.6	-	1.7	1.4	1.4	-	-	-	1.4	1.5	1.4	1.4	1.7	BRAI	191-2
193	THYR	0.7	0.4	0.6	0.5	0.5	-	-	-	0.7	0.6	0.6	0.9	0.7	THYR	193
201	HDDG	1.7	1.6	2.0	2.4	2.0	1.9	1.9	2.2	1.3	2.0	1.7	1.6	1.6	HDDG	201
200,202	NHOD	1.8	1.3	1.6	1.5	1.4	-	-	-	1.4	1.8	1.6	1.7	1.6	NHOD	200,202
203	MMYE	1.4	1.5	1.4	1.7	1.6	-	-	-	1.6	1.3	1.4	1.6	1.4	MMYE	203
204-8	LEUK	1.6	1.5	1.5	1.6	1.6	1.5	1.3	1.4	1.6	1.4	1.5	1.5	1.4	LEUK	204-8
140-208	TOTA	1.9	1.7	1.8	1.4	1.4	1.7	1.6	1.5	1.5	1.8	1.3	1.7	1.7	TOTA	140-208
TOTAL-162	TOTA-LUNG	1.4	1.2	1.2	1.1	1.2	1.3	1.4	1.2	1.1	1.5	1.2	1.3	1.3	TOTA-LUNG	TOTAL-162

**TABLE 9A - HIGHEST / LOWEST RATIOS FOR INCIDENCE IN EUROPEAN CANCER REGISTRY REGIONS, MALES, 1978-82**

SITE	ICD-9	1st Highest / 1st Lowest	2nd Highest / 2nd Lowest
MPHA	140-9	10.2 (49.1 / 4.8) (France, Bas-Rhin / UK, South Thames)	9.7 (47.3 / 4.9) (France, Calvados / UK, Birmingham)
OESO	150	24.9 (29.9 / 1.2) (France, Calvados / Romania, County Cluj)	6.7 ( 16.7 / 2.5 ) (France, Bas-Rhin / Hungary, Szabolcs)
STOM	151	3.8 (44.0 / 11.5) (Italy, Parma / France, Istre)	3.5 ( 43.7 / 12.4) (Poland, Nowy Sacz / Ireland, Southern)
COLO	153	6.3 (25.9 / 4.1) (UK, North Scotland / Romania, County Cluj)	5.3 (24.4 / 4.6) (UK, NE Scotland / Poland, Nowy Sacz)
RECT	154	3.0 (21.5 / 7.2) (FRG, Saarland / Spain, Zaragoza)	2.7 (20.2 / 7.5) (Hungary, Vas / Poland, Nowy Sacz)
LIVE	155	102.0 (10.2 / 0.1) (Switz., Geneva / Ireland, Southern)	8.6 (8.6 / 1.0) (Italy, Parma / Neth., Eindhoven)
GALL	156	5.7 (4.0 / 0.7) (Italy, Ragusa / Romania, County Cluj)	4.9 (3.9 / 0.8) (Poland, Cracow City /Switz., Neuchâtel)
PANC	157	3.4 (10.4 / 3.1) (Switz., Neuchâtel / Spain, Tarragona)	2.6 (10.0 / 3.9) (Finland / France, Istre)
LARY	161	6.1 (17.2 / 2.8) (Spain, Navarra / Sweden)	5.2 (16.2 / 3.1) (Italy, Varese / FRG, Hamburg)
LUNG	162	4.1 (100.4 / 24.7) (UK, West Scotland / Iceland)	3.7 (94.4 / 25.3) (Neth., Eindhoven / Sweden)
PLEU	163	23.0 (2.3 / 0.1) (Sweden / Spain, Tarragona)	9.0 (1.8 / 0.2) (UK, West Scotland / Iceland)
BONE	170	15.5 (3.1 / 0.2) (Switz., Neuchâtel / UK, North Scotland)	5.8 (2.9 / 0.5) (France, Doubs / Italy, Ragusa)
CONN	171	5.0 (3.5 / 0.7) (Switz., Basel / Hungary, Vas)	4.4 (3.5 / 0.8) (Italy, Ragusa / Spain, Zaragoza)
MELA	172	7.4 (8.9 / 1.2) (Switz., Geneva / Poland, Nowy Sacz)	7.4 (8.9 / 1.2) (Norway / Romania, County Cluj)
SKIN	173	62.9 (69.2 / 1.1) (Switz., Basel / Switz., Zürich)	14.0 (68.8 / 4.9) (Switz., Vaud / FRG, Hamburg)
PROS	185	5.1 (50.1 / 9.8) (Switz., Basel / Romania, County Cluj)	4.5 (45.9 / 10.3) (Sweden / Poland, Nowy Sacz)
TEST	186	13.8 (8.3 / 0.6) (Switz., Basel / Italy, Ragusa)	7.1 (7.8 / 1.1) (Denmark / Spain, Tarragona)
BLAD	188	3.7 (27.8 / 7.6) (Switz., Basel / Hungary, Szabolcs)	3.5 (27.3 / 7.7) (Italy, Varese / Hungary, Vas)
KYDN	189	7.2 (12.2 / 1.7) (Iceland / Romania, County Cluj)	5.4 (11.3 / 2.1) (Sweden / Italy, Ragusa)
EYE	190	8.0 (1.6 / 0.2) (France, Doubs / FRG, Hamburg)	4.3 (1.3 / 0.3) (Switz., Basel / Hungary, Szabolcs)
BRAI	191-2	3.9 (9.4 / 2.4) (Sweden / Hungary, Szabolcs)	3.4 (8.6 / 2.5) (Poland, Cracow City / France, Calvados)
THYR	193	18.7 (5.6 / 0.3) (Iceland / Spain, Navarra)	7.8 (3.1 / 0.4) (Switz., Neuchâtel / Poland, Warsaw City)
HODG	201	4.7 (4.7 / 1.0) (Italy, Varese / Hungary, Szabolcs)	3.5 ( 4.5 / 1.3) (Italy, Ragusa / Romania, County Cluj)
NHOD	200,202	5.5 (11.5 / 2.1) (Switz., Vaud / Hungary, Vas)	4.5 (10.8 / 2.4) (Switz., Basel / Hungary, Szabolcs)
MMYE	203	4.3 (4.3 / 1.0) (UK, North Scotland / Hungary, Szabolcs)	3.9 (4.3 / 1.1) (UK, East Scotland / Poland, Warsaw City)
LEUK	204-8	3.3 (9.9 / 3.0) (Italy, Varese / Hungary, Szabolcs)	2.2 (9.2 / 4.2) (France, Doubs / France, Calvados)
UNKN	159, 165 195-9	7.0 (18.3 / 2.6) (France, Bas-Rhin / Hungary, Vas)	4.8 (18.1 / 3.8) (FRG, Saarland / German Dem. Rep.)
TOTA (-SKIN)	TOTAL (-173)	1.9 (334.5 / 174.4) (Italy, Varese / Romania, County Cluj)	1.8 (330.2 / 188.4) (France, Bas-Rhin / Hungary, Szabolcs)
TOTA (-SKIN+LUNG)	TOTAL (-173+162)	2.0 (270.0 / 135.2) (France, Bas-Rhin / Hungary, Szabolcs)	1.8 (254.0 / 139.7) (Italy, Varese / Romania, County Cluj)

**TABLE 9B - HIGHEST / LOWEST RATIOS FOR INCIDENCE IN EUROPEAN CANCER REGISTRY REGIONS, FEMALES, 1978-82**

SITE	ICD-9	1st Highest / 1st Lowest	2nd Highest / 2nd Lowest
MPHA	140-9	4.0 (4.8 / 1.2) (Switz., Neuchâtel / Spain, Tarragona)	3.3 (4.6 / 1.4) (Switz., Geneva / German Dem. Rep.)
OESO	150	51.0 (5.1 / 0.1) (UK, East Scotland / Hungary, Szabolcs)	46.0 (4.6 / 0.1) (Ireland, Southern / Hungary, Vas)
STOM	151	4.7 (19.9 / 4.2) (Italy, Parma / Ireland, Southern)	3.4 (17.1 / 5.0) (Italy, Varese / Switz., Vaud)
COLO	153	5.3 (21.7 / 4.1) (UK, NE Scotland / Romania, County Cluj)	4.4 (20.9 / 4.8) (UK, North Scotland / Poland, Nowy Sacz)
RECT	154	3.2 (13.2 / 4.1) (FRG, Saarland / Poland, Nowy Sacz)	2.2 (11.4 / 5.1) (Switz., Neuchâtel / Italy, Ragusa)
LIVE	155	18.3 (5.5 / 0.3) (Spain, Zaragoza / Ireland, Southern)	9.4 (4.7 / 0.5) (Spain, Navarra / France, Calvados)
GALL	156	10.8 (8.6 / 0.8) (Poland, Warsaw City / UK, North Scotland)	7.3 (8.0 / 1.1) (Poland, Cracow City / Romania, County Cluj)
PANC	157	3.7 (7.0 / 1.9) (Denmark / France, Doubs)	3.7 (7.0 / 1.9) (UK, East Scotland / Spain, Tarragona)
LARY	161	23.0 (2.3 / 0.1) (Switz., Neuchâtel / Spain, Tarragona)	14.0 (1.4 / 0.1) (Poland, Warsaw City / Switz., Zürich)
LUNG	162	10.2 (28.6 / 2.8) (UK, West Scotland / France, Doubs)	9.5 (26.6 / 2.8) (UK, SE Scotland / Italy, Ragusa)
PLEU	163	7.0 (0.7 / 0.1) (Switz., Geneva / France, Bas-Rhin)	7.0 (0.7 / 0.1) (Sweden / France, Isère)
BONE	170	6.7 (2.0 / 0.3) (Switz., Neuchâtel / UK, North Scotland)	4.3 (1.7 / 0.4) (Spain, Zaragoza / FRG, Hamburg)
CONN	171	3.4 (2.4 / 0.7) (FRG, Saarland / Poland, Nowy Sacz)	3.1 (2.2 / 0.7) (FRG, Hamburg / Poland, Warsaw City)
MELA	172	7.5 (10.5 / 1.4) (Norway / Spain, Zaragoza)	6.0 (9.6 / 1.6) (Switz., Geneva / Romania, County Cluj)
SKIN	173	80.2 (48.1 / 0.6) (Ireland, Southern / Switz., Zürich)	20.0 (44.1 / 2.2) (Switz., Vaud / FRG, Hamburg)
BREA	174	3.9 (72.2 / 18.4) (Switz., Geneva / Poland, Nowy Sacz)	3.1 (71.6 / 22.9) (Neth., Eindhoven / Hungary, Szabolcs)
CERV	180	4.5 (24.6 / 5.5) (German Dem. Rep. / Finland)	3.5 (20.2 / 5.7) (Poland, Cracow City / Spain, Navarra)
CORP	182	3.9 (16.9 / 4.3) (Switz., Zürich / Poland, Nowy Sacz)	3.8 (16.8 / 4.4) (Switz., Neuchâtel / Romania, County Cluj)
OVAR	183	2.8 (15.3 / 5.4) (Norway / Spain, Zaragoza)	2.6 (15.2 / 5.8) (Sweden / Hungary, Szabolcs)
BLAD	188	14.4 (7.2 / 0.5) (UK, SE Scotland / Italy, Ragusa)	5.4 (6.5 / 1.2) (UK, West Scotland / Hungary, Vas)
KYDN	189	5.8 (7.6 / 1.3) (Iceland / Romania, County Cluj)	4.3 (6.4 / 1.5) (Sweden / Spain, Tarragona)
EYE	190	11.0 (1.1 / 0.1) (Switz., Geneva / FRG, Hamburg)	9.0 (0.9 / 0.1) (UK, West Scotland / Italy, Parma)
BRAI	191-2	7.7 (10.0 / 1.3) (Iceland / Hungary, Szabolcs)	5.2 (9.3 / 1.8) (Sweden / Italy, Ragusa)
THYR	193	10.2 (13.3 / 1.3) (a) (Iceland / Poland, Warsaw City)	3.9 (5.4 / 1.4) (b) (Switz., Basel / Poland, Cracow City)
HODG	201	4.9 (3.9 / 0.8) (Switz., Neuchâtel / Hungary, Szabolcs)	3.1 (2.5 / 0.8) (Italy, Varese / Ireland, Southern)
NHOD	200,202	9.3 (6.5 / 0.7) (UK, SE Scotland / Poland, Nowy Sacz)	5.8 (6.4 / 1.1) (Switz., Vaud / Hungary, Szabolcs)
MMYE	203	16.0 (3.2 / 0.2) (Switz., Neuchâtel / Hungary, Szabolcs)	4.0 (2.8 / 0.7) (UK, East Scotland / Ireland, Southern)
LEUK	204-8	3.0 (8.0 / 2.7) (Italy, Varese / Hungary, Szabolcs)	2.2 (7.6 / 3.4) (Italy, Parma / UK, East Scotland)
UNKN	159, 165 195-9	5.9 (13.6 / 2.3) (FRG, Saarland / Hungary, Vas)	4.2 (12.7 / 3.0) (UK, South Western / France, Calvados)
TOTA (-SKIN)	TOTAL (-173)	2.1 (240.7 / 114.2) (Denmark / Hungary, Szabolcs)	1.9 (237.2 / 124.5) (UK, SE Scotland / Poland, Nowy Sacz)
TOTA (-SKIN+LUNG)	TOTAL (-173+162)	2.1 (224.0 / 107.1) (Denmark / Hungary, Szabolcs)	1.8 (216.8 / 119.7) (Switz., Neuchâtel / Poland, Nowy Sacz)

(a) Ratio 1st Highest / 2nd Lowest  
(b) Ratio 2nd Highest / 3rd Lowest

**TABLE 10A - HIGHEST / LOWEST RATIOS FOR MORTALITY  
IN EUROPEAN COUNTRIES, MALES, 1978-82**

Site	ICD-9	1st Highest / 1st Lowest	2nd Highest / 2nd Lowest
MPHA	140-9	9.2 (15.6 / 1.7) (France / Greece)	4.0 (7.9 / 2.0) (Hungary / Netherlands)
OESO	150	11.1 (13.3 / 1.2) (France/ Romania)	6.2 (8.1 / 1.3) (Scotland / Bulgaria)
STOM	151	2.6 (31.6 / 12.1) (Hungary/ Greece)	2.5 (30.4 / 12.2) (Poland / Denmark)
INTE	152-4,159	3.6 (27.5 / 7.7) (Luxembourg/ Greece)	3.4 (27.3 / 8.1) (Czechoslovakia / Romania)
LIVE	155.0	10.1 (9.1 / 0.9) (Spain / Ireland)	9.7 (8.7 / 0.9) (Bulgaria / Portugal)
GALL	156	11.7 (3.5 / 0.3) (Hungary / Greece)	4.1 (3.3 / 0.8) (Czechoslovakia / Bulgaria)
PANC	157	2.3 (10.1 / 4.3) (Luxembourg / Spain)	2.1 (9.5 / 4.6) (Finland / Portugal)
LARY	161	13.9 (11.1 / 0.8) (France / Sweden)	7.6 (7.6 / 1.0) (Spain / Norway)
LUNG	162	4.2 (83.5 / 20.1) (Scotland / Portugal)	3.2 (77.8 / 24.6) (Belgium / Sweden)
PLEU	163	15.0 (1.5 / 0.1) (a) (Netherlands / Ireland)	5.0 (1.0 / 0.2) (b) (France / Northern Ireland)
BONE	170	4.7 (2.8 / 0.6) (Greece / Netherlands)	4.5 (2.7 / 0.6) (Yugoslavia / Norway)
CONN	171	4.3 (1.3 / 0.3) (Hungary / Bulgaria)	3.4 (1.0 / 0.3) (Norway / Greece)
SKIT	172-3	3.3 (3.3 / 1.0) (Norway / Greece)	2.7 (3.2 / 1.2) (Switzerland / Luxembourg)
PROS	185	3.2 (19.9 / 6.2) (Norway / Romania)	3.1 (19.8 / 6.3) (Switzerland / Bulgaria)
TEST	186	6.0 (1.8 / 0.3) (GDR / Portugal)	4.0 (1.2 / 0.3) (Switzerland / Spain)
BLAD	188	2.8 (9.1 / 3.3) (Denmark / Romania)	2.2 (8.6 / 4.0) (Belgium / Bulgaria)
KYDN	189	4.3 (6.8 / 1.6) (Czechoslovakia / Bulgaria)	3.3 (6.3 / 1.9) (Sweden / Yugoslavia)
EYE	190	4.0 (0.4 / 0.1) (c) (Scotland / Bulgaria)	4.0 (0.4 / 0.1) (d) (Ireland / Czechoslovakia)
BRAI	191-2	2.9 (6.7 / 2.3) (Greece / Bulgaria)	2.3 (6.3 / 2.8) (Belgium / FRG)
THYR	193	4.5 (0.9 / 0.2) (Switzerland / Greece)	4.5 (0.9 / 0.2) (Austria / Spain)
HODG	201	3.3 (3.0 / 0.9) (Yugoslavia / Luxembourg)	2.6 (2.3 / 0.9) (Switzerland / Romania)
NHOD	200,202	2.8 (4.4 / 1.6) (Finland / Yugoslavia)	2.3 (4.1 / 1.8) (Netherlands / Greece)
MMYE	203	6.6 (3.3 / 0.5) (Norway / Bulgaria)	4.7 (2.8 / 0.6) (Sweden / Yugoslavia)
LEUK	204-8	2.1 (7.1 / 3.4) (Czechoslovakia / Yugoslavia)	1.9 (7.0 / 3.7) (Luxembourg / Romania)
TOTA (-LUNG)	TOTAL (-162)	2.0 (155.3 / 76.4) (France / Romania)	1.7 (151.2 / 88.9) (Hungary / Bulgaria)
TOTA	TOTAL 140-208	2.1 (213.3 / 103.2) (Belgium / Romania)	1.7 (213.0 / 125.3) (Czechoslovakia / Bulgaria)

(a) Ratio 1st Highest/ 3th Lowest

(b) Ratio 2nd Highest/ 4th Lowest

(c) Ratio 1st Highest/ 2nd Lowest

(d) Ratio 2nd Highest/ 3th Lowest

**TABLE 10B - HIGHEST / LOWEST RATIOS FOR MORTALITY  
IN EUROPEAN COUNTRIES, FEMALES,  
1978-82**

Site	ICD-9	1st Highest/ 1st Lowest	2nd Highest/ 2nd Lowest
MPHA	140-9	2.5 (1.5 / 0.6) (Scotland / Austria)	2.3 (1.4 / 0.6) (Northern Ireland / Greece)
OESO	150	10.0 (4.0 / 0.4) (Scotland / Bulgaria)	9.8 (3.9 / 0.4) (Ireland / Czechoslovakia)
STO	151	2.7 (14.5 / 5.4) (Portugal / France)	2.3 (14.2 / 6.2) (Bulgaria / Denmark)
INTE	152-4,159	2.9 (20.2 / 6.9) (Luxembourg / Greece)	2.7 ( 18.7 / 7.0) (Ireland / Romania)
LIVE	155.0	17.7 (7.1 / 0.4) (Poland / Portugal)	15.7 (6.3 / 0.4) (Spain / Ireland)
GALL	156	13.5 (8.1 / 0.6) (Hungary / Greece)	5.0 (5.5 / 1.1) (Czechoslovakia / England & Wales)
PANC	157	3.0 (7.1 / 2.4) (Denmark / Spain)	2.4 (6.6 / 2.7) (Sweden / Greece)
LARY	161	6.0 (0.6 / 0.1) (Ireland / Finland)	5.0 (0.5 / 0.1) (Yugoslavia / GDR)
LUNG	162	6.4 (23.2 / 3.6) (Scotland / Portugal)	4.6 (17.3 / 3.8) (England & Wales / France)
PLEU	163	4.0 (0.4 / 0.1) (a) (Luxembourg / Belgium)	4.0 (0.4 / 0.1) (b) (Italy / Bulgaria)
BONE	170	6.0 (1.8 / 0.3) (Luxembourg / Norway)	4.3 (1.7 / 0.4) (Yugoslavia / Finland)
CONN	171	3.5 ( 0.7 / 0.2) (Netherlands / Bulgaria)	3.5 ( 0.7 / 0.2) (Hungary / Italy)
SKIT	172-3	3.0 (2.4 / 0.8) (Luxembourg / Greece)	2.8 (2.2 / 0.8) (Ireland / Spain)
BREA	174	2.8 (28.2 / 9.9) (England & Wales / Romania)	2.2 (27.9 / 12.7) (Scotland / Yugoslavia)
UTER	179-182	2.7 (14.5 / 5.3) (Hungary / Greece)	2.3 (12.6 / 5.4) (Poland / Finland)
OVAI	183	4.7 (10.8 / 2.3) (Denmark / Spain)	3.8 (9.0 / 2.4) (Sweden / Portugal)
BLAD	188	3.8 (3.0 / 0.8) (Scotland / Bulgaria)	3.0 (2.4 / 0.8) (Denmark / Romania)
KYDN	189	4.3 (3.9 / 0.9) (Denmark / Bulgaria)	4.0 (3.6 / 0.9) (Sweden / Greece)
EYE	190	2.0 (0.2 / 0.1) (c) (Scotland / Austria)	2.0 (0.2 / 0.1) (d) (Northern Ireland / Belgium)
BRAIN	191-2	2.8 (4.8 / 1.7) (Belgium / Bulgaria)	2.2 (4.2 / 1.9) (Denmark / FRG)
THYR	193	2.8 (1.1 / 0.4) (Luxembourg / Greece)	2.8 (1.1 / 0.4) (Austria / Spain)
HODG	201	4.5 (1.8 / 0.4) (Yugoslavia / Romania)	3.0 (1.5 / 0.5) (Switzerland / Bulgaria)
NHOD	200,202	3.0 (2.7 / 0.9) (Scotland / Greece)	2.5 (2.5 / 1.0) (Sweden / Yugoslavia)
MMYE	203	5.0 (2.0 / 0.4) (Sweden / Bulgaria)	5.0 (2.0 / 0.4) (Norway / Yugoslavia)
LEUK	204-8	2.0 (4.7 / 2.4) (Luxembourg / Yugoslavia)	1.7 (4.5 / 2.6) (Hungary / Romania)
TOT (- LUNG)	TOTAL (-162)	1.9 (119.3 / 63.1) (Denmark / Romania)	1.6 (117.3 / 75.0) (Hungary / Greece)
TOT	TOTAL 140-208	2.0 (135.0 / 68.1) (Scotland / Romania)	1.6 (134.2 / 81.4) (Denmark / Bulgaria)

(a) Ratio 1st Highest/ 3th Lowest  
(b) Ratio 2nd Highest/ 4th Lowest  
(c) Ratio 1st Highest/ 2nd Lowest  
(d) Ratio 2nd Highest/ 3th Lowest